"A RANDOMISED, BLINDED, PLACEBO-CONTROLLED, THREE ARMED PARALLEL STUDY ON ELECTROPHOTONIC IMAGE CHANGES DURING HOMOEOPATHIC PATHOGENETIC TRIAL USING MOLECULAR AND ULTRA-MOLECULAR DOSES - A REPROVING"

By

Dr BANUPRIYA. D

17TH BATCH POST GRADUATE TRAINEE,

DEPARTMENT OF HOMOEOPATHIC PHARMACY

SESSION – 2015-2018

Abstract

Background: The implicit system of Homoeopathy medicine rest upon the Fundamental principle, "Law of Simila". This study attempts to find out the ability of the dynamic Homoeopathic medicines to produce changes in the Healthy Human Beings during Homoeopathic Pathogenetic Trial through Objective Scientific Data "Electro Photonic Image" parameters and subjective symptoms.

Aims and Objectives: To find out the changes produced by the placebo, the Belladonna – 6C (Molecular doses) and the Belladonna – 200 C (Ultra Molecular Doses) on the healthy human being through Electro Photonic Images using Bio Well instrument. To find out the difference in the production of symptoms in the placebo group and the Belladonna – 6C and 200 C group during Homoeopathic Pathogenetic Trial.

Materials and Methods: The study population were self-reported apparently healthy volunteers from NIH campus, (Sample Size = 150; Dropouts = 15; Final Sample size = 135); it was a three-armed trial with, Belladonna – 6C group and Belladonna – 200C group and the placebo group. The study design was triple blinded. The study design was framed as a 4 weeks protocol. The Electro Photonic Emission from ten fingers of the participants have been recorded using BIO WELL instrument and the Questionnaire data of each participant has been collected each week during the trial.

Results: Direct analysis showed a statistically significant difference in eight parameters (P-value <0.05) out of twelve parameters. Derived analysis revealed that Form Coefficient parameter (P-value <0.001) is most sensitive to identify the placebo effect and the drug effect. The gender analysis revealed only female group showed the significant changes in the EPI parameters. The questionnaire analysis revealed a significant difference among the three groups. The Post Hoc analysis showed the number of symptoms and the score of the Q - Form - 2 in the groups showed the trend: Belladonna 6C > Belladonna200C > Placebo.

Conclusion: This study gave statistically significant results in both primary and secondary outcome measures, we may conclude momentarily that the Electro Photonic Emissions from the human body may serve as a parameter to differentiate the placebo effect from the Homoeopathic medicine effect in Homoeopathic Pathogenetic Trials. The same result should be reproduced to establish the photonic concept in Homeopathy.

Acknowledgement

The success and final outcome of this project required a lot of guidance, assistance, support and participation from many people and I am extremely privileged to have got this all along the completion of this study trial. All that I have done is only due to such guidance and support and I would not forget to thank them!

First and foremost, I would like to thank the ***Supreme Divine*** and their representatives none other than ***my family members*** who gave me the freedom to experiment and freedom to spend my time and money on research and supported me morally and financially during hardships. My lovely gratitude to each and every atom of National Institute of Homoeopathy, the prestigious Institution with ever-changing Directors but unchanging care and support from Former Directors & Incharges, ***Dr S. K. Nanda sir & Dr Abhijit Chattopadhyay sir,*** my humble gratitude! My heartful gratitude to the present Director Incharge, ***Dr Gautam Ash sir***, for his encouragement and tremendous support for implicating new ideas.

Starting the sentence with "I would like to thank" may not be appropriate because the encouragement and support from my guide were beyond the words of gratitude. This project would have been impossible without my guide, a visionary who saw the possibilities when other people pointed out the chances of failure. He is my guide, a beam of hope, ***Prof. Dr Dilip Panakkada sir, (HOD, Dept. of Homoeopathic Pharmacy)***, who trusted my ideas and confidence than I trusted myself. His words, "OK, Do It" & "Find Out" gave me the immense strength to bring about the clarity among the chaos! Sir, your Guidance! Let it be forever!

I owe my deep gratitude to ***Prof. Dr Konstantin Korotkov sir, (Deputy Director of Saint – Petersburg Federal Research Institute of Physical Culture, Russia)*** for inventing the BIOWELL instrument and made it accessible throughout the world and for his Co-guidance and suggestions regarding the importance of Gender analysis that added value to this project. I thank ***Dr Krishna Madappa sir, (President of The Institute of Science, Spirituality and Sustainability, USA)*** who encouraged a lot in doing this project and his discussions regarding Physics, Electrophotonics and Metaphysics helped me in understanding the core. I would like to thank ***Dr Guru Deo sir, (Asst. Professor, Morarji Desai National Institute of Yoga, Delhi)***

Table of Contents

List of Figures

List of Tables

List of Abbreviations

- **H. P. I**……………………………………………..Homoeopathic Pathogenetic Trial
- **E. P. I**…………………………………………………….. Electro Photonic Imaging
- **G. D. V**…………………………………………………Gas Discharge Visualisation
- **O. A. M**…………………………………………….. Office of Alternative Medicine
- **C. A. M**………………………………………….Complementary and Alternative Medicine
- **U. S. N. I. H**…………………………………United States National Institute of Health
- **N. I. H**……………………………………………...National Institute of Homoeopathy
- **H. F**……………………………………………………………….High Frequency
- **G. H. Q**…………………………………………………..General Health Questionnaire
- **S. O. D**……………………………………………………………Self Observation Day
- **S. V. Y. A. S. A**…………………Swami Vivekananda Yoga Anusandhana Samsthana
- **S. P. S. S**………………………………………..Statistical Package for Social Sciences
- **P. G. T**……………………………………………………...Post Graduate Trainee
- **U. G**……………………………………………………………….Under Graduate
- **Q- FORM**…………………………………………………….Questionnaire Form
- **Sig**……………………………………………………Significance Value / P – Value
- **F**………………………………………….Fisher Test Value (In Statistics - ANOVA)

List of Appendices

1

Introduction

1.1 Homoeopathy and Research

Homoeopathy, the system of medicine, which is approximately 222 years old, is still in the budding phase when research and scientific significance are concerned. As an add-on to its immateriality, this field is still in the sprouting stage, when we consider the modus operandi of the Homoeopathic Potencies and its Standardisation.

To prove the efficacy of any medical system, a Prospective, Controlled and Blinded Clinical Trials should give statistically significant results to influence the meta-analysis. But the meta-analysis of the Homoeopathic clinical Trials so far conducted was not favourable as the trials were imbued with bias[26-28]. This, in turn, created an obsession in Homoeopathic clinical researchers to conduct more Clinical Trials on specific nosological terms and parameters with a group of indicated medicine to that particular disease, which ultimately masked the individualisation concept of Homoeopathy[26] and thereby leading to the results that tend to confirm the scientific implausibility of Homoeopathy.

When we analyse the Law of Similia; we could identify the two parts in this concept of "Similia Similibus Curentur"[1,2], 'The ability of a substance to produce the symptoms on the healthy human being' & 'The ability of a substance to alleviate the symptoms that which it is capable of producing'. All the Clinical Trials were designed in such a way to prove the second part of the concept. Only a few experiments were conducted with statistical

significance to prove the first part of the concept which is termed as "Drug Proving"[1] in a former version; later it has been transformed with a modified study design and now termed as "Homoeopathic Pathogenetic Trial".

1.2 Homoeopathic Drug Proving

Homoeopathic drug proving is the process of understanding the pathogenetic powers of the drugs, (pathos = suffering, genetic = producing). Homoeopathic drug proving has a unique study design as it is conducted on healthy human beings, with dynamised Homoeopathic drugs. Before Dr Hahnemann, many personalities like Paracelsus, Albert Von Haler etc., made an exhaustive study of drug proving methods [23]. The pure and unadulterated effects of drug substances in pure symptomatic form can be acquired only by healthy human drug proving. Hahnemann defines drug proving in § 105 as, "the process of acquiring the knowledge of instruments intended for the cure of the natural disease, investigating the pathogenetic power of medicine"[1,2]. This protocol has been designed to assess the subatomic[34] changes in the healthy human beings when homoeopathic potency is administered during drug proving, i.e. Homoeopathic Pathogenetic Trial to assess the Electro Photonic Emission Pattern through the BIO WELL device[48].

1.3 Research Questions

The research questions that provoked the ideas to design the trial were:

- Do the Homoeopathic drug substance in molecular (within Avogadro Number) and ultra-molecular doses (above Avogadro Number) produce any significant changes in the bio-field which is reflected as Electro Photonic Emissions of the human beings during Homoeopathic Pathogenetic Trial?
- Is there any significant difference between the parameters of the Electro Photonic Image (EPI) obtained during the intervention period and the baseline parameters among the three groups during the Homoeopathic Pathogenetic Trial?

1.4 Hypothesis

Two Hypothesises were framed based on the research questions.

1.4.1 Hypothesis – I: The Null Hypothesis assumes that "Homoeopathic drug substance in molecular and ultra-molecular doses do not produce any changes in the bio-field of the human beings during Homoeopathic Pathogenetic Trial". The Alternative Hypothesis assumes that "Homoeopathic drug substance in molecular and ultra-molecular doses produce significant changes in the bio-field of the human beings during Homoeopathic Pathogenetic Trial"

1.4.2 Hypothesis – II: The Null Hypothesis assumes that "There is no significant difference between the parameters of the Electro Photonic Images (EPI) obtained during the intervention period and the baseline parameters, among the three groups in Homoeopathic Pathogenetic Trial". The Alternative Hypothesis assumes that "There is a significant difference in the parameters of the Electro Photonic Images (EPI) obtained during the intervention period, from the baseline parameters, among the three groups in Homoeopathic Pathogenetic Trial".

1.5 Background and Justification

The background and Justification of the study protocol and the basic concepts have been briefly jotted out. The implicit system of homoeopathy medicine rests upon the fundamental principles and law of similar. This study is an attempt to justify scientifically, three fundamental principles of homoeopathy among eight set in stone principles[2, 23].

The Theory of Vital Force, the Doctrine of Drug Proving, the Doctrine of Drug Dynamisation - an attempt to justify scientifically using Bio Well device, assessing the Electro Photonic Emissions from the human body in the Homoeopathic Pathogenetic Trial (HPT) (drug proving), using Investigational Proving Substance (Belladonna) in molecular and ultramolecular doses The electro-photonic images (EPI) can be correlated to the scientific concept of Plasma /Gas in the Biofield, which was termed as Vital Force or Vital Principle by Dr Samuel Hahnemann in his Organon of Medicine. In the HPT, the primary action of the drug on the vital force produces symptoms of that particular drug in the body and mind of the provers[1,2]. The investigational proving substance (Belladonna), in 6 C and 200 C will be administered. The Homoeopathic Potency 6 C, Molecular dose, that contains molecules of the original drug substance, within Avogadro limits[16]. The Homoeopathic Potency 200 C, Ultra-molecular dose, the potency that does not contain any molecules of the original drug substance, above the Avogadro limits.

2
Aims and Objectives

- To explore the subatomic level changes in the healthy human being during HPT using molecular and ultra-molecular doses of the Homoeopathic potencies.

- To find out the difference produced by the homoeopathic potencies and the placebo during HPT in the EPI.

- To find out the difference between the effect of molecular doses and the ultra-molecular doses in healthy human being

- To find out the similarity in the changes in the produced during HPT.

- To find out the reproducibility of the symptoms of the particular drug during reproving.

- To assess the possibility of considering Electro Photonic Emission Parameters as a scientific objective data in HPT.

- To correlate the changes produced in the Electro Photonic Image parameters with the subjective symptoms produced during HPT.

3

Review of Literature

3.1 VITAL FORCE AND BIOFIELD

Here is a glimpse of philosophies by the stalwarts, The Vital Force theory is a philosophical, scientific and spiritual belief that organic material contained a vital force that enables them to live. The resulting vitalism theory was first proposed in the 16th century and lasted till mid- 19th century. Dr Samuel Hahnemann explains about this governing force or principle in **§9-§16** in Organon of Medicine[1, 2].

3.1.1 BOGER'S VIEW

Dr C.M. Boger in "Studies on the philosophies of healing" states it as vital energy, his statement as follows, "*energy as we understand it is of threefold form, spiritual, dynamic and physical…… In homoeopathy we are more particularly concerned with dynamic energy ….this dynamic energy Hahnemann called the dynamic, the spirit like vital force animating the material body. In the human body, we have present all three forms of energy; The physical in tissues; The dynamic in the brain and nervous system; The spiritual in the mind*". On disease and cure, Dr C. M. Boger refers "*the rhythm of dynamic force" ….. we must remain within the rhythm peculiar to our own vital force. Sickness is the disturbance of rhythm of the vital force, either increasing or lowering it…….*and he explains the law of similar with the

synchronicity of the rhythm,…….*if the pace were exactly synchronous there would be no effect, it acts by modifying the disturbing force by changing the rhythm. we know it because the similar potentized remedy administered to a sick person tends to establish equilibrium and brings about the smoothness of action, a restoration to orderly action in sick person'* [7]

3.1.2 STUART CLOSE'S VIEW

Dr Stuart Close, in "The Genius of Homoeopathy", Chapter IV, The scope of homoeopathy, regretted that "*the therapeutic principle is known, the technique of prescribing has been developed, a large number of remedies have been prepared but the field of action has not been clearly defined*".In another chapter, the development of Hahemannian philosophy in the sixth edition of the Organon. Dr Stuart Close states that "*To Hahnemann belongs the honour of having been the first physician to connect biology and psychology with physics in a practical system of medicinal therapeutics and to give an impulse to studies in BIODYNAMICS, which has gained momentum continuously ever since*" [8].

3.1.3 KENT'S VIEW

In "Kent lectures on homoeopathic philosophy" on simple substance, Dr J.T. KENT states that "*….everything in the universe has its aura or atmosphere, every star and planet has an atmosphere, the sun's atmosphere is its light and heat, every human being has his atmosphere or aura, every animal has its atmosphere or aura. This aura is present in all entities,…… this aura becomes useful and introduces a prominent sphere in the study of homoeopathic*" [9]

3.2 ATTEMPT TO BRIDGE GAP USING ARISTOTLE'S FIRST PRINCIPLE TECHNIQUE

Though these above philosophies give us infinite possibilities to research on that topic, it also gives us finite clues to correlate scientifically. All the biological process are governed by biophysical and biochemical changes that are happening inside and outside the human cells. The modern system of medicine works on the biochemical substrate to modify those reactions in the diseased individual with molecular components as medicines. But when we consider the biochemical plane, homoeopathy, the potencies contains the intangible, immeasurable properties. So the possibilities of detecting the changes and framing the modus operandi are not feasible. This infeasibility of Homoeopathic potencies on that molecular

substrate does not mean that the Homoeopathic potencies are incapable of producing any effect on the human body.

Though it requires ponderous effort to investigate to its full extent, "the first principle thinking" [29] approaches rather than analogy gives some clues amongst the maze. When we consider molecules, they are actually the clusters of atoms and atoms, in turn, are made of proton, neutron and electron. If the homoeopathic medicines contain some properties beyond the molecules, the word "beyond" may be correlated momentarily to the subatomic or interatomic planes within this limited knowledge. So, the parameter that has to be selected to assess the action or effectiveness of Homoeopathic medicine should be correlated with this subatomic or interatomic substrate.

As a result of this thinking process, we may assume that Homoeopathic potencies may affect or influence the subatomic or interatomic substrate not only in the process of curing but also in the process of "DRUG PROVING" if the "Law of Similia" holds true [1,2]. The law of similia states that the ability of the substance to cure the disease is based on its capability of producing the same disease. According to the first principle of thinking, the concept that has to be proved is the ability of the substance to produce the disease in the dynamic dose. The research should be focused on Drug Proving rather than clinical trials on the diseased

3.3 BIO FIELD

By combining these philosophies in mind and on a search to a modern scientific explanation, it is found that similar studies were made to explain these concepts in scientific terms. From the article, Biofield Science and Healing: History, Terminology, and Concepts.

Figure 3.1. (Left): Illustration of Magnetic field surrounding the magnet;

Figure 3.2. (Right): Illustration of Bio-field surrounding the human body.

The term biofield was proposed in 1992 by an ad hoc committee of CAM practitioners and researchers convened by the newly established Office of Alternative Medicine (OAM) at the US National Institute of Health (NIH), The committee defined biofield as," *a massless field not necessarily electromagnetic that surrounds and permeate living bodies and affects the body". The Ukranian histologist Alexander Gurwitsch, PhD, coined the term morphogenetic field, to describe the highly coherent and dynamic process that appeared to be guiding the development of the unfolding embryo as well as biological regeneration" Gurwitsch also discovered mitogenetic radiation, ultraviolet light emission during cell division in onion root. One line research on endogenous bio-field followed from the early discovery by Gurwitsch as mentioned above of ultraviolet light emission during cell division* [3]

Recent studies have reported evidence for a variety of bio-photon mediated regulatory processes including cell-cell communication, cell-cell orientation sensing, secretion of regulatory neurotransmitters, modulation of respiratory activity in white blood cells and accelerated seed germination. These findings, as well as results of research correlating bio-photon emission with human physiology, suggest the existence of coherent bio-photon fields that play fundamental roles in intercellular signalling and human health**.**

3.4 BIO FIELD AND GAS DISCHARGE VISUALIZATION

In another article related to bio-field devices, gas discharge visualization in the bio-field assessment is discussed. "An Overview of Biofield Devices, Modalities using gas or plasma"[3], Gas discharge visualization is an important example of the use of plasma in biofield science. Based on Kirlian effect, a high frequency, high voltage field is used to stimulate weak photon emission, followed by application of modern optics, electronics and computer processing to form images of the weak photon emission. A recent review of GDV research applied to medicine and psychology can be found in the book, Electro-photonic applications in medicine: GDV bio-electrography**.**

In the recent time using GDV camera the normative study on the parameter of the EPI in the INDIAN population was carried out, development of normative data of electro-photonic imaging technique for a healthy population in India[5] : A normative study, Gas discharge visualization (GDV) utilizing EPI technique is based on coronal electrical discharge surrounding an object when exposed to a high electrical field. The mechanism through which the picture has been captured is explained in Figure 3.3,

Figure 3.3. Scheme of the GDV device. (1) Object of examination ; (2) transparent electrode; (3) gas discharge; (4) optical emission; (5) generator; (6) optical system; (7, 8) video transformer; (9) computer; (10) case

The characteristics of this electric field are high voltage of 10 kV at a frequency of 1024 Hz and low current that is in microAmperes. In particular, the fingertips are placed on a dielectric glass plate of the instrument and when such voltage characteristics are applied to the underside of the glass plate to generate a high electrical field, collision of electrons take place in the surrounding air molecules around the fingertips. These wrenched out electrons induce ionization of the air molecules and produce a glow around the finger. Further, this process is captured as a snapshot by a charged coupled device camera placed underneath the glass plate and then registered in a form of an EPI image.

All 10 finger images are processed through the EPI software and numerical values based on the number of pixel count are extracted corresponding to sections representing diverse organ systems in the body. In EPI, the correlation of finger sectors of the images, organs, and systems is based not only on empirical findings but also supported by the acupuncture meridian system and scientifically found circulatory system called Bonghan system[5]

3.5 SCIENCE BEHIND ELECTROPHOTONIC IMAGING

3.5.1 THE ELECTRONS AND PHOTONS

All tangible matters in solid, liquid and gaseous state are made up of elements, elements are made up of molecules and molecules, in turn, are made up of atoms. Each individual atom is made up of protons, neutrons and electrons. Each atom contains a certain number of protons and neutrons in its nucleus surrounded by electrons in their respective orbitals[24]

Photons are light particles, it is localized in space and possess the energy and momentum but it has no mass. Photons travel with the velocity of light. How photon differs from electron? The electron has mass, photons do not. Electrons have an electric charge, photons do not. Electrons may be stationary, photons move only at the velocity of light. Electrons are constituents are ordinary matter, photons are not. The energy of a photon depends only on its frequency, that of an electron depends on its velocity and position[35]

Figure 3.4. (Left) Illustration of the valence electrons; Figure 3.5. (Right) Illustration of Photonic Emissions.

3.5.2 PHOTONIC EMISSIONS

The energy levels of atoms and molecules can have only certain quantized values. Transitions between these quantized states occur by the photon processes absorption, emission, and stimulated emission. Taking the electron transitions associated with visible and ultraviolet interactions with the matter as an example, absorption of a photon will occur only when the quantum energy of the photon precisely matches the energy gap between the initial and final states. In the interaction of radiation with matter, if

there is no pair of energy states such that the photon energy can elevate the system from the lower to the upper state, then the matter will be transparent to that radiation. An Electron absorbs a photon and gets excited. But electrons can remain in the excited state only for short period, then electron comes to the ground state by emitting a photon[36]

If an electron is already in an excited state (an upper energy level, in contrast to its lowest possible level or "ground state"), then an incoming photon for which the quantum energy is equal to the energy difference between its present level and a lower level can "stimulate" a transition to that lower level, producing a second photon of the same energy. This is stimulated emission of photons. *In this Electro Photonic Imaging technique, the electron and photons emitted are due to the stimulated emissions with the help of the Electromagnetic Field.*

3.5.3 QUANTUM BIOPHYSICAL MODEL

From the book "Electro Photonic Analysis in Medicine – GDV Bio Electrography Research", the part one of this book explains the basic concept that governs and justify this Electro Photonic Emission. This explores the candidate mechanisms in physiology and biophysics through which EPI data from biological subjects can reflect the state of health in a human being. EPI assessment methods can be understood using quantum biophysical models of entropy.

'The main reservoir of free energy in biological processes is electron excited states of the complex molecular system. This quantum model supports an argument that EPI techniques provide indirect judgment about the level of energy reservoir at the molecular level in structure protein complexes'

'Collections of delocalized excited π- electrons in protein macromolecules provide an energy reservoir for physiological processes. Specific structural protein complexes within the mass of the skin provide channels of heightened electron conductivity, stimulated impulse emission from the skin are also developed mainly by transport of delocalized π- electrons. Most attention in this sphere has been focused on concepts of electron tunnel transport between separate protein molecules carriers, separated from one another by energy barriers". Thus EPI assessment provides the state of health from the subatomic level through the delocalized π- electrons[15]

3.6 THE PARAMETERS OF THE EPI

The parameters that have been considered in this study design has been tabulated below. The parameters of the Biowell output is mainly based on the electro-photonic emission pattern. The parameters were tabulated in Table 3.1

S.NO.	PARAMETERS	S.NO.	PARAMETERS
1.	ENERGY	7.	RIGHT AREA
2.	EMOTIONAL PRESSURE	8.	RIGHT ENERGY
3.	FORM COEFFICIENT	9.	LEFT AREA
4.	ENTROPY COEFFICIENT	10.	LEFT ENERGY
5.	LEFT RIGHT SYMMETRY	11.	FRONT AREA
6.	ORGAN BALANCE	12.	FRONT ENERGY

Table 3.1 The Parameters of Gas Discharge Visualisation – EPI Parameters

3.6.1 SECTORS OF THE EPI PATTERNS

The EPI emission patterns were divided into particular sectors. The sectors were divided based on the Diagnostic map. The diagnostic map was first proposed by Dr Peter Mandel in Germany, which was based on the traditional Chinese meridians/ energy channels

These sectors were assessed through various clinical trials in Russia conducted in various medical institutions and it was modified by Dr Korotkov based on the Empirical Data. So, the diagnostic map proposed by Dr Peter Mondal differs from the map defined by Dr Korotkov based on the empirical data[42]. It is illustrated in Figure 3.7.

3.6.2 EPI PALETTE DESCRIPTIONS

The Electro Photonic Emission's original image has been shown in grey scale. A grey colour palette containing 256 shades of grey (from black to white) is used. The coloured palate, the brightest glow points are coloured in blues, the less bright ones are coloured in reds, oranges and violets. All image points removed by the noise filtering algorithm are displayed as white background. The Energy Field program is designed to process EPI and to build a model of the human energy field using the information obtained from 10 EPI of

human fingers. The creation of the energy field is based on a diagnostic map. The Energy Field shows the human energy field as an image around the human contour and represents it in tables and diagrams in numeric form[42].

The picture of the grey palette, coloured palette and the Energy field contours has been shown in the Figure.

Figure.3.6. Illustration of Grey Palette, Coloured Palette and Energy Field respectively.

In the Electro Photonic Emissions, the Intensity of light is measured in relative computer units from 0 to 255. This corresponds to the wavelengths from 480 nm to 800 nm which in turn depends on the CCD camera used in the instrument.

3.6.3 BRIEF EXPLANATION OF THE PARAMETERS[42]

The explanation of each parameter of the Electro Photonic Emissions and their significance has been described in brief.

ENERGY: The Energy of Light in Joules, is calculated for both the whole image and for each sector of the EPI in the palette. E (colour) = E multiplied by 360/a. E= Energy of the sector; a = the width of the sector.

EMOTIONAL PRESSURE: It is correlated to the level of stress. Level of organism involved in the state of stress-adaptation; Balance of activity of sympathetic and parasympathetic nervous systems. The calculations are based on the transformation of the

initial image from the spherical coordinate frame into the Descartes system of one-dimensional curves with Euler equations, according to the brightness and vector equidensities.

FORM COEFFICIENT: It correlates with the multi-circuit control of physiology regulation; The higher FC, the more regulation systems are involved in the process. It is calculated according to the formula: $FC = aL2 /S$, where L is the length of the BIO-gram external contour and S is the BIO-gram area. It is characteristic of the complexity of the contour of the image.

Figure 3.7. The Sectors classified based on Diagnostic Map from Empirical Data.

ENTROPY COEFFICIENT: It is a measure of chaos in the regulation of biological and physiological functions. It is calculated by the ratio of the electro-photonic emission's external contour to the internal contour.

LEFT RIGHT SYMMETRY: The observation of the L-R symmetry with regard to the body's axes is of great significance when analyzing the person's condition. Various sets of organs in our body are symmetric but their functioning condition always differs.

ORGAN BALANCE: Based on the sector classification, each organ emission pattern were correlated and interpreted. The energy and the pattern of each organ are analysed with the comparison of the left and right side emission pattern.

RIGHT AREA: Number of the pixel covered in the right sector of the EPI.

RIGHT ENERGY: Energy in Joules in the right sector of the EPI.

LEFT AREA: Number of pixels covered in the left sector of EPI.

LEFT ENERGY: Energy in Joules in the left sector of the EPI.

FRONT AREA: Number of pixels in the front sector of the EPI.

FRONT ENERGY: Energy in Joules in the front sector of the EPI.

3.7 GDV RESEARCH PAPERS

On searching "PubMed" database with the keyword Electro Photonic Imaging and Gas Discharge Visualization. Totally 22 items were found out of which 18 are related to this electro-photonic imaging, and 03 articles on electron photonic imaging and 02 articles are related to the bio-magnetic field. In the book, "Electro Photonic Analysis in Medicine", totally 161 reference papers were given which includes presentations in the international scientific congress.

3.8 GDV AND HOMOEOPATHY – THE LEAP

Needless to say that homoeopathy medicine acts in subatomic level as it contains no material in the macro scale. Here, the researches conducted and considered as an additional evidence that electronic transmission of energy plays an important role.

3.8.1 GAS DISCHARGE VISUALIZATION OF HOMOEOPATHIC MEDICINES

In 2003, in the journal of alternative and complementary medicine an article on, **"**Gas Discharge Visualization Evaluation of Ultra-molecular doses of Homoeopathic Medicine under Blinded Controlled Condition" was published by IR Bell et al, "this study aimed to determine the feasibility of using gas discharge visualization GDV to differentiate ultra-molecular doses of homoeopathic remedies from solvent control. This study assessed four

split samples each of 30 potencies of three homoeopathic remedies from mineral, plant and animal kingdom and GDV measurements, involving the application of four different voltage levels were performed over 10 successive images on each of 10 drops from each sample"[16]

Figure 3.8. The experimental setup model used by IR Bell Et al. 1. Liquid testing unit; 2. liquid drop; 3.dielectric plate; 4. Electro photonic emission; 5. Electrical impulse generator; 6. Optical system; 7. CCD camera; 8. Video Digitizer; 9. IBMPC; 10. GDV as a whole.

The image parameters were compared and concluded that GDV technology may provide an electromagnetic probe into the properties of homoeopathic remedies as distinguished from the solvent control**.**

3.8.2 MAGNETIC PHOTONIC RESONANCE AND HOMOEOPATHY

Dr Karin Lenger performed an experiment using Tesla coils to produce an electromagnetic field and placing the homoeopathic pellets in near magnetic field. The statement in the research paper states, "Their electromagnetic properties are proved by a newly developed magnetic resonance method using two different Tesla coils which generate longitudinal waves at distinct resonance frequencies in the HF range at low micro Voltages. When laid into the maximum of the magnetic field, homoeopathic high potencies with frequencies being in resonance with those of the coils attenuated the magnetic Held. Therefore, it can be concluded that homoeopathic potencies consist of magnetic photons. For the first time, the degree of each potency could be measured and characterized by its specific

micro voltage input level which separated the photons from their carrier molecule of sugar at their resonance frequency."

In the magnetic photon resonance experiment, they used Tesla coils to produce a magnetic field, the characteristics of the field is produced by high frequency but low voltage but in this experiment, the electromagnetic field will be produced by an electrical impulse having high voltage, high frequency but low current in microampere[37]. In Gas Discharge Visualisation Technique carried out by Dr Iris bell et al used four levels of voltages but in this protocol, the samples are exposed to the stable voltage at the fourth stage- 24kilo volts.

3.8.3 DIAGNOSTIC VALUE OF THE GDV CAMERA

The early diagnostic value of GDV camera has been evaluated then sensitivity and specificity has been considered for diagnosing disease conditions. These are the research papers that show statistically significant conclusions that state the effectiveness of GDV in diagnosis.

- Identifying patients with Colon Neoplasia with Gas Discharge Visualization Techniques
- Effect of mobile phone induced electromagnetic field on brain haemo-dynamics and human stem cell functioning possible mechanism link to cancer risk and early diagnostic values of the electro-photonic imaging[42]

In another article published in the International Journal of biomedical imaging, "Gas Discharge Visualisation an Imaging and Modeling Tool for Medical Biometrics". This article states that "*in the disease condition, electrical activity of human body is changed as compared to electrical activity in health state, the electron communication is altered and therefore the natural electro-photonic emission of the organism is changed.*"[13]

Similarly, in homoeopathic drug proving due to the biomimicry of production of disease symptoms, there are tremendous chances for the altered electron communication which may produce changes in the EPI. And the experiment conducted by Dr Bell et al, in 2003, on gas discharge visualization evaluation of ultramolecular doses of homoeopathic medicine under blinded controlled conditions concluded that GDV technology may provide an electromagnetic probe into the properties of homoeopathic remedies. Therefore, these remedies when administered to a healthy human being may produce variation in the imaging parameters.[16]

3.9 A SEARCH ON BELLADONNA IN RANDOMISED CONTROLLED DRUG PROVING TRIALS

On searching "Pub Med" database with keywords homoeopathic drug proving and homoeopathic pathogenetic trials including only human trials totally 14 articles were published in various journals. Upon belladonna '03' articles were found involving the study design of the randomized double-blind placebo-controlled trial.

3.9.1 RESEARCH IN THE YEAR 1998

"The randomized double-blind placebo-controlled trial of homoeopathic proving of belladonna C30**".** This study aimed at testing the hypothesis that individuals using an infinitesimal dilution of belladonna would record more true symptoms on a questionnaire that contained both true and false belladonna proving symptoms, than those receiving placebo, but they were unable to distinguish between belladonna 30c and placebo using primary outcome mean[17]. 60 volunteers entered the study and 47 completed data collection. The major drawback of this study is it included a limited number of questions. The importance given for physical generals and mental general symptoms were not equally divided, as the homoeopathic drug may produce changes either in mind and/ or body this was not taken into consideration.

3.9.2 RESEARCH IN THE YEAR 2000

"The effect of homoeopathic belladonna 30 CH in healthy volunteers – a randomized double-blind experiment". This study aims at whether the symptoms produced during drug proving were due to specific effects or chance fluctuations. They tested this hypothesis that homoeopathic substance can bring about symptoms different from observation and placebo in a double-blind placebo-controlled crossover design with baseline observation[18]. But after this trial, they concluded that there is no indication that belladonna 30CH produces symptoms different from placebo or from no intervention group. The drawback of this study was the dosage pattern adopted, subjects were instructed to take two globules on Tuesday and Wednesday each that is too small to produce the symptoms in the provers

3.9.3 RESEARCH IN THE YEAR 2003

"Ultra-molecular homoeopathy has no observable clinical effects. A randomized double-blind placebo-controlled proving trial of belladonna".This study assessed the proving of homoeopathy remedy belladonna given at an ultra-molecular dose 30 C, they recruited 253

healthy subjects the study design included study duration as 4 weeks with 1 week run-in period, 2 weeks of treatment intervention and were followed up for 1 week. But the result showed no significant group difference in proving rates were observed and concluded that ultra molecular homoeopathy had no observable clinical effects[19]. In this trial, they used the questionnaire with totally 12 questions in which 5 symptoms were belladonna symptoms and 5 symptoms were not belladonna symptoms and 2 symptoms for internal consistency**.**

Although controversies exist on the action of belladonna in the healthy human provers. This study takes up the challenge to re-evaluate its efficacy in the subatomic, electro-photonic emission properties in the homoeopathic pathogenetic trial in the molecular and ultra-molecular doses using GAS DISCHARGE VISUALISATION TECHNIQUE, along with an assessment of proving symptoms through a questionnaire.

3.9.4 RESEARCH IN THE YEAR 2009

In the year 2009, the research was conducted and published, "Homoeopathic pathogenetic trials produce specific symptoms different from the placebo". This study was a double-blinded, randomized three-armed trial, an experimental pathogenetic study in 25 healthy volunteers who took either one of two homoeopathic remedies, Natrum muriaticum and Arsenicum album in 30CH or identical placebo. This study concluded that homoeopathic pathogenetic trial produces specific symptoms different from the placebo[20]**.**

On reviewing all the literature related to this topic, this study design should fill the gap that exists between the studies that have been conducted by Dr IR Bell et al and Dr Karin Lenger on Electro photonic emissions and Magnetic Photons respectively and its correlation with the human body during Drug Proving trial.

4

Materials and Methods

4.1 Study Setting

This study was conducted in the PG pharmacy lab, THE DEPARTMENT OF HOMEOPATHIC PHARMACY, National Institute of Homoeopathy (N.I.H.), Kolkata, WEST BENGAL, during the period of 2017-2018 on the self-reported apparently healthy volunteers interested in homoeopathic drug proving.

4.2 Selection of Samples

Samples were self-reported apparently healthy volunteers from N.I.H. campus, Undergraduates and Post Graduate Trainees. They were included after General and systemic Physical Examination and Mental Assessment through GHQ-12 questionnaire.

4.3 Inclusion and Exclusion Criteria

4.3.1 Inclusion Criteria:

- Age of the volunteers should be between 18-40 years

- Includes both male and females

- Physically and mentally apparently healthy volunteers are taken after general examination procedures and GHQ-12 [64]

- Volunteers must be 02 months clear of any homoeopathic medicine and no change in health status in last 3 weeks
- Volunteers to be intelligent enough to answers the questionnaire and record carefully the facts, subjective and objective symptoms generated by during drug proving

4.3.2 Exclusion Criteria:

- Volunteers suffering from any acute or chronic diseases
- Volunteers under any kind of medical treatment
- Hysterical and anxious person
- Women during pregnancy, puerperium and while breastfeeding
- A person who undergone surgery in last 02 months
- Participants in another clinical or proving trial during last 06 months
- Volunteers having any cut in fingers and/ or absent fingers
- Volunteers if they had smoked/ taken alcohol on the day of measurement

4.4 Study Design

It was a randomized, double-blinded, placebo-controlled, parallel study of Three armed HOMOEOPATHIC PATHOGENETIC TRIAL. Blinding: The participants, assessor and Principal Investigator were blinded.

ARMS	INTERVENTIONS
Group A	Homoeopathic molecular doses -6C.
Group B	Homoeopathic ultra-molecular doses-200C.
Group C	Control group- placebo i.e. non- medicated pills.

Table 4.4 Three arms of the trial along with the interventions have been tabulated.

This study design includes PRETEST PHASE, INTERVENTION PHASE AND POST TEST PHASE.

Pre-test phase: It included obtaining baseline parameters of EPI and general examination of the subjects physically and with a GHQ-12 questionnaire.

Intervention phase: It includes,

Run in the period- All the subjects were taken placebo for a week and EPI data have been collected (subjects were blinded about the run-in period).

 Drug administration period- In this period homoeopathic medicinal substance in molecular and ultra-molecular doses were taken by the respective group and control group were maintained. EPI data were collected along with the prepared Q-FORM (Questionnaire form containing additional form) on the respective scheduled days.

Antidote period- In this period the antidote for that particular medicine were taken by the volunteers and EPI data and Q- FORM were collected on the scheduled days respectively.

4.4.1 Scheduled Days During Intervention Period

- DAY 1, 2, 3,4 – the particular doses (12 doses) of either drug or placebo were taken orally by the subjects 03 times in a day, (morning, afternoon, evening, night), 30 minutes before food.
- DAY 5 – EPI DATA were collected (one dose is taken before EPI data collection)
- DAY 6, 7 – Self Observation days (S.O. DAYS), where the subjects filled the Q-FORM and wrote the additional physical and mental changes experienced in the additional form.

Post-test phase:

This phase was considered as WASHOUT PERIOD when neither medicine nor placebo was taken. After 07 days EPI data were collected.

4.4.2 Study Design Time Period

Therefore, the time period of this study design from the intervention period excluding consent form collection, physical examination and baseline data collection is- **04 weeks** per person.

- RUN IN PERIOD- 01 WEEK
- DRUG ADMINISTRATION PERIOD- 01WEEK
- ANTIDOTE PERIOD – 01 WEEK.
- POST TEST PHASE – 01 WEEK.

Total protocol took six months to collect data, the first two months were dedicated for creating awareness about the drug proving and study design to collect the samples, started in the month of May 2017. The Trial has been conducted in two batches. The First batch consists of 67 participants, trial conducted from the first week of July 2017 to the first week of August 2017. The second batch consist of 83 members, underwent the trial from the second week of September 2017 to the second week of October 2017. The data extraction was done in the month of November and December 2017. The blinded envelop has been opened on 1st January 2018. The statistical analysis of the Primary outcome has been done in the month of February and March. the scoring of the questionnaire has been done in the month of April and May 2018. The statistical analysis of the Questionnaire has been done in the month of June 2018.

PHASE	GROUP – A	GROUP- B	GROUP-C
RUN IN PHASE	Day 1 to 4- Placebo-non-medicated globules of 30 size will be taken by the subject.	Day 1 to 4- Placebo-non-medicated globules of 30 size will be taken by the subject.	Day 1 to 4- Placebo- non-medicated globules of 30 size will be taken by the subject.
MAIN INTERVENTION PHASE	Day 1 to 4-medicated globules – BELLADONNA-**6C** (12 doses)	Day 1 to 4-medicated globules- BELLADONNA-**200C** (12 doses)	Day 1 to 4- non-medicated globules- PLACEBO (12 doses)
ANTIDOTE PHASE	Day 1 to 4- medicated globules CAMPHOR-**06**(12 Doses) Instructed to take coffee for 03 days	Day 1 to 4- medicated globules CAMPHOR -**200**(12 doses) Instructed to take coffee for 03 days	Day 1 to 4- non-medicated globules- PLACEBO (12 doses)

Table 4.5 Intervention chart including Runin period, Main Intervention Period, Antidote Period. **Note.** [Dosage pattern- 12 doses; 5 globules per dose (03 doses in a day for 04 days)]. The data were collected after 4 days of the dosage of the respective interventions. Q Forms has been collected after data collection of the EPI.

Post Test Phase: Wash out Period: Dose free period, neither medicine nor placebo given. EPI DATA COLLECTED AFTER ONE WEEK.

4.5 Brief of Procedures

At the baseline, written consent form-INFORMED CONSENT FORM- ICF**[29]** were collected from all the subjects included in this study.

All the subjects underwent a general examination of the physical body like Pulse, B.P., checking for Pallor, Clubbing, Jaundiced, Oedema, auscultation of S1 and S2 heart sounds and vesicular breath sound and mental health assessment through GHQ-12 Questionnaire.

The baseline data of the ELECTROPHOTONIC IMAGE was collected as PRETEST DATA.

Pre-test phase was followed by **Intervention phase**, this phase was carried out as scheduled in the intervention chart.

This intervention phase is followed by a **Post-test phase** that was a washout period and after one week EPI data were collected.

The Trial has been conducted in two batches. The First batch consists of 67 participants, trial conducted from the first week of July 2017 to the first week of August 2017. The second batch consist of 83 members, underwent the trial from the second week of September 2017 to the second week of October 2017.

In the month of November and December of 2017, data extraction process from the BIO-WELL software was done. The extracted data has been submitted to the Principal Investigator and the Guide, Prof. Dr Dilip Panakkada, (H.O.D., Dept. of Homoeopathic Pharmacy. The blinded envelope from the Hahnemann Publishing & Co. Pvt. Ltd., has been collected and opened on 1st January 2018 in the presence of two faculties, Prof. Dr Gautam Ash., (H.O.D., Department of Anatomy & Pediatrics) and Dr Gita Sri Pal.,(Reader, Dept. of Homoeopathic Pharmacy). According to the randomisation chart number the data has been classified into three groups A, B and C, representing Belladonna – 6C, Belladonna – 200 C and the Placebo group respectively. The data analysis has been done at two places uses two different statistical software, R – Studio STATISTICAL SOFTWARE has been used by Prof. Dr Judu Ilavarasu, Department of Psychology and Bio-energy, SVYASA University, Bangalore, for the statistical analysis. The results were rechecked using IBM SPSS software version 0.001 (14 days trial version) by the assessor (Dr Banupriya. D) in N.I.H., Kolkata.

5

Observations and Results

5.1 Content Overview

The Observations and Results section has been divided into three categories for portraying the distribution of the data and the results comprehensively.

S.NO	SECTION	CONTENTS
1.	Distribution of the Ungrouped and Grouped Data	1. Age Distribution 2. Gender Distribution 3. Academic Category Distribution
2.	Primary Outcome Measures	1. Direct Analysis 2. Derived Analysis 3. Gender Analysis
3.	Secondary Outcome Measures	1. Analysis of questionnaire form

Table 5.01 Overview of the Presentation

5.2 AGE DISTRIBUTION
5.2.1 AGE DISTRIBUTION OF UNGROUPED DATA

Age distribution of the total samples (i.e.) ungrouped data has been tabulated and represented as a graph.

Age Categories	Number of samples	Percentage (%)
15-19	12	8
20-24	86	57.2
25-29	28	18.6
30-34	22	15
35-39	1	0.6
40-44	1	0.6

Table 5.02 Age Distribution of the Ungrouped Data

**AGE DISTRIBUTION
(UNGROUPED DATA)**

Graph 5.01 Age Distribution of the Ungrouped Data

5.2.2 AGE DISTRIBUTION OF THE GROUPED DATA

Age categories (years)	Group A (%)	Group B (%)	Group C (%)
15-19	8	12	4
20-24	48	62	62
25-29	22	14	20
30-34	18	12	14
35-39	4	0	0
40-44	4	0	0

Table 5.03 Age Distribution of the Grouped Data.

Note. Group A = Belladonna – 6C, Group B = Belladonna – 200C, Group C = Placebo group.

Graph 5.02 Age Distribution of the Grouped Data

5.3 GENDER DISTRIBUTION

GENDER	NO OF SAMPLES
MALE	72
FEMALE	78

Table 5.04 Gender Distribution of Ungrouped Data.

5.3.1 GENDER DISTRIBUTION OF THE GROUPED DATA

Gender	Group A	Group B	Group C
Male	21	27	24
Female	29	23	26

Table 5.05 Gender Distribution of the Grouped Data

Note. Group A = Belladonna – 6C, Group B = Belladonna – 200, Group C = Placebo

GENDER DISTRIBUTION (GROUPED DATA)

■MALE ■FEMALE

	GROUP A	GROUP B	GROUP C
■MALE	21	27	24
■FEMALE	29	23	26

Graph 5.03 Gender Distribution

5.4 ACADEMIC CATEGORY DISTRIBUTION

Academic Batch	Number of Samples	Percentage (%)
PGT - 16	14	9.4
PGT - 17	11	7.3
PGT - 18	14	9.4
PGT - 19	1	0.6
TOTAL	**40**	**26.7**

Table 5.06 Academic Category Distribution of Post Graduate Trainees

Academic Batch	Number of Samples	Percentage (%)
UG - 23	7	4.7
UG - 24	9	6
UG - 25	12	8
UG - 26	27	18
UG - 27	30	20
UG - 28	25	16.6
TOTAL	**110**	**73.3**

Table 5.07 Academic Category Distribution of Under Graduate Trainees

5.5 PRIMARY OUTCOME MEASURES

5.5.1 DIRECT ANALYSIS - BASELINE DATA ANALYSIS

Before entering into the trial the baseline data of the Electro Photonic Image changes were recorded and analysed. Data has been analysed using R statistics.

Parameter	Distribution of Data	Test Statistics	P – value
Emotional Pressure	Skewed Distribution	Kruskal Wallis Test	0.6132
Energy	Skewed Distribution	Kruskal Wallis Test	0.0543
Left Right Symmetry	Skewed Distribution	Kruskal Wallis Test	0.5904
Organ Balance	Skewed Distribution	Kruskal Wallis Test	0.7091
Entropy Coefficient	Skewed Distribution	Kruskal Wallis Test	0.8082
Form Coefficient	Skewed Distribution	Kruskal Wallis Test	0.4981
Left Area	Skewed Distribution	Kruskal Wallis Test	0.3007
Left Energy	Skewed Distribution	Kruskal Wallis Test	0.2071
Front Area	Skewed Distribution	Kruskal Wallis Test	0.2361
Front Energy	Skewed Distribution	Kruskal Wallis Test	0.1714
Right Area	Normal Distribution	One Way ANOVA	0.2984
Right Energy	Normal Distribution	One Way ANOVA	0.1474

Table 5.08 Baseline Parameter Distribution and Outcome Measures

5.5.2 OUTCOME OF DIRECT ANALYSIS

The data of all the parameters given in Table 5.09, showed the skewed distribution in the Normality test. So, Kruskal Wallis test (Non-parametric Test) has been used to analyse these data with the help of IBM SPSS Statistical software and verified with R statistics.

Parameter	EPI 0 – P value	EPI 1 – P value	EPI 2 – P value
Emotional Pressure	0.613	0.157	0.567
Energy	0.054	0.455	**0.023**
Entropy Coefficient	0.808	0.597	0.555
Form Coefficient	0.498	**< 0.001**	**0.041**
Front Area	0.236	0.397	**0.013**
Front Energy	0.221	0.171	**0.011**
Left Area	0.301	0.302	**0.018**
Left Energy	0.207	0.116	**0.015**
Left Right Symmetry	0.590	0.784	0.076
Organ Balance	0.709	0.995	0.440

Table 5.09 Outcome of Direct Analysis

Note. EPI – Electro Photonic Image, EPI 0 = Baseline Data (Pre Data), EPI 1 = Run in period Data (First week), EPI 2 = Intervention Data (Second week).

5.5.3 RIGHT AREA AND RIGHT ENERGY

These two parameters (right area and right energy) were normally distributed, so Repeated measures ANOVA has been used to analyse the data using SPSS software.

Tests of Within-Subjects Contrasts		
Source	RIGHT AREA	Sig.
RIGHTAREA	Linear	.913
	Quadratic	.053
RIGHTAREA * GROUP	Linear	.106
	Quadratic	.366
Error(RIGHTAREA)	Linear	Nil
	Quadratic	Nil

Table 5.10 Right Area (a)

Tests of Between-Subjects Effects					
Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Intercept	1187032928021.4	1	1187032928021.4	11225.144	.000
GROUP	431758937.437	2	215879468.719	2.041	.134
Error	13958693951.141	132	105747681.448	Nil	Nil

Table 5.11 Right Area (b)

Tests of Within-Subjects Contrasts		
Source	RIGHT ENERGY	Sig.
RIGHTENERGY	Linear	.060
	Quadratic	.088
RIGHTENERGY * GROUP	Linear	.255
	Quadratic	.467
Error(RIGHTENERGY)	Linear	Nil
	Quadratic	Nil

Table 5.12 Right Energy (a)

Tests of Between-Subjects Effects					
Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Intercept	158660.589	1	158660.589	4730.712	.000
GROUP	213.736	2	106.868	3.186	.045
Error	4427.071	132	33.538	Nil	Nil

Table 5.13 Right Energy (b)

Right Area and Right Energy show statistically significant difference among the groups.

5.5.4 POST HOC ANALYSIS

The parameters that have shown the statistically significant difference among the groups have been analysed to find out where the actual difference occurred among the three groups. The outcome of the Post Hoc analysis has been represented in the graph and tabulated. The Drug effect of the Parameter Energy, the placebo effect and the Drug effect of the Parameter 'Form coefficient' and the Front Energy hasbeen tabulated in the Table 5.14.

ENERGY - EPI – 2 (DRUG EFFECT)	FORM COEFFICIENT – EPI 1 (PLACEBO EFFECT)

Pairwise Comparisons of GROUP

Each node shows the sample average rank of GROUP.

Sample1-Sample2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj.Sig.
PLACEBO-BELLADONNA-6C	7.467	8.246	.905	.365	1.000
PLACEBO-BELLADONNA-200C	22.267	8.246	2.700	.007	.021
BELLADONNA-6C-BELLADONNA-200C	-14.800	8.246	-1.795	.073	.218

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is .05.
Significance values have been adjusted by the Bonferroni correction for multiple tests.

Pairwise Comparisons of GROUP

Each node shows the sample average rank of GROUP.

Sample1-Sample2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj.Sig.
PLACEBO-BELLADONNA-6C	52.633	8.245	6.383	.000	.000
PLACEBO-BELLADONNA-200C	54.067	8.245	6.557	.000	.000
BELLADONNA-6C-BELLADONNA-200C	-1.433	8.245	-.174	.862	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is .05.
Significance values have been adjusted by the Bonferroni correction for multiple tests.

FORM COEFFICIENT – EPI – 2 (DRUG EFFECT)	FRONT AREA - EPI – 2 (DRUG EFFECT)

Pairwise Comparisons of GROUP

Each node shows the sample average rank of GROUP.

Sample1-Sample2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj.Sig.
BELLADONNA-200C-BELLADONNA-6C	16.722	8.245	2.028	.043	.128
BELLADONNA-200C-PLACEBO	-19.078	8.245	-2.314	.021	.062
BELLADONNA-6C-PLACEBO	-2.356	8.245	-.286	.775	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is .05.
Significance values have been adjusted by the Bonferroni correction for multiple tests.

Pairwise Comparisons of GROUP

Each node shows the sample average rank of GROUP.

Sample1-Sample2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj.Sig.
PLACEBO-BELLADONNA-6C	9.933	8.246	1.205	.228	.685
PLACEBO-BELLADONNA-200C	24.200	8.246	2.935	.003	.010
BELLADONNA-6C-BELLADONNA-200C	-14.267	8.246	-1.730	.084	.251

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is .05.
Significance values have been adjusted by the Bonferroni correction for multiple tests.

POST HOC OF FRONT ENERGY					
Sample1-sample2	Test statistics	Std. Error	Std. Test Statistics	Sig.	Adj. Sig.
BELLADONNA200C-BELLADONNA6C	12.156	8.246	1.474	.140	.421
BELLADONNA200C-PLACEBO	24.678	8.246	2.993	.003	.008
BELLADONNA6C-PLACEBO	-12.522	8.246	-1.519	.129	.387

Table 5.14 Results of Post Hoc Analysis (a)

LEFT AREA – EPI 2 (DRUG EFFECT)	LEFT ENERGY - EPI 2 (DRUG EFFECT)
RIGHT AREA – EPI 2 (DRUG EFFECT)	RIGHT ENERGY – EPI 2 (DRUG EFFECT)

Table 5.15 Results of Post Hoc Analysis (b)

The Post Hoc Test for RIGHT AREA – EPI – 2 shows the significant difference exists between the placebo group and Belladonna – 200 group P-value = 0.049. The Post Hoc Test for RIGHT ENERGY – EPI – 2 shows the significant difference exists between the placebo group and Belladonna – 200 group, the P-value = 0.013.

5.5.5 DERIVED ANALYSIS

In the Derived Analysis, the actual difference among the EPI 0, EPI 1, EPI 2 were obtained to analyse the Placebo effect (x), Drug effect(y) and Difference between the Placebo and Drug effect(z). The parameter Form Coefficient showed a significant difference in all the three effects. Placebo Effect, P value <0.001, the Drug Effect, P value = 0.027, the difference between the placebo and drug effect, P value < 0.001. The analysis has been done using IBM SPSS statistical software. The graphical representation of the derived analysis has been shown in the Table 5.16.

PLACEBO EFFECT	DRUG EFFECT

DIFFERENCE BETWEEN PLACEBO AND DRUG EFFECT

Table 5.16 Results of Placebo Effect, Drug Effect and Difference between the Effects

5.5.6 GENDER ANALYSIS OBSERVATION AND RESULTS

In Gender Analysis the Male group has a significant difference in the parameter Form Coefficient during the Run in period EPI - 1, P value <0.001. The Female group gave the statistically significant difference in the Parameter Form Coefficient during Run-In Period EPI – 1, the P-value < 0.001. During the Intervention Period (EPI – 2) eight parameters gave statistically significant difference among the groups. The Parameters along with the significant values has been shown in Table 5.17.

PARAMETERS	P-VALUE (EPI – 2)
FRONT AREA	0.001
FRONT ENERGY	0.003
LEFT AREA	0.006
LEFT ENERGY	0.005
RIGHT AREA	0.002
RIGHT ENERGY	0.003
LEFT RIGHT SYMMETRY	0.045
ORGAN BALANCE	0.012

Table 5. 17 Statistically Significant Parameters - Female Group - Result

Thus, the drug Belladonna during HTP influenced the Female group more than the Male Group. For the Gender analysis, the data has been grouped separately as Male and Female and each of the Dataset has been analysed by the statistical test (Kruskal Wallis / One Way ANOVA) based on the normality of the Distribution.

5.6 SECONDARY OUTCOME MEASURE - QUESTIONNAIRE ANALYSIS

5.6.1 Q FORM – 1 ANALYSIS

The Q – FORM – 1 constitutional questionnaire, analysed by repertorising peculiar symptoms. The percentage of belladonna symptoms in the constitution of each individual has been analysed from Q Form and it is found to be similar among the group.

5.6.2 Q FORM – 2 ANALYSIS

The Q- FORM - 2 has been measured in Likert scale with 30 items and the scoring system of the Questionnaire Form – 02 has been tabulated.

SYMPTOM SEVERITY	SCORES
NOT AT ALL	0
A LITTLE	1
MODERATE	2
RATHER MUCH	3
VERY STRONG	4

Table 5. 18 Scoring System

Maximum score – 120; Minimum score – 0

The sample size of the questionnaire in each group was not equal.

Group A = 29, Group B = 35, Group C = 34. The parameters and the statistical results have been tabulated.

The statistical analysis has been done by IBM SPSS software, the tabulation of the statistical output and the graphical representations has been given in the Table 5.19 & Table 5.20.

TOTAL SCORE (T)						TOTAL SCORE (G)

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	447.648[a]	2	223.824	3.779	.026
Intercept	6074.234	1	6074.234	102.553	.000
GROUP	447.648	2	223.824	3.779	.026

Estimated Marginal Means of SCORE

NO. OF BELLADONNA SYMPTOMS (T)						NO. OF BELLADONNA SYMPTOMS (G)

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	42.528[a]	2	21.264	4.073	.020
Intercept	614.647	1	614.647	117.741	.000
GROUP	42.528	2	21.264	4.073	.020

Estimated Marginal Means of BELL SYMPTOMS

TOTAL MARKED SYMPTOMS (T)						TOTAL MARKED SYMPTOMS (G)

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	116.068[a]	2	58.034	4.011	.021
Intercept	1430.227	1	1430.227	98.857	.000
GROUP	116.068	2	58.034	4.011	.021

Estimated Marginal Means of MARKED SYMPTOMS

Table 5.19 Results of the Analysis of Q Form – 02 (a)

NO. OF ADDITIONAL SYMPTOMS (T)						NO. OF ADDITIONAL SYMPTOMS

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	2.773[a]	2	1.387	.420	.659
Intercept	263.046	1	263.046	79.584	.000
GROUP	2.773	2	1.387	.420	.659

GRAND TOTAL SYMPTOMS (T)						GRAND TOTAL SYMPTOMS(G)

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	149.126[a]	2	74.563	4.083	.020
Intercept	2843.476	1	2843.476	155.716	.000
GROUP	149.126	2	74.563	4.083	.020

Table 5.20 Results of the Analysis of Q Form – 02 (b)

5.6.3 Q FORM – 3 ANALYSIS

The Q FORM – 03 did not show any significant difference among the group. There is no adverse effect or the persistence of belladonna symptoms after the antidote period.

The Q Form – 02 has been analysed using IBM SPSS statistical software and the test statistics was One Way ANOVA as all the data were normally distributed.

6
Discussion

6.0 DISCUSSION

This exploratory study on Electro Photonic Image changes in the Homoeopathic Pathogenetic Trial has been designed to address the problem of having an Objective Scientific Data (EPI) apart from the Subjective Data (symptoms experienced by the prover) during Homoeopathic Drug Proving. This study was an attempt to differentiate between the effect of the placebo and the effect of Homoeopathic medicines on the healthy human beings that ultimately gave statistically significant results in both the aspects of objective data and subjective data analysis.

This study population included self-reported apparently healthy volunteers of undergraduate students and postgraduate trainees from the National Institute of Homoeopathy. They have been included in the trial after checking the physical and mental health status by general physical and systemic examination and GHQ -12 questionnaire. The total sample size was 150 initially, the dropouts from the trial were 15. The Final sample size for analysing the primary outcome measures were 135. In the present trial, the age group inclusion criteria were between 18 to 40 years. Out of 150 participants, 57.2% of the participants belong to the age category of 20 – 24 years, 18% of the participants belong to 25 – 29 years of age. It was observed that the gender distribution among the group were Male = 72 and Female = 78. In the study population, 73% belong to an undergraduate category and 27% belong to the postgraduate category.

In this study, the analysis of the Electro photonic Image changes was considered as the Primary outcome and the analysis of the subjective symptoms recorded in the questionnaires was considered as a Secondary outcome.

6.1 CRITICAL ANALYSIS OF THE MAJOR FINDINGS

Primary outcome measures: Three-way analysis approach has been adopted to find out the actual significance of the primary outcome parameters. *First approach*: Direct analysis

involves analysing the values of the parameters recorded. At the Baseline, the data collected before entering into the trial (EPI-0) do no show any significant difference in any of the parameters among the three groups, the P-value >0.05 in all the parameters. During the Run-in period (EPI-1), only one parameter "Form Coefficient" gave the statistically significant difference among the groups. The post hoc analysis revealed the significant difference exists between the placebo group and Belladonna – 6C group (P-value<0.001); the placebo group and Belladonna – 200 C group (P-value<0.001).

The main intervention period (EPI-2) analysis revealed that there exists a statistically significant difference among the groups in eight out of twelve parameters. Energy (P-value=0.023); Form Coefficient (P-value=0.041); Front Area (P-value=0.013); Front Energy (P-value=0.011); Left Area (P-value=0.018); Left Energy (P-value=0.015); Right Area (P-value<0.001); Right Energy (P-value<0.001). The post hoc analysis revealed that the significant difference exists between the placebo group and the Belladonna – 200C group. It also confirmed that there is no statistically significant difference in the EPI parameters, exist between the Placebo group and Belladonna – 6C group.

Thus from the Direct analysis, it is evident that Electro Photonic Image parameters of the placebo group and the Belladonna – 6C (Molecular doses) group are similar but the Electro Photonic Image parameters of the Belladonna – 200C (Ultra Molecular doses) group is significantly different from that of the Placebo group.

Second approach: In the Derived Analysis approach, the Placebo effect and the Drug effect has been derived from the existing values of the parameters. To find the Placebo effect (x) the Baseline parameter values have been subtracted from the Run-in period parameter values. X = EPI 1 – EPI 0. To find the Drug effect (y) the Baseline parameter values have been subtracted from the main Intervention parameter values. Y = EPI 2 – EPI 0. To find the difference between the Placebo effect and the Drug effect (z), the Run-in period parameter values have been subtracted from the main Intervention parameter values. Z = EPI 2- EPI 1. The derived analysis showed highly significant difference exists among the group in only one parameter that is "Form Coefficient". The form coefficient parameter showed the statistically significant difference in Placebo Effect (P-value <0.001), Drug Effect (P-value = 0.027) and the difference between the placebo effect and the drug effect (P-value<0.001).

Thus the derived analysis signifies that Form coefficient is a sensitive parameter to assess the placebo effect. It also signifies that there exists a difference between the placebo effect and the drug effect.

Third approach: The Gender Analysis has been done to find out the predominance of action of the Homoeopathic medicine through the EPI parameters. The Male data analysis results gave the statistically significant difference in only one parameter "Form Coefficient" during Run-in period (P-value <0.001), no other parameters showed any difference among the groups during the main Intervention period.

The data of the Female participants showed the statistically significant difference in one parameter "Form Coefficient" during the Run-in period. During the main Intervention Period (EPI-2) statistically significant difference exists in eight out of twelve parameters. Front Area (P-value=0.001), Front Energy (P-value=0.003), Left Area (P-value=0.006), Left Energy (P-value=0.005), Right Area (P-value=0.002), Right Energy (P-value=0.003), Left Right Symmetry (P-value=0.045), Organ Balance (P-value = 0.012)

When comparing the Gender analysis with Direct and Derived analysis, it clearly denotes that the changes in the EPI has been contributed solely by the Female participants and the Form Coefficient parameter showed significant difference in the Male and Female participants among the group during the Run-in Period, it confirms that the effect of placebo represented by the Form Coefficient parameter. In addition to the parameter in the direct analysis, two new parameters showed a significant difference in the female participants among the groups, they are "Left-Right Symmetry" and "Organ Balance".

6.2 CRITICAL ANALYSIS OF THE ADDITIONAL FINDINGS

Secondary outcome measures: Q Form-1: It is the constitutional questionnaire form, that facilitates the participants to introspect more on their own individuality thereby it helps to find the changes produced by the drug in their individuality during the intervention period. The characteristic individualising symptoms were converted into rubrics and repertorised using synthesis repertory with the help of the RADAR 10 software. The percentage of belladonna symptoms in their constitution has been determined by the calculation, No. of Rubrics covered by Belladonna divided by the Total No. of Rubrics that is multiplied by hundred to get the percentage measure. The percentage of Belladonna in the constitution among the groups do not show any significant difference.

Q Form-2: It is a 30 item questionnaire consisting of 50% of Belladonna symptoms and 50% of Non -Belladonna symptoms in Likert scoring scale (0,1,2,3). The outcome parameters showed a significant difference among the group.

Score: the score is calculated by adding all the scores based on the intensity of the symptoms marked by the participants. The statistical analysis showed a significant difference exists among the groups, P-value = 0.026.

Total Number of Belladonna Symptoms: This is calculated by adding the number of Belladonna symptoms marked in each questionnaire. The statistical analysis showed a significant difference among the groups P-value=0.020.

Total Number of Marked symptoms: This is calculated by including both the Belladonna and Non-Belladonna symptoms marked by the participants. The statistical analysis showed a significant difference among the groups P-value = 0.021,

Total Number of Additional Symptoms: This is calculated by counting the number of additional symptoms written by the participants. The statistical analysis did not show any

significant difference among the group P-value = 0.659, because participants in the placebo group also given their own constitutional symptoms in the additional symptoms column.

Grand Total of all the symptoms: This is calculated by adding the total marked symptoms and additional symptom irrespective of the remedy. The statistical analysis showed statistically significant difference among the groups P-value = 0.020.

The Post hoc analysis revealed that Belladonna – 6C group produced a more significant number of scores and symptoms than Belladonna – 200C group and Placebo group. Belladonna – 200c group produces more symptoms when compared to the Placebo group. So the trend may be represented as Belladonna – 6C group > Belladonna – 200 C group > Placebo group. Test statistics applied was One-way ANOVA as all the parameters were normally distributed. IBM SPSS statistical software tool was used for analysis.

Q Form 3: This questionnaire is a descriptive form to identify any adverse symptoms after antidoting the medicine. There were no such significant symptoms retained after antidoting the medicine.

6.3 BASIC STRUCTURE AND THE LIMITATIONS OF THE STUDY

This study was designed in such a way to find the difference between the placebo effect and the Homoeopathic medicine effect in molecular and ultra-molecular doses. So, it may not be considered as a complete standardised drug proving. The protocol was designed to find the placebo effect or the ability of the human mind to produce the imaginary symptoms that were actually their own constitutional individuality during the Run-in period.

The study population included the students from undergraduates and postgraduates, it has been conducted in two batches. The First batch consists of 67 participants, trial conducted from the first week of July 2017 to the first week of August 2017. The second batch consist of 83 members, underwent the trial from the second week of September 2017 to the second week of October 2017.

In the month of November and December of 2017, data extraction process from the BIO-WELL software was done. The extracted data has been submitted to the Principal Investigator and the Guide, Prof. Dr Dilip Panakkada, (H.O.D., Dept. of Homoeopathic Pharmacy. The blinded envelope from the Hahnemann Publishing & Co. Pvt. Ltd., has been collected and opened on 1st January 2018 in the presence of two faculties, Prof. Dr Gautam Ash., (H.O.D., Department of Anatomy & Pediatrics) and Dr Gita Sri Pal.,(Reader, Dept. of Homoeopathic Pharmacy). According to the randomisation chart number the data has been classified into three groups A, B and C, representing Belladonna – 6C, Belladonna – 200 C and the Placebo group respectively.

The trial has been conducted for 3 weeks, each week consist of 12 doses of medicine intake. The participants were provided with a phial containing the doses of the respective medicines or the placebo at the beginning of each week and the phial was collected at the end of the

fourth day of the week. The actual drawback was there is no solid evidence apart from the verbal report of the participants regarding the regularity of the dosage intake. Having an adequate manpower to supervise the dosage intake would have made this trial more bias-free. But to overcome this bias to a certain extent, the participants were instructed to take the dosage during the EPI data recording. All the EPI data were collected when the globules were still present on the tongue of the participants.

In this protocol, dietary restrictions have not been insisted because a slight change in the diet regimen may naturally lead to physiological change that may influence the Electro Photonic Emission pattern. The participants were instructed to carry out the day to day work in the normal fashion, no lifestyle regulations have been advised apart from the restriction of alcohol drinking and cigarette smoking on the day of the data recording.

6.4 FUTURE DIRECTIONS FOR THE IMPROVEMENT OF THE STUDY DESIGN

Future studies should be carried out with strict dietary and lifestyle regimen involving the participants to be dedicated only to the drug proving during the trial period, devoid of all the other responsibility. During the trial period, the sole responsibility and the work of the participants should be self-observation and recording of symptoms each day along with the intensity of the symptoms.

The symptoms experienced by the participants should be described verbally each day and the descriptions should be video recorded to observe the gesture, tone of the voice and facial expression changes during the trial period. Along with this rigorous proceedings the Electro Photonic Emission patterns should be recorded at least thrice a day during the trial period.

This collective pattern of Electro Photonic Emissions may serve as a Big Data to derive the actual signature of the Electro Photonic Emissions that characterise the particular homoeopathic medicine thereby providing a solid objective scientific data in near future that may allay the propaganda of Homoeopathy as a Pseudoscience

7

Conclusion

<div style="background:#9fc5e8">CONCLUSION</div>

Homoeopathy works on the principle of Similia that the ability of the drug to alleviate the disturbance in the diseased depends on the ability of the drug to produce the similar disturbance in the healthy beings. As Homoeopathy is based on "Individualisation", the clinical trial protocols based on nosological terms and specific nosological prescriptions fail to give statistically significant result during the meta-analysis, which can prove the scientific efficacy of Homoeopathy that is actually difficult to be denied by the people those who got cured by it and those who treated them. Rather focusing on the disease curing ability of the Homoeopathic medicines, this study focused on the disease-producing ability of the Homoeopathic medicines in the molecular and ultra-molecular doses under the blinded controlled conditions.

The primary outcome measures showed the statistically significant difference between the Belladonna – 200C and the Control group, but it did not indicate any significant difference between the Belladonna – 6C and the Control group; Belladonna – 200C and the Belladonna – 6C. The secondary outcome measures, the questionnaire analysis revealed that the Belladonna – 6C group produced more symptoms than Belladonna – 200C. The Belladonna – 200C group produced more symptoms than the Control group. Though rigorous Homoeopathic Pathogenetic Trial with different medicines and the reproducibility of the same results matters significantly, we may conclude momentarily that the Electro Photonic Image parameters may identify and differentiate the effect of placebo from the effect of Ultra-molecular potencies of Belladonna through this Homoeopathic Pathogenetic Trial protocol design. This study leads to a roundabout way where Photonics and Homoeopathy meets. In 2003, Dr Iris Bell et all conducted an experiment with Homoeopathic dilutions and concluded that Electro Photonic Emission Pattern may serve as an electromagnetic probe in the identification of Homoeopathic medicines. In 2011 and in 2017, Dr Karin Lenger conducted an experiment with Homoeopathic medicated globules and concluded that Magnetic Photons are responsible for the action of Homoeopathic medicines on the Human being. Thus this study bridges the gap between the laboratory results and the Homoeopathic Pathogenetic trial that supports the concept of Photons in Homeopathy. The most often encountered question in the field of Homoeopathy was, " What is that in Homoeopathy medicines (beyond Avogadro Number) that bring about changes in the Human body?", the answer would be "PHOTONS" if the results could be reproduced in near future.

<div align="right">

8

Summary

</div>

The study design of Homoeopathic Pathogenetic trial is a three-armed, placebo-controlled, triple-blinded trial of sample size 150 with 15 dropouts. The final sample size of the primary outcome analysis was 135 (45 in each group). The three arms were Belladonna – 6C, Belladonna – 200C, the Placebo group.

The Electro Photonic Image Parameters were the Primary outcome measures. The questionnaire data collected during the Intervention period were the Secondary outcome measures. It is a four-week protocol, started with the collection of Informed consent sheet followed by a Physical and Mental assessment of the participants to include in the trial. The baseline data were collected before starting the trial. The first week of the trial was the Run in the period followed by Main Intervention Period and Antidote Period. The final week of the trial was the Washout period. The data of the Electro Photonic Emissions from ten fingers of the participants were collected each week at the end of the dosage schedule. Participants were instructed to take one dose of the respective intervention substance during EPI data collection. The questionnaire forms were collected at the end of each week.

After completion of the data collection and the Data extraction, the blinding envelope has been opened and the data were classified accordingly and the analysis was done. The primary outcome parameters were Emotional Pressure, Energy, Form coefficient, Entropy Coefficient, Organ Balance, Left Right Symmetry, Front Area, Front Energy, Left Area, Left Energy, Right Area, Right Energy, totally 12 parameters.

Three-way analysis has been done, first is the Direct analysis, it showed no difference among the group before entering the trial, the statistically significant difference in the parameter Form Coefficient (P value<0.001) during Run in the period and the statistically significant difference in 8 out of 12 parameters during the Intervention Period. The eight parameters were, Energy (P-value=0.023); Form Coefficient (P-value=0.041); Front Area (P-value=0.013); Front Energy (P-value=0.011); Left Area (P-value=0.018); Left Energy (P-value=0.015); Right Area (P-value<0.001); Right Energy (P-value<0.001). The Right Area and the Right energy parameter gave highly significant difference among the group. The post hoc analysis revealed that the significant difference exists between the placebo group and the Belladonna – 200C group. It also confirmed that there is no statistically significant difference in the EPI parameters, exist between the Placebo group and Belladonna – 6C group.

 From the Derived analysis, the form coefficient parameter showed the statistically significant difference in Placebo Effect (P-value <0.001), Drug Effect (P-value = 0.027) and the difference between the placebo effect and the drug effect (P-value<0.001).

 Gender Analysis revealed that the data of the Female participants showed the statistically significant difference in one parameter "Form Coefficient" during the Run-in period. During the main Intervention Period (EPI-2) statistically significant difference exists in eight out of twelve parameters. Front Area (P-value=0.001), Front Energy (P-value=0.003), Left Area (P-value=0.006), Left Energy (P-value=0.005), Right Area (P-value=0.002), Right Energy (P-value=0.003), Left Right Symmetry (P-value=0.045), Organ Balance (P-value = 0.012), whereas Male participant showed difference only in the Form coefficient parameter.

The secondary outcome measure parameters from the questionnaires were the score, the total number of Belladonna symptoms, the total number of additional symptoms, the total number of marked symptoms and the Grand total symptoms. Out of this five parameter, four parameters gave statistically significant difference among the group. Score (P-value = 0.026), the total no.of Belladonna symptoms (P-value = 0.020), total no. of marked symptoms (P-value = 0.021), the Grand total of all the symptoms (P-value = 0.020).

The Post hoc analysis revealed that Belladonna – 6C group produced a more significant number of scores and symptoms than Belladonna – 200C group and Placebo group. Belladonna – 200c group produces more symptoms when compared to the Placebo group. So the trend may be represented as Belladonna – 6C group > Belladonna – 200 C group > Placebo group.

Thus we can conclude the Electro photonic image parameters serves as an objective data to find the difference between the placebo and the Belladonna group (molecular and ultramolecular doses). The post hoc revealed that the Right Area and Right Energy has a highly significant difference among the group. The gender analysis revealed that Female participants influenced the results more than the male participants. These results hereby confirmes the right-sided affinity and the female predominance effect of the Belladonna in the ultramolecular doses. The primary outcomes were well supported by the results of the questionnaire analysis.

<div align="right">

9

</div>

References/ Bibliography

1. Hahnemann S. Organon of medicine. 6th ed. Delhi: B Jain Publishers Pvt Ltd; 2005. Translated by William Boericke

2. Hahnemann S. Organon of Medicine. 5th ed. New Delhi: B. Jain Publishers (P) Ltd; 2015. Translated from the Fifth edition with an appendix by Dudgeon, RE, M.D., with additions and alternations as per Sixth edition translated by Boerick, W, M.D. and Introduction by Krauss, J, M.D.

3. Rubik B, Muehsam D, Hammerschlag R, Jain S. Biofield Science and Healing: History, Terminology, and Concepts. Global Advances in Health and Medicine. 2015;4(suppl):8–14.

4. What Was Vital Force Theory? [Internet]. Reference. IAC Publishing; [cited 2018Jul4]. Available from: https://www.reference.com/science/vital-force-theory-ee6df0a05a344639

5. Kushwah KK, Srinivasan TM, Nagendra HR, Ilavarasu JV, Development of normative data of electro-photonic imaging technique for a healthy population in India: A normative study, International Journal of Yoga. 2016Jun;9:49–56.

6. Korotkov K, Yakovlev E. ELECTROPHOTONIC ANALYSIS IN MEDICINE - GDV BIO ELECTROGRAPHY RESEARCH. Createspace Independent Publishers; 2013. ISBN: 978-1481932981

7. Boger CM. Studies in the philosophy of healing and other writing including the study in the materia medica and taking the case. Delhi: B. Jain Publishers; 2003.

8. Close S. The Genius of Homoeopathy- lectures and essays on homoeopathic philosophy-, M.D. B. Jain Publishers (P) Ltd.; 2008.

9. Kent JT. Lectures on Homoeopathic Philosophy. New Delhi: B. Jain Publishers (P) Ltd.; 2008.

10. Yakovleva EG, Buntseva OA, Belonosov SS, Fedorov ED, Korotkov K, Zarubina TV. Identifying Patients with Colon Neoplasias with Gas Discharge Visualization Technique. J Altern Complement Med. 215ADNov;21(11). doi: 10.1089/acm.2014.0168. Epub 2015 Aug. PMID: 26302046

11. Korotkov K, Shelkov O, Shevtsov A, Mohov D, Paoletti S, Mirosnichenko D, Labkovskaya E, Robertson L Stress reduction with osteopathy assessed with GDV electrophotonic imaging: effects of osteopathy treatment. *Journal of Alternative Complement Medicine* .2012Mar;18(3):251–7.

12. Drozdovski A, Gromova I, Korotkov K, Shelkov O, Akinnagbe F. Express-evaluation of the psycho-physiological condition of Paralympic athletes. *Journal of Sports Medicine*. 2012 Dec 5;3:215-22. doi: 10.2147/OAJSM.S35888. collection 2012. PMID:24198605

13. Kostyuk N, Cole P, Meghanathan N, Isokpehi RD, Cohly HH.
Gas discharge visualization: an imaging and modelling tool for medical biometrics. *International Journal of Biomedical Imaging.* 2011;2011:196460. doi: 10.1155/2011/196460. Epub 2011 May 19.PMID:21747817

14. Kostyuk N, Rajnarayanan RV, Isokpehi RD, Cohly HH. Int J Environ Res Public Health. 2010 May;7(5):1984-95. doi: 10.3390/ijerph7051984. Epub 2010 Apr 28. PMID:20623006

15. Korotkov KG, Matravers P, Orlov DV, Williams BO. Application of electrophoton capture (EPC) analysis based on gas discharge visualization (GDV) technique in medicine: a systematic review. of Alternative Complement Medicine. 2010 Jan;16(1):13-25. doi: 10.1089/acm.2008.0285. Review. PMID: 19954330

16. Bell IR, Lewis DA 2nd, Brooks AJ, Lewis SE, Schwartz GE. Gas discharge visualization evaluation of ultramolecular doses of homoeopathic medicines under blinded, controlled conditions. Journal of Alternative Complement Medicine. 2003 Feb;9(1):25-38. PMID: 12676033

17. Kathryn Goodyear George Lewith DM MRCP1 J Lorraine Low PhD Randomized double-blind placebo-controlled trial of homoeopathic 'proving' for Belladonna C30. *Journal of Royal Society of Medicine* 1998;91:579-582

18. Harald Walacha, Horst KoÈsterb, Thomas Hennigb, Gunther Haag. The effects of homoeopathic belladonna 30CH in healthy volunteers-a randomized, double-blind experiment, *Journal of psychosomatic research* 50 (2001) 155-160

19. Brien S, Lewith G, Bryant T, Ultra Molecular Homoeopathy has no observable clinical effects. A randomised double-blind placebo-controlled proving trial of Belladonna 30C. *British Journal of Clinical Pharmacology*. 56,562-568, doi:10.1046/j.1365-2125.2003.01900.x

20. Möllingera H, Schneider R, Walach H, Homeopathic Pathogenetic Trials Produce Specific Symptoms Different from Placebo*., Forsch Komplementmed* 2009;16:105–110 Published online: April 9, 2009, DOI: 10.1159/000209386

21. Hahnemann S. BELLADONNA [Internet]. Homoeopathy. 2016 [cited 2016Sep4]. Available from: https://hpathy.com/e-books/materia-medica-pura-samuel-hahnemann/belladonna/

22. Bhargav H, Srinivasan TM, varambally S, Gangadhar BN, Koka P. Effect of mobile phone induced electromagnetic field on brain haemo-dynamics and human stem cell functioning.. possible mechanism link to cancer risk and early diagnostic values of electrophotonic imaging. Journal of Stem cells, 2015; 10(4) 287.94. doi.jsc 2015.10.4.287.

23. Babu GN. COMPREHENSIVE STUDY OF ORGANON- An attempt to understand the Organon of Medicine as a scientific treatise.. 1st ed. New Delhi: B. Jain Publishers (P) Ltd; 2009. ISBN: 978-81-319-0767-2.

24. Homoeopathic Case-Record Form (HCRF) [Internet]. The Other Song. [cited 2016Jul4]. Available from: http://theothersong.com/clinic/patient-care/homoeopathic-case-record-form-hcrf/

25. Informed Consent Form Templates. World Health Organization. World Health Organization;2011.
Available from: http://www.who.int/rpc/research_ethics/informed_consent/en/

26. Robert T. Mathie, Nitish Ramparsad, Lynn A. Legg, Jürgen Clausen, Sian Moss, Jonathan R. T. Davidson, Claudia-Martina Messow, and Alex McConnachie. Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis. *Systematic Rev*iew. 2017; 6: 63. Published online 2017 Mar 24. doi: 10.1186/s13643-017-0445-3

27. Mathie RT, Lloyd SM, Legg LA, Clausen J, Moss S, Davidson JR, Ford I. Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. *Systematic Review*. 2014 Dec 6;3:142. doi: 10.1186/2046-4053-3-142.

28. Linde, K, Clausius, N, Ramirez, G et al. Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. *Lancet*. 1997; 350: 834–843

29. Irwin T. Aristotle's First Principles. Clarendon Press; Revised edition.May 31, 1990;

30. rcodeprogramming@gmail.com. What is R ? [Internet]. R Statistics.Net - Main. 2015 [cited 2018Jul4]. Available from: http://rstatistics.net/what-is-r/

31. Analytics [Internet]. IBM Cognitive advantage reports. IBM Corporation; [cited 2018Jul4]. Available from: https://www.ibm.com/analytics/spss-trials

32. *HOMOEOPATHIC PHARMACOPOEIA OF INDIA* (FIRST ed., Vol. FIRST). (1971). doi:http://ccrhindia.nic.in//admnis/admin/showimg.aspx?ID=12536

33. BEISER, A. (2017). *FUNDAMENTALS OF PHYSICS WITH APPLICATION* (5TH ed.). Chennai, Tamilnadu: McGraw Hill Education (India) Private Limited.

34. VERMA, H. C. (1992). *CONCEPTS OF PHYSICS* (1st ed. Vol. 1). NEW DELHI: BHARATHI BAWAN

35. R. M., & SIVAPRASATH, K. (2015). *MODERN PHYSICS* (15th ed.). NEW DELHI: S CHAND &COMPANY PVT. LTD.

36. Quantum Processes. Retrieved January 31, 2018, from http://hyperphysics.phy-astr.gsu.edu/hbase/mod5.html

37. Karin, L. (2017). Homeopathy—A Regulation Therapy Healing Hypo- or Hyper-functions of Pathological Pathways by Magnetic Photons according to the Resonance Principle. *Journal of Life Sciences, 11*(2). doi:10.17265/1934-7391/2017.02.001

38. Lenger, K., Bajpai, R., & Drexel, M. (2008). Delayed luminescence of high homeopathic potencies on sugar globuli. *Homeopathy, 97*(3), 134-140. doi:10.1016/j.homp.2008.05.003

39. Bell, I. R., Lewis, D. A., Brooks, A. J., Lewis, S. E., & Schwartz, G. E. (2003). Gas Discharge Visualization Evaluation of Ultramolecular Doses of Homeopathic Medicines Under Blinded, Controlled Conditions. *The Journal of Alternative and Complementary Medicine, 9*(1), 25-38. doi:10.1089/107555303321222928

40. Korotkov, K. G., & Korotkin, D. A. (2001). Concentration dependence of gas discharge around drops of inorganic electrolytes. *Journal of Applied Physics, 89*(9), 4732-4736. doi:10.1063/1.1360700

41. Lenger, K. (2006). Homeopathy-an energetic medicine. Subtle Energies & Energy Medicine, 2006. *Subtle Energies & Energy Medicine,* (15), no. 3:225-243.

42. KOROTKOV, K. (2014). *ENERGY FIELDS ELECTROPHOTONIC ANALYSIS IN HUMANS AND NATURE.* Retrieved from http://ww.bio-well.eu/assets/files/papers/GDV%20in%20Medicine.pdf

43. Popp, FA. Properties of Biophotons and their theoretical applications. *Indian Journal of Experimental Biology*,41, May 2003, pp- 391-402.

44. Magnetci.com Logo [Internet]. Logos download. 2016 [cited 2018Jul1]. Available from: http://logosolusa.com/magnetci-com-logo.html.

45. Seg [Internet]. EnviEstudos.[cited2018Jul1]. Available from http://www.enviestudos.com/certificacao-breeam/seg-4/.

46. Vijaya. What does Valence Electron mean? [Internet]. TutorVista Blog. 2016 [cited 2018Jul1]. Available from: https://blog.tutorvista.com/2016/08/valence-electron-mean/

47. V Bundzen, P & Korotkov, Konstantin & K Korotkova, A & Mukhin, Valery & Priyatkin, N. (2005). Психофизиологические корреляты успешности соревновательной деятельности спортсменов олимпийского резерва [Psychophysiological correlates of the success in the competitive activity in athletes of the Olympics reserve] in Russian. Fiziologiia cheloveka. 31. 84-92.

48. Bio-Well GDV Camera 1.0 & 2.0 and Software Manual Ver. 05-2018, pg- 3-5. Availablefrom:http://www.bio-well.com/assets/files/2018_05_BioWell_Manual.pdf

49. What is EPI/GDV Bio-Electography? [Internet]. GDV-USA | The Science of Transformation to 'Wellness and Wholeness'. [cited 2018Jul1]. Available from: http://gdvusa.org/

50. Waterman MW. Electro Photonic Imaging [Internet]. Living Well Being, GDV & Consulting.[cited2018Jul4].Availablefrom:https://www.livingwellbeing.net/portfolio.html

51. Albrecht H, Wijk RV, Dittloff S. A new database on basic research in homeopathy. Homeopathy. 2002;91(3):162–5.

52. Rahnama M, Tuszynski JA, Bókkon I, Cifra M, Sardar P, Salari V. Emission Of Mitochondrial Biophotons And Their Effect On Electrical Activity Of Membrane Via Microtubules. Journal of Integrative Neuroscience. 2011;10(01):65–88.

53. Tang R, Dai J. Biophoton signal transmission and processing in the brain. Journal of Photochemistry and Photobiology B: Biology. 2014;139:71–5.

54. Sun Y, Wang C, Dai J. Biophotons as neural communication signals demonstrated by in situ biophoton autography. Photochemical & Photobiological Sciences. 2010;9(3):315.

55. Grass F, Klima H, Kasper S. Biophotons, microtubules and CNS, is our brain a "Holographic computer"? Medical Hypotheses. 2004;62(2):169–72.

56. Bansal N, Zelnick LR, Himmelfarb J, Chertow GM. Bioelectrical Impedance Analysis Measures and Clinical Outcomes in CKD. American Journal of Kidney Diseases. 2018;

57. Lamb MJE, Byrne CD, Wilson JF, Wild SH. Evaluation of Bioelectrical Impedance Analysis for Identifying Overweight Individuals at Increased Cardiometabolic Risk: A Cross-Sectional Study. PLoS ONE. 2014;9(9).

58. Loscri V, Vegni AM. Capacity Evaluation of a Quantum-Based Channel in a Biological Context. IEEE Transactions on NanoBioscience. 2016;15(8):901–7.

59. Nakano T, Moore MJ, Wei F, Vasilakos AV, Shuai J. Molecular communication and networking: opportunities and challenges. IEEE Transactions on Nanobioscience. 2012 Jun;11(2):135-48. doi: 10.1109/TNB.2012.2191570

60. Yabrov A, Okunev Y. Medicine without drugs – a new direction for application of nanotechnology. Medical Hypotheses. 2004;63(1):149–54.

61. Pezard L, Nandrino JL. The dynamic paradigm in psychopathology: "chaos theory", from physics topsychiatry].[Article in French] Encephale. 2001 May-Jun;27(3):260-8

62. Sherr J, Quirk T, Tournier AL. Do Homeopathic Pathogenetic Trials generate recognisable and reproducible symptom pictures?: Results from a pilot pathogenetic trial of Ozone 30c. Send toHomeopathy. 2014 Apr;103(2):108-12. doi: 10.1016/j.homp.2013.12.001.

63. Pritha Mehra, Anil Khurana, Renu Mittal, Bhopal Singh Arya, Rajpal, Raj K Manchanda, Karuna Singh, Anil K Vichitra, Goutam Rakshit, Jai P Singh, Maya Padmanabhan Homoeopathic pathogenetic trial of *Withania somnifera*: A multicentric, double-blind, randomised, placebo-controlled trial Indian Journal of Homoeopathic 2017 : 11(2) : 97-108

64. María del Pilar Sánchez-López and Virginia Dresch. The 12-Item General Health Questionnaire (GHQ-12): Reliability, external validity and factor structure in the Spanish population. Psicothema 2008. Vol. 20, nº 4, pp. 839-843 ISSN 0214 - 9915 CODEN PSOTEG

65. Central Council for Research in Homoeopathy Director General, Central Council for Research in Homoeopathy, New Delhi, India Homoeopathic Drug Proving: Randomised double-blind placebo-controlled trial. Indian Journal of Research in Homoeopathy,2015;9, (1): 3-11.

10

Appendices

10.1 Glossary

- **Homoeopathic Pathogenetic Trial:**

  Drug Proving also termed as Homoeopathic Pathogenetic Trial (HPT) is a process in which drug substances are put into a trial on healthy human volunteers and their pathogenetic effects are observed, noted and compiled as the first step to introduce the drug in the Homoeopathic Materia Medica.

- **Avogadro Number:**

  The number of molecules in a mole of a substance, approximately 6.0225×10^{23}, also known as Avogadro's Constant

- **Electro Photonic Emissions:**

  When the object is placed in an electromagnetic field, it is primarily electrons, and to certain degree photons, which are 'extracted' from the surface of the object. This process is called 'Electro Photonic emissions'

- **Ultra Molecular Doses:**

  In homoeopathy, it is a characteristic of the highest dilution of remedies, the substances are attenuated until no molecules of the original substance are present in the solution (to the 24th decimal or 12th centesimal). This is called Ultramolecular.

- **BIO WELL:**

  BIO WELL is a non-invasive Health Scan Camera using the most advanced method of the Health Checking, the Energetic functioning of the Human Body. It analyses the Body's Bio energy field, Organ's Energy and Organ System working on the Principle of "Electro – Photon Imaging" – EPI.

- **Electro Magnetic Field:**

  Electro Magnetic Fields are a combination of invisible electric and magnetic fields of force. They are produced by natural phenomenon like Earth's Magnetic Field but also by Human activities. It is produced mainly through the use of electricity.

- **Tesla Coil:**

It is an electrical resonant transformer circuit designed by the Electrical Scientist the Genius Nikola Tesla in 1891. It is used to produce high voltage, low current, High frequency alternating Current electricity.

- **GHQ 12:**

General Health Questionnaire is a well developed and validated, uni-dimensional scale questionnaire having 12 items, used as a screening instrument for minor psychiatric morbidity.

- **Likert's Scale:**

It is a psychometric scale used in research that employs questionnaires. It is the most widely used approach to scaling responses in survey research, such that the term s often used interchangeably with a *rating scale*. The scale is named after its inventor, psychologist Rensis Likert.

10.2 Data Collection Format

CONSENT FORM COLLECTION

Before entering the trial Informed Consent Form has been collected from all the participants

PRE TRIAL DATA COLLECTION

As a pre-trial data collection, EPI – 0 (pre-trial Electro Photonic Emission) has been recorded.

RUN IN PERIOD DATA COLLECTION

During the Run-in period, after the completion of 12 doses of placebo, the data EPI - 1 has been collected on the 5th day of the first week of the trial followed by Q FORM - 1 collection on the 7th day.

INTERVENTION PERIOD DATA COLLECTION

During the Intervention period, after the completion of 12 doses of their respective investigational substance, the data EPI - 2 has been collected on the 5th day of the second week of the trial followed by Q FORM – 2, collection on the 7th day.

ANTIDOTE PERIOD DATA COLLECTION

During the Antidote period, after completion of 12 doses of their respective antidote drug, the data EPI - 3 has been collected on the 5th day of the third week of the trial followed by Q FORM – 3, collection on the 7th day.

WASHOUT PERIOD DATA COLLECTION

During the washout period, the final week of the protocol, the final data EPI – 4 has been collected at the end of the week.

10.3 Questionnaire

GHQ-12

IN THE PAST FOUR WEEKS HAVE YOU ENCOUNTERED ANY OF THE FOLLOWING SITUATIONS?

S.NO	SITUATIONS	OFTEN	SOME TIMES	SELDOM	NEVER
A	Feeling that you had not made good use of time				
B	Feeling that you were not decisive				
C	Feeling that you had suffered from pressure				
D	Feeling that you could not overcome your own difficulties				
E	Feeling unhappy or distressed				
F	Able to lead a happy life				
G	Able to face your own difficulties				
H	Sleepless because of worrying something				
I	Having lost self-confidence				
J	Able to concentrate on doing anything				
K	Feeling that you were a useful person				
L	Feeling happy in general				

A

Q- FORM -01

CONFIDENTIAL

NAME:

D.O.B:

SEX:

Address:

Mobile no.:

E-mail:

Religion:

Diet : veg / non-veg

Marital status:

If a student, you belong to U.G.   /   P.G.

BATCH: UG-   / PG-

Nationality:

Language known:

1. Do you have any sensation of pain/ discomfort/complaints anywhere in your body?

   If so, express the type of sensation or the pain that you get in your words. Express the sensation or pain as it feels to you. Please jot it down in the tabular column.

S.NO.	Where is the trouble?	What exactly do you feel or have there?	What are the factors that make this trouble better or worse?	Any complaint or symptom associated with this complaint.

   Yes/No; External/Internal; PhysicalEmotional……..

2. Have you had any other major illness in childhood, if so, please mention from what complaints you suffered from?

S.NO.	Disease suffered from	Age (approx.)	Duration	Medication was taken	Fully recovered or not	Any other particulars

Yes/No; Chronic/No; Recovered

3. Do you suffer from any allergic conditions, please specify?

   Yes/No

4. Which substances are you addicted to – like alcohol or any other beverages, internet, shopping, any drug substances like smoking, tobacco, supari, pan, cannabis, alcohol, LSD, marijuana, cocaine, etc.?

   Yes/No; Type of addiction

5. How is your appetite (hunger)?

   Hi/Mod/Lo

   Imp/Not Impt

   NA

6. When are you hungry?

7. What happens if you have to remain hungry for a long time

8. Do you have a habit of eating fast?

9. How much thirst do you have?

10. How frequently do you drink and how much?

11. Please put one plus mark(+) if you like /dislike the food or if the food disagrees. Put two plus marks (++), if you strongly like/dislike the food or if the food strongly disagrees.

FOODS	LIKE	DISLIKE	DISAGREE
Salty			
Bitter			
Spicy			
Sour			
Sweet			
Exotic			
Bread			
Cheese			
Eggs			

Chicken			
Red meat			
Pork			
Fish			
Fatty food/ fried food			
Cabbage			
Onion			
Tea			
Coffee			
Milk			
Curds			
Fruits			
Warm food			
Cold food			
Ice			
Ice cream			
Any other			

12. Any problem in urination?

13. Any strong smell of urine? What is it like?

14. Any difficulty in flow?? Slow to start, interrupted, feeble, dribbling, etc.?

15. Do you have any problem regarding your stools?

16. When and how many times a day do you pass stools? Are you satisfied after passing stools?

17. When is it urgent?

18. Do you have to strain for the stool? Even if soft?

19. How much do you sweat?

20. On which part do you sweat the most?

21. Does the sweat smell? What kind of smell? Does the sweat stain the clothes? What colour?

22. Any complaints after sweating?

23. Do you perspire on the palms or soles?

24. When do you get fever or chill? Which brings it on?

25. With fever which part feels hot? With chill which part feels cold?

26. Do you experience any sense of heat or cold in any part of your body at any particular time?

27. Do you have burning or heat or cold feeling in your palms or soles?

28. Describe your posture in sleep (eg. On back, abdomen, sides) are you uncomfortable in any position?

29. How is your sleep pattern

30. During sleep do you grind/ snore/ dribble saliva/ sweat/ keep mouth open/ walk/ talk/ moan/ weep/ become restless/ wake up with jerk, etc.?

31. Describe anything unusual about your sleep?

32. How much do you cover/ uncover any part?

33. Circle the types of dreams that you have:

ANIMALS Cats Dogs Horse Wild animals Snakes	Robbers Thieves Anxious Fearful Ghosts	Travelling Riding Flying Swimming Drowning	Houses Fruits Trees Water Snow
Death, whose? Dead bodies Dead person Parts of body Suicide	Being hungry Being thirsty Drinking Eating	Fire Lightning Storm Rain	Accidents Falling Shooting Wars
Talking Singing Dancing Pleasant	Business Money Day's work Forgotten work	Vomiting Passing stool Urinating Blood-bleeding Excrements/soiling	Romantic Sexual pleasure Rape Nakedness
Pain illness Sickness Mutilations	Praying Religious Temple Church God	Failure/ exams Unsuccessful efforts- for what? Missing train Being unprepared	Grief Weeping Vexation Quarrels Jealousy Insults
Police Imprisonment Crime Murder Killing Poison	Misfortunes Insecurity Danger Being pursued -by whom? -For what?	Of people Children Parties Feasts Marriage	Of events Remote Recent Future Prophetic
Physical exertion	Mental exertion	Fatigue	Others….

If any other, specify in the space below:

MIND

1. Are you anxious? About which matters?

2. Are you fearful of anything such as animals, people, being alone, darkness, death, disease, robbers, sudden noise, thunder, of the future, of something unknown, high places etc.,?

3. Are you doubtful or suspicious? Of what?

4. What are you jealous of? Of whom? From what symptoms do you suffer when you get jealous?

5. Generally, how would you describe yourself as, slow / medium/ fast pace?

6. How long do you remember hurts caused to you by others?

7. Are you revengeful?

8. What are you proud of? Does your pride easily hurt?

9. Do you ever become suicidal? When? If so, in what manner do you contemplate to end your life? Even then, are you afraid of dying?

10. When are you cheerful?

11. Are you sexual minded?

12. Any unwanted thought anytime? What are they?

13. Have you any imaginary sensations or fears?

14. How is your memory? For what is it poor? E.g. names, places, faces, what you have read, etc.

15. Are you easily irritated?

16. What makes you angry? Do you get violent?

17. What bodily symptoms do you develop when angry? E.g. trembling, sweating, etc.,

18. Do you like the company? Or like to remain alone?

19. How seriously are you affected by disorder and uncleanliness in your surrounding?

20. What are the greatest grieves that you have gone through in your life?

21. What are the greatest joys that you have had in your life?

22. What activities you deeply like?

23. Are there any matters which you deeply dislike?

24. In your opinion, which aspect of your mind and moods are not agreeable to you, that in spite of your awareness and maturity, you are unable to change?

25. Give a clear-cut picture of your situation in life and your relationship with each of your family members, friends and associates at work.

26. How does the future look to you?

27. When you are free, what thoughts come to your mind?

28. Are you worried or unhappy over any personal, domestic, economic, social or any other conditions? If so describe in detail.

29. What are your three wishes?

1.

2.

3.

Childhood:

   1. Describe your nature as a child?

   2. What was your fear as a child?

   3. Any recurrent dreams in your childhood?

   4. Any incident in your childhood that had a major effect on you?

   5. Do you know of anything about your mother's history during pregnancy?

Parts of the body affected:

Vertigo: do you have giddiness or vertigo?

Faintness: do you ever feel faint? When?

Head: do you get headaches?

Eyes & vision: e.g. redness, burning, difficulty in reading, etc.

Ears & sense of hearing: e.g. ear pain, difficulty hearing, etc.,

Nose & sense of smell: e.g. bleeding from the nose, any problem with smell, etc.

Face & facial expression: e.g. acne, pigmentation, moles, warts, etc,

Mouth: e.g. ulcers, bad smell from mouth, etc

Teeth & gums: e.g. carious teeth, stained teeth, bleeding or swollen gums, etc,

Tongue & taste: e.g. sense of taste, any cracks, coating, etc.

Lips: e.g. cracked, peeling of skin, etc

Throat: pain, difficulty in swallowing, trouble with voice or speech, etc

Cold and cough:

Do you catch a cold often? What factors generally bring on the cold?

Describe the symptoms during cold, nature of discharge from nose,

Do you get a cough? What brings on the cough?

Is it more at any particular time?

Breathing:

Any difficulty in breathing? How frequent is it?

What brings it on or Make it worse / better?

Do you have any trouble in back, limbs or joints? Describe in detail.

Do you have complaints in the skin like itching, eruptions, ulcers, warts, corns, peeling, change in colour, spots, etc. ?

Is there any complaint or abnormality of the nails or the skin around?

Is there any complaint with the hair such as falling, greying, dandruff, dryness, oily, poor/ excessive /unusual growth?

Please draw/ colour something which comes to your mind spontaneously at this very moment or something that you draw/ doodle repetitively.

Reference: Homoeopathic Case Record Form- THE OTHER SONG- International Academy of Advanced Homoeopathy

Q-FORM -02

NAME: **DATE:**

BATCH: UG/PG:

S.NO.	SYMPTOMS	NOT AT ALL	A LITTLE	MODER ATE	RATHER MUCH	VERY STRONG
1.	**Head feels heavy**					
2.	**Twisting in the stomach in the morning**					
3.	**Aching pain, pressure headache in forehead**					
4.	**Numbness in the face around the mouth**					
5.	**A headache so bad on moving that it made the eyes close**					
6.	**Contraction of umbilicus during sleep**					
7.	**Pulsation of blood vessels in the head**					
8.	**Bluish discolouration of the chin**					
9.	**Heat in the head and face with redness**					
10.	**The delusion that the heart is too large**					
11.	**Swelling of the face especially of the lips, swollen eyelids**					
12.	**Chest pain – burning at night**					
13.	**Difficulty in swallowing**					
14.	**Cold tears from eyes**					
15.	**Sudden appearance and disappearance of the symptoms**					
16.	**Shaking of extremities at night**					
17.	**Sees imaginary things like Ghosts, Black animals on the walls, furniture**					
18.	**Tearing pain in the abdomen in the afternoon**					
19.	**Fear of imaginary animals**					
20.	**Itching in the earlobes at night**					
21.	**Unable to sleep because of fear and anxiety**					
22.	**Vertigo in crowd**					
23.	**During sleep, waking with a jerk**					
24.	**Back pain during daytime**					
25.	**Frightful dreams**					
26.	**Feeling of electric shock in the abdomen extending to limbs**					

27.	**Wants to run away during fear**					
28.	**Pain in the heart when spoken loudly**					
29.	**Laughing disposition – uncontrollable loud laughter**					
30.	**The coldness of the face with palpitation**					

ADDITIONAL SYMPTOMS EXPERIENCED WITH THE DAY/TIME OF OCCURRENCE:

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

Q- FORM- 03

NAME: **DATE:**

BATCH: UG/PG:

CHANGES OBSERVED IN THE MIND:

CHANGES OBSERVED IN THE PHYSICAL BODY:

VERTIGO:

APPETITE:

DESIRE:

AVERSION:

THIRST:

URINE:

STOOL:

SLEEP:

DREAMS:

MENSES (If applicable):

SWEAT:

DRESSING PATTERN:

HANDWRITING:

GESTURE:

10.4 Scales for Outcome Assessment

S.NO.	PARAMETERS	EXPLANATION
1.	*ENERGY*	The Energy of Light in Joules is calculated for both the whole image and for each sector of the EPI in the palette. E (corr) = E multiplied by 360/a. E= Energy of the sector; a = the width of the sector
2.	*EMOTIONAL PRESSURE*	It is correlated to the level of stress. Level of organism involved in the state of stress-adaptation; Balance of activity of sympathetic and parasympathetic nervous systems
3.	*FORM COEFFICIENT*	It correlates with the multi-circuit control of physiology regulation; The higher FC, the more regulation systems are involved in the process
4.	*ENTROPY COEFFICIENT*	It is a measure of chaos in the regulation of biological and physiological functions
5.	*LEFT RIGHT SYMMETRY*	The patterns in the left and right side were compared on the basis of area, contour and energy.
6.	*ORGAN BALANCE*	Each organ sectors have been analysed to determine the balance between the right and left EPI.
7.	*LEFT AREA*	The area in pixels of the left sector
8.	*LEFT ENERGY*	Energy in Joules of the left sector

9.	**RIGHT AREA**	The area in pixels of the right sector
10.	**RIGHT ENERGY**	Energy in Joules of the right sector
11.	**FRONT AREA**	The area in pixels of the front sector
12.	**FRONT ENERGY**	Energy in Joules of the front sector

Table 10.4 Parameters of EPI

PARAMETERS OF THE SECONDARY OUTCOME MEASURES – Q - FORM

The parameters were considered for the Q FORM -02 that has been filled by the participants during Intervention Period.

Score: the score is calculated by adding all the scores based on the intensity of the symptoms marked by the participants.

Total Number of Belladonna Symptoms: This is calculated by adding the number of Belladonna symptoms marked in each questionnaire.

Total Number of Marked symptoms: This is calculated by including both the Belladonna and Non-Belladonna symptoms marked by the participants.

Total Number of Additional Symptoms: This is calculated by counting the number of additional symptoms written by the participants.

Grand Total of all the symptoms: This is calculated by adding the total marked symptoms and additional symptom irrespective of the remedy.

10.5 Special Methods

Electro Photonic Imaging technique is a quick, easy and non intrusive technique using computer registration and analysis of electro-photonic emissions of different objects, including biological (specifically the human fingers) resulting from placing the object in the high intensity electromagnetic field (high voltage – 10kv at a frequency of 1024 Hz) on the device lens.

When the scan is conducted a weak electrical current i.e. in milli-ampere is applied to the fingertips for less than millisecond thereby producing Electro Magnetic Field.

The object response to this stimulus is the formation of variation of an "electron cloud" composed of light energy photons. The electron glow of this discharge which is invisible to the human eye is captured by the camera system and translated and transmitted back in the graphical representation.

The data has been recorded from all the ten fingers of the participants.

10.1 Method of Collecting Data Using BIO WELL Instrument

10.6 Tools

INVESTIGATIONAL DRUG SUBSTANCE

1. Belladonna -6C, 200C.
2. Camphor- 6C, 200C.
3. Globules made of cane sugar- size 30

All the medicinal substance used in the intervention were prepared by HAHNEMANN PUBLISHING Co. Pvt. Ltd., (HAPCO), Kolkata, WEST BENGAL. All the investigational drug substance were blinded and appeared similar. After completion of the final data extraction, the denominations were revealed by the HAPCO.

BIO WELL INSTRUMENT AND BIO WELL SOFTWARE

The information about the instrument as follows: **Product content**: BIO WELL DEVICE, USB CABLE, FINGER INSERT, LARGE FINGER INSERT, LENS CLEANING CLOTH, CALIBRATION UNIT, CALIBRATION CABLE, CALIBRATION STAND.

Device dimensions: 4.5" LENGTH, 4.75" WIDTH, 4.5" HEIGHT

Device weight: BIO WELL: 2.25 lbs, Calibration Pack:0.45 lbs

Figure 10.2.   Bio Well Instrument & Product content

10.7
Information Sheet & Consent Form

NATIONAL INSTITUTE OF HOMOEOPATHY

An Autonomous Organization under the Ministry of
AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy)

I.C.F. - INFORMED CONSENT FORM

INFORMATION SHEET:

This informed consent form is for men and women who we are inviting to participate in research on HOMOEOPATHIC PATHOGENETIC TRIAL (DRUG PROVING). The title of our research project is "**A RANDOMIZED BLINDED PLACEBO-CONTROLLED THREE ARMED PARALLEL STUDY ON ELECTROPHOTONIC IMAGE (EPI) CHANGES DURING HOMOEOPATHIC PATHOGENETIC TRIAL (HPT) USING MOLECULAR AND ULTRAMOLECULAR DOSES-** *A REPROVING"*

The informed consent form has two parts,

1. Information sheet – to share information about the research with you
2. Certificate of consent- for signature if you agree to take part

You will be given a copy of the full informed consent form.

PART- I INFORMATION SHEET:

INTRODUCTION:

I am Dr BANUPRIYA.D, B.H.M.S., 17TH BATCH PGT, belong to the DEPARTMENT OF HOMOEOPATHIC PHARMACY, doing research on HOMOEOPATHIC DRUG PROVING. I am going to give you information and invite you to be part of this research. You do not have to decide today whether or not you will participate in the research. Before you decide, you can talk to anyone you feel comfortable with about the research. If you do not understand anything/ if you have questions later, you can ask them.

PURPOSE OF RESEARCH:

Homoeopathy, a well-known system of alternative and complementary medicine, is being criticized even today as placebo and pseudo-science. This research is undertaken to analyze changes in the human energy field by ELECTRO-PHOTONIC EMISSIONS from the human body during the administration of homoeopathic medicines in lower potency (low power) and medium potency (medium power) in apparently healthy human being during drug proving that include a control group to differentiate its effect from the placebo.

TYPE OF RESEARCH INTERVENTION:

This research will involve administration of homoeopathy medicine in low power to GROUP-1, the medium power to GROUP-2 and GROUP – 3 as the control they receive placebo (i.e.) dummy medicine / pretended medicine / non - medicated globules. The energy field of the participants will be recorded 05 times,

Recording the ELECTRO-PHOTONIC EMISSIONS is a non- invasive procedure, it takes maximum 10 minutes for assessment per reading. In this assessment all 10 fingers are kept inside this instrument (GDV-BIOWELL) one by one, then ELECTRO PHOTONIC EMISSIONS are captured and analyzed.

The participants will be asked to fill the questionnaire forms Q-FORM 1,2,3 during the research.

PARTICIPANT SELECTION:

We are inviting all adults who are apparently healthy to participate in the research on homoeopathic drug proving.

VOLUNTARY PARTICIPATION:

Your participation in this research is entirely voluntary. It is your choice whether to participate or not. You may change your mind later and stop participating even if you agreed earlier.

INFORMATION ON TRIAL DRUG:

The information on the trial drug is blinded. It can be assured that it does not produce any toxicological/adverse effect to the participants as it contains no crude matter in it.

PROCEDURE AND PROTOCOL:

1. Before starting the trial the ELECTROPHOTONIC IMAGE (EPI- 1) will be taken for all the participants
2. Then participants are randomized into three groups (A, B, C) containing an equal number of male and female
3. The intervention period will be totally 04 weeks
4. **1st week**- the participants in all the three groups will be asked to take 05 globules 03 times a day (morning, afternoon, night) before food, for 04 days from the IPS-01 (one dram container filled with globules)
5. On 5th day EPI-02 will be taken and the participants will be observing themselves (body and mind) and fill the Q-FORM-01 on 6th and 7th day and it will be submitted on the following day.
6. **2nd week**- the participants in all the three groups will be asked to take 05 globules, 03 times a day (morning, afternoon, night) before food, for 04 days from the IPS -02 (one dram container filled with globules.
7. On 5th day EPI-03 will be taken and the participants will be observing themselves (body and mind) and fill the Q-FORM -02 on 6th and 7th day and it will be submitted on the following day.
8. **3rd week**- the participants in all the groups will be asked to take 05 globules, 03 times a day (morning, afternoon, night) before food, for 04 days from IPS-03(one dram container filled with globules. The participants will be asked to drink coffee every day morning for 04 days.
9. On 5th day EPI-04 will be taken and the participants will be observing themselves (body and mind) and fill the Q-FORM-03 on 6th and 7th day and it will be submitted on the following day.
10. **4th week**- the participants will be the medicine free period for about 04 days. On 5th day EPI-05 will be taken and the intervention ends.

In between this intervention period if any participants experience discomfort, it will be analyzed whether it is due to medicine or due to any other causes, if it is due to medicine it will be antidoted immediately and the participants may stop the next dosage.

ABOUT THE ELECTROPHOTONIC IMAGING TECHNIQUE:

The EPI should be taken at the same time as the day of the previous measurement. The participants will be asked to present themselves in the pharmacy PG lab for the EPI assessment at the same time of that day for all the EPI assessments 01 to 05. On the day of measurement, the participants should not smoke or have alcohol

Description of the process:

1. The participants have to keep the fingertip one by one in the gas discharge visualization BIO-WELL Camera and the photonic emissions from the fingertips are photographed, the single assessment two readings will be taken. First reading with-out filter and the second reading with filter, and it takes less than 10 minutes
2. The participants will be asked to submit the Q-form on receiving next scheduled IPS containers of medicine.
3. Participants will be given three different Q-FORMS – 01, 02 and 03 on week 01,02 and 03 respectively.
4. Participants should fill the respective answers for the questions about their general sensation and function then should mark the symptoms experienced by them by putting a tick mark in the respective box. Participants are also encouraged to write the symptoms experienced during this trial in the additional form.

DURATION:

The research duration is about 05 to 08 weeks in total. During that time it will be necessary for the participant to come to the PG pharmacy lab for EPI assessment on day 05 of week 01,02,03 and 04 at the same time of the day on each visit.

In total, you will be asked to come 05 times to the PG pharmacy lab in 01 months. The research will be finished when final EPI -05 is taken.

SIDE EFFECTS AND RISK:

As already mentioned homoeopathy medicine has no crude material of the original substance. So, there will be no adverse effect, only but the appearance of temporary symptoms that actually fade away with intake of antidote.

However, we will follow you closely and keep track of any unwanted effects or any problems. If any effect is noticed that we are not aware of the dosage will be stopped immediately and antidote. If this is necessary we will discuss it together with you and you will always be consulted before we move to the next step.

BENEFITS:

If you participate in this research, you will have the following benefits:

1. The immunity of your body increases after the drug proving
2. The ability to introspect increases
3. You will get free energy assessment of your whole body through EPI- GDV BIO-WELL camera.

REIMBURSEMENT:

You will not be given any money to take part in this research. But, you will get certain benefits.

To take an ELECTRO-PHOTONIC EMISSION image of the whole body , in INDIA, it cost starts from about Rs.800/- per assessment, by participating in this research your energy status is measured for about 05 times that worth Rs.4000/- and at the end of this research your energy status in the EPI will be mailed to you personally.

CONFIDENTIALITY: The information that we collect from this research project will be kept confidential. It will not be shared with or given to any except the guide, co-guide and researchers involved in this project.

SHARING THE RESULTS: the knowledge that we get form doing this project will be shared with you through meetings before it is made widely available to the public. Confidential information will not be shared.

RIGHT TO REFUSE / WITHDRAW: You do not have to take part in this research if you do not wish to do so. You may also stop participating in the research at any time you choose. It is your choice and all your rights will still be respected.

This proposal has been reviewed and approved by IEC which is a committee whose task is to make sure that research participants are protected from harm.

WHO TO CONTACT: if you have any question you may ask it now or later, even after the study has started. If you wish to ask question later, you may contact following,

Dr BANUPRIYA.D,

Contact number: 9007647950

Email Id: 0toinfinitee@gmail.com.

PART – II - CONSENT SHEET:

I have read the foregoing information or it has been read to me. I have had the opportunity to ask questions about it and any questions that I have asked have been answered to my satisfaction. I consent voluntarily to participate as a participant in this research.

NAME OF THE PARTICIPANT:

SIGNATURE OF THE PARTICIPANT:

DATE:

STATEMENT BY THE RESEARCHER/ PERSON TAKING CONSENT:

I have accurately read out the information sheet to the potential participant, and to the best of my ability made sure that the participant understands that the following will be done.

1. He/she will be taking either homoeopathic potencies or placebo according to the randomized allotment and blinded about the drug substance/placebo which they are taking
2. He/she have to be present on the 5TH day of each week of the intervention phase for EPI assessment of human energy field which is a non- invasive procedure.
3. Symptoms of the particular drug taken may manifest in the mind and body after that phase the drug will be an antidote
4. He /she has to observe the changes in the mind and body and should fill out the questionnaire- Q-FORM 01, 02, 03 and should submit on the following week.

I confirm that the participant was given an opportunity to ask questions about the study and all the questions asked by the participant have been answered correctly and to the best of my ability. I confirm that the individual has not been coerced into giving consent and the consent has been given freely and voluntarily.

A copy of the informed consent form – ICF has been provided to the participant.

NAME OF RESEARCHER / PERSON TAKING THE CONSENT:

SIGNATURE OF RESEARCHER / PERSON TAKING THE CONSENT:

DATE:

10.8 Reports of EPI

BR – 116 – UG 27 – EPI 0

Right thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Right fore
1. Cervical zone
2. Thorax zone
3. Lumbar zone
4. Sacrum
5. Coccyx, Pelvis minor zone
6. Blind gut
7. Appendix
8. Ascending colon
9. Transverse colon

Right middle
1. Thorax zone, Respiratory system
2. Immune system
3. Gallbladder
4. Liver
5. Right kidney
6. Cardiovascular system
7. Cerebral zone (vessels)

Right ring
1. Pituitary gland
2. Thyroid gland
3. Pancreas
4. Adrenal
5. Urino-genital system
6. Spleen
7. Nervous system
8. Hypothalamus
9. Epiphysis

Right little
1. Duodenum
2. Ileum
3. Mammary glands (for women), Respiratory system
4. Right kidney
5. Heart
6. Coronary vessels

Left thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Left fore
1. Descending colon
2. Sigmoid colon
3. Rectum, Prostate
4. Coccyx, Pelvis minor zone
5. Sacrum
6. Lumbar zone
7. Thorax zone
8. Cervical zone
9. Transverse colon

Left middle
1. Cardiovascular system
2. Left kidney
3. Liver
4. Abdominal zone
5. Immune system
6. Thorax zone, Respiratory system
7. Cerebral zone (vessels)

Left ring
1. Hypothalamus
2. Nervous system
3. Spleen
4. Urino-genital system
5. Adrenal
6. Pancreas
7. Thyroid gland
8. Pituitary gland
9. Epiphysis

Left little
1. Left part of heart
2. Left kidney
3. Mammary glands (for women), Respiratory system
4. Jejunum
5. Right part of heart
6. Coronary vessels

ORGAN BALANCE :

1. Heart 2. Colon - transverse 3. Pancreas 4. Liver 5. Pituitary gland 6. Thyroid gland 7. Adrenals 8. Spine - cervical zone 9. Spine - thorax zone 10. Spine - lumbar zone 11. Sacrum 12. Coccyx, Pelvis minor zone 13. Kidneys 14. Ears, nose, maxillary sinus 15. Throat, larynx, trachea 16. Cerebral zone (vessels) 17. Mammary glands (for women), Respiratory system 18. Coronary vessels 19. Thorax zone 20. Epiphysis 21. Hypothalamus 22. Spleen 23. Right eye 24. Left eye 25. Jaw, Teeth 26. Cerebral zone (cortex)

BR- 116 – UG 27 – EPI 1

Right thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Right fore
1. Cervical zone
2. Thorax zone
3. Lumbar zone
4. Sacrum
5. Coccyx, Pelvis minor zone
6. Blind gut
7. Appendix
8. Ascending colon
9. Transverse colon

Right middle
1. Thorax zone, Respiratory system
2. Immune system
3. Gallbladder
4. Liver
5. Right kidney
6. Cardiovascular system
7. Cerebral zone (vessels)

Right ring
1. Pituitary gland
2. Thyroid gland
3. Pancreas
4. Adrenal
5. Urino-genital system
6. Spleen
7. Nervous system
8. Hypothalamus
9. Epiphysis

Right little
1. Duodenum
2. Ileum
3. Mammary glands (for women), Respiratory system
4. Right kidney
5. Heart
6. Coronary vessels

Left thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Left fore
1. Descending colon
2. Sigmoid colon
3. Rectum, Prostate
4. Coccyx, Pelvis minor zone
5. Sacrum
6. Lumbar zone
7. Thorax zone
8. Cervical zone
9. Transverse colon

Left middle
1. Cardiovascular system
2. Left kidney
3. Liver
4. Abdominal zone
5. Immune system
6. Thorax zone, Respiratory system
7. Cerebral zone (vessels)

Left ring
1. Hypothalamus
2. Nervous system
3. Spleen
4. Urino-genital system
5. Adrenal
6. Pancreas
7. Thyroid gland
8. Pituitary gland
9. Epiphysis

Left little
1. Left part of heart
2. Left kidney
3. Mammary glands (for women), Respiratory system
4. Jejunum
5. Right part of heart
6. Coronary vessels

ORGAN BALANCE :

1. Heart 2. Colon - transverse 3. Pancreas 4. Liver 5. Pituitary gland 6. Thyroid gland 7. Adrenals 8. Spine - cervical zone 9. Spine - thorax zone 10. Spine - lumbar zone 11. Sacrum 12. Coccyx, Pelvis minor zone 13. Kidneys 14. Ears, nose, maxillary sinus 15. Throat, larynx, trachea 16. Cerebral zone (vessels) 17. Mammary glands (for women), Respiratory system 18. Coronary vessels 19. Thorax zone 20. Epiphysis 21. Hypothalamus 22. Spleen 23. Right eye 24. Left eye 25. Jaw, Teeth 26. Cerebral zone (cortex)

81

BR- 116 – UG 27 – EPI 2

Right thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Right fore
1. Cervical zone
2. Thorax zone
3. Lumbar zone
4. Sacrum
5. Coccyx, Pelvis minor zone
6. Blind gut
7. Appendix
8. Ascending colon
9. Transverse colon

Right middle
1. Thorax zone, Respiratory system
2. Immune system
3. Gallbladder
4. Liver
5. Right kidney
6. Cardiovascular system
7. Cerebral zone (vessels)

Right ring
1. Pituitary gland
2. Thyroid gland
3. Pancreas
4. Adrenal
5. Urino-genital system
6. Spleen
7. Nervous system
8. Hypothalamus
9. Epiphysis

Right little
1. Duodenum
2. Ileum
3. Mammary glands (for women), Respiratory system
4. Right kidney
5. Heart
6. Coronary vessels

Left thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Left fore
1. Descending colon
2. Sigmoid colon
3. Rectum, Prostate
4. Coccyx, Pelvis minor zone
5. Sacrum
6. Lumbar zone
7. Thorax zone
8. Cervical zone
9. Transverse colon

Left middle
1. Cardiovascular system
2. Left kidney
3. Liver
4. Abdominal zone
5. Immune system
6. Thorax zone, Respiratory system
7. Cerebral zone (vessels)

Left ring
1. Hypothalamus
2. Nervous system
3. Spleen
4. Urino-genital system
5. Adrenal
6. Pancreas
7. Thyroid gland
8. Pituitary gland
9. Epiphysis

Left little
1. Left part of heart
2. Left kidney
3. Mammary glands (for women), Respiratory system
4. Jejunum
5. Right part of heart
6. Coronary vessels

ORGAN BALANCE :

1. Heart 2. Colon - transverse 3. Pancreas 4. Liver 5. Pituitary gland 6. Thyroid gland 7. Adrenals 8. Spine - cervical zone 9. Spine - thorax zone 10. Spine - lumbar zone 11. Sacrum 12. Coccyx, Pelvis minor zone 13. Kidneys 14. Ears, nose, maxillary sinus 15. Throat, larynx, trachea 16. Cerebral zone (vessels) 17. Mammary glands (for women), Respiratory system 18. Coronary vessels 19. Thorax zone 20. Epiphysis 21. Hypothalamus 22. Spleen 23. Right eye 24. Left eye 25. Jaw, Teeth 26. Cerebral zone (cortex)

82

BR – 116 – UG 27 – EPI 3

Right thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Right fore
1. Cervical zone
2. Thorax zone
3. Lumbar zone
4. Sacrum
5. Coccyx, Pelvis minor zone
6. Blind gut
7. Appendix
8. Ascending colon
9. Transverse colon

Right middle
1. Thorax zone, Respiratory system
2. Immune system
3. Gallbladder
4. Liver
5. Right kidney
6. Cardiovascular system
7. Cerebral zone (vessels)

Right ring
1. Pituitary gland
2. Thyroid gland
3. Pancreas
4. Adrenal
5. Urino-genital system
6. Spleen
7. Nervous system
8. Hypothalamus
9. Epiphysis

Right little
1. Duodenum
2. Ileum
3. Mammary glands (for women), Respiratory system
4. Right kidney
5. Heart
6. Coronary vessels

Left thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Left fore
1. Descending colon
2. Sigmoid colon
3. Rectum, Prostate
4. Coccyx, Pelvis minor zone
5. Sacrum
6. Lumbar zone
7. Thorax zone
8. Cervical zone
9. Transverse colon

Left middle
1. Cardiovascular system
2. Left kidney
3. Liver
4. Abdominal zone
5. Immune system
6. Thorax zone, Respiratory system
7. Cerebral zone (vessels)

Left ring
1. Hypothalamus
2. Nervous system
3. Spleen
4. Urino-genital system
5. Adrenal
6. Pancreas
7. Thyroid gland
8. Pituitary gland
9. Epiphysis

Left little
1. Left part of heart
2. Left kidney
3. Mammary glands (for women), Respiratory system
4. Jejunum
5. Right part of heart
6. Coronary vessels

ORGAN BALANCE :

1. Heart 2. Colon - transverse 3. Pancreas 4. Liver 5. Pituitary gland 6. Thyroid gland 7. Adrenals 8. Spine - cervical zone 9. Spine - thorax zone 10. Spine - lumbar zone 11. Sacrum 12. Coccyx, Pelvis minor zone 13. Kidneys 14. Ears, nose, maxillary sinus 15. Throat, larynx, trachea 16. Cerebral zone (vessels) 17. Mammary glands (for women), Respiratory system 18. Coronary vessels 19. Thorax zone 20. Epiphysis 21. Hypothalamus 22. Spleen 23. Right eye 24. Left eye 25. Jaw, Teeth 26. Cerebral zone (cortex)

BR – 116 – UG 27 – EPI 4

Right thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Right fore
1. Cervical zone
2. Thorax zone
3. Lumbar zone
4. Sacrum
5. Coccyx, Pelvis minor zone
6. Blind gut
7. Appendix
8. Ascending colon
9. Transverse colon

Right middle
1. Thorax zone, Respiratory system
2. Immune system
3. Gallbladder
4. Liver
5. Right kidney
6. Cardiovascular system
7. Cerebral zone (vessels)

Right ring
1. Pituitary gland
2. Thyroid gland
3. Pancreas
4. Adrenal
5. Urino-genital system
6. Spleen
7. Nervous system
8. Hypothalamus
9. Epiphysis

Right little
1. Duodenum
2. Ileum
3. Mammary glands (for women), Respiratory system
4. Right kidney
5. Heart
6. Coronary vessels

Left thumb
1. Right eye
2. Right ear, Nose, Maxillary sinus
3. Jaw, Teeth right side
4. Throat, Larynx, Trachea, Thyroid gland
5. Jaw, Teeth left side
6. Left ear, Nose, Maxillary sinus
7. Left eye
8. Cerebral zone (cortex)

Left fore
1. Descending colon
2. Sigmoid colon
3. Rectum, Prostate
4. Coccyx, Pelvis minor zone
5. Sacrum
6. Lumbar zone
7. Thorax zone
8. Cervical zone
9. Transverse colon

Left middle
1. Cardiovascular system
2. Left kidney
3. Liver
4. Abdominal zone
5. Immune system
6. Thorax zone, Respiratory system
7. Cerebral zone (vessels)

Left ring
1. Hypothalamus
2. Nervous system
3. Spleen
4. Urino-genital system
5. Adrenal
6. Pancreas
7. Thyroid gland
8. Pituitary gland
9. Epiphysis

Left little
1. Left part of heart
2. Left kidney
3. Mammary glands (for women), Respiratory system
4. Jejunum
5. Right part of heart
6. Coronary vessels

ORGAN BALANCE :

1. Heart 2. Colon - transverse 3. Pancreas 4. Liver 5. Pituitary gland 6. Thyroid gland 7. Adrenals 8. Spine - cervical zone 9. Spine - thorax zone 10. Spine - lumbar zone 11. Sacrum 12. Coccyx, Pelvis minor zone 13. Kidneys 14. Ears, nose, maxillary sinus 15. Throat, larynx, trachea 16. Cerebral zone (vessels) 17. Mammary glands (for women), Respiratory system 18. Coronary vessels 19. Thorax zone 20. Epiphysis 21. Hypothalamus 22. Spleen 23. Right eye 24. Left eye 25. Jaw, Teeth 26. Cerebral zone (cortex)

197 A

Q-FORM -02 NAME: Rajib Purkait DATE: 04/10/17
BATCH: UG/PG: 17th, PGT.

S.NO.	SYMPTOMS	NOT AT ALL	A LITTLE	RATHER	MUCH	VERY STRONG
1.	Head feels heavy	✓				
2.	Twisting in the stomach in morning		✓			
3.	Aching pain, pressure headache in forehead			✓		
4.	Numbness in the face around the mouth	✓				
5.	Headache so bad on moving that it made the eyes close	✓				
6.	Contraction of umbilicus during sleep	✓				
7.	Pulsation of blood vessels in the head		✓			
8.	Bluish discoloration of the chin	✓				
9.	Heat in the head and face with redness			✓		
10.	Delusion that heart is too large	✓				
11.	Swelling of the face especially of the lips, swollen eyelids	✓				
12.	Chest pain – burning at night	✓				
13.	Difficulty in swallowing	✓				
14.	Cold tears from eyes	✓				
15.	Sudden appearance and disappearance of the symptoms		✓			
16.	Shaking of extremities at night	✓				
17.	Sees imaginary things like Ghosts, Black animals on the walls , furniture	✓				
18.	Tearing pain in the abdomen in the afternoon	✓				
19.	Fear of imaginary animals		✓			
20.	Itching in the ear lobes at night	✓				
21.	Unable to sleep because of fear and anxiety	✓				
22.	Vertigo in crowd		✓			
						P.T.O

Q-FORM -02   NAME: Rajib Purkait   DATE: 04/10/17

BATCH: UG/PG:

23.	During sleep, waking with a jerk	✓				
24.	Back pain during day time		✓			
25.	Frightful dreams	✓				
26.	Feeling of electric shock in the abdomen extending to limbs	✓				
27.	Wants to run away during fear	✓				
28.	Pain in the heart when spoken loudly	✓				
29.	Laughing disposition – uncontrollable loud laughter	✓				
30.	Coldness of face with palpitation	✓				

ADDITIONAL SYMPTOMS EXPERIENCED WITH THE DAY/TIME OF OCCURANCE:

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

S = 10

SM = A

B.S = 5

AS = 0

T.S = 8

(170) (B) (11)

Q-FORM -02   NAME: MUKTA JAIN   DATE: 12·07·2017
BATCH: UG/PG: 28ᵗʰ Batch

S.NO.	SYMPTOMS	NOT AT ALL	A LITTLE	RATHER	MUCH	VERY STRONG	
1.	Head feels heavy				✓		−3
2.	Twisting in the stomach in morning		✓				−1
3.	Aching pain, pressure headache in forehead				✓		−3
4.	Numbness in the face around the mouth	✓					
5.	Headache so bad on moving that it made the eyes close	✓					
6.	Contraction of umbilicus during sleep	✓					
7.	Pulsation of blood vessels in the head			✓			−2
8.	Bluish discoloration of the chin	✓					
9.	Heat in the head and face with redness			✓			−2
10.	Delusion that heart is too large	✓					
11.	Swelling of the face especially of the lips, swollen eyelids	✓					
12.	Chest pain – burning at night		✓				−1
13.	Difficulty in swallowing		✓				−1
14.	Cold tears from eyes	✓					
15.	Sudden appearance and disappearance of the symptoms	✓					
16.	Shaking of extremities at night	✓					
17.	Sees imaginary things like Ghosts, Black animals on the walls , furniture	✓					
18.	Tearing pain in the abdomen in the afternoon	✓					
19.	Fear of imaginary animals	✓					
20.	Itching in the ear lobes at night	✓					
21.	Unable to sleep because of fear and anxiety	✓					
22.	Vertigo in crowd		✓				−1
						P.T.O	

Q-FORM -02   NAME: DATE:

BATCH: UG/PG:

23.	During sleep, waking with a jerk				✓		−3
24.	Back pain during day time				✓		−3
25.	Frightful dreams	✓					
26.	Feeling of electric shock in the abdomen extending to limbs	✓					
27.	Wants to run away during fear	✓					
28.	Pain in the heart when spoken loudly	✓					
29.	Laughing disposition – uncontrollable loud laughter	✓					
30.	Coldness of face with palpitation			✓			−1

ADDITIONAL SYMPTOMS EXPERIENCED WITH THE DAY/TIME OF OCCURANCE:

1. RUNNING NOSE −1
2. WATERING EYES −1
3. MILD FEVER −1
4. COUGH AND COLD −1
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

$S = 21$

$MS = 11$

$BS = 6$

$AS = 4$

$TS = 15$

126 (C)

Q-FORM -02 NAME: QUHELY GHOSH DATE:
BATCH: UG/PG: 26th

S.NO.	SYMPTOMS	NOT AT ALL	A LITTLE	RATHER	MUCH	VERY STRONG
1.	Head feels heavy	✓				
2.	Twisting in the stomach in morning	✓				
3.	Aching pain, pressure headache in forehead	✓				
4.	Numbness in the face around the mouth	✓				
5.	Headache so bad on moving that it made the eyes close	✓				
6.	Contraction of umbilicus during sleep	✓				
7.	Pulsation of blood vessels in the head	✓				
8.	Bluish discoloration of the chin	✓				
9.	Heat in the head and face with redness	✓				
10.	Delusion that heart is too large	✓				
11.	Swelling of the face especially of the lips, swollen eyelids	✓				
12.	Chest pain – burning at night	✓				
13.	Difficulty in swallowing	✓				
14.	Cold tears from eyes	✓				
15.	Sudden appearance and disappearance of the symptoms	✓				
16.	Shaking of extremities at night	✓				
17.	Sees imaginary things like Ghosts, Black animals on the walls , furniture	✓				
18.	Tearing pain in the abdomen in the afternoon	✓				
19.	Fear of imaginary animals	✓				
20.	Itching in the ear lobes at night	✓				
21.	Unable to sleep because of fear and anxiety	✓				
22.	Vertigo in crowd	✓				
						P.T.O

Q-FORM -02   NAME: QUHELY GHOSH DATE:

BATCH: UG/PG: 26th

23.	During sleep, waking with a jerk	✓				
24.	Back pain during day time	✓				
25.	Frightful dreams	✓				
26.	Feeling of electric shock in the abdomen extending to limbs	✓				
27.	Wants to run away during fear	✓				
28.	Pain in the heart when spoken loudly	✓				
29.	Laughing disposition – uncontrollable loud laughter	✓				
30.	Coldness of face with palpitation	✓				

ADDITIONAL SYMPTOMS EXPERIENCED WITH THE DAY/TIME OF OCCURANCE:

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

$S = 0$

$M S = 0$

$BS = 0$

$Ad = 0$

$TS = 0$

90

10.9 Master Chart

GROUP A- BELLADONNA-6 C GROUP -EPI 0 (PRE INTERVENTION READING)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
101	SHANTHIADHIKARI- 16 PGT	MALE	A	3.44	42.91	93.81	82.62	2.25	2.65	58750	22.31	61976	22.92	60315	22.77
102	NIMI DEBBARMA- 25 UG	FEMALE	A	3.72	46.14	96.57	89.79	1.95	2.33	56699	20.62	57384	19.92	59666	22.19
106	HOZAIFA AYUBI- 23 UG	MALE	A	4.2	50.7	98.06	95.67	2.14	2.48	66987	26.22	65346	25.05	66632	26.62
113	SAGAR SAHA- 28 UG	MALE	A	2.73	47.24	98.95	94.88	2.26	2.6	66772	25.85	65854	25.92	67756	26.88
117	SUBHASHREE MODAK- 28 UG	FEMALE	A	3.35	46	98.45	91.15	2.53	2.91	65673	28.3	67007	28.8	67904	29.11
119	MONIKA VASHISHT- 25 UG	FEMALE	A	3.52	42.87	95.26	88.8	2.16	2.77	55302	20.53	56609	21.46	59012	22.72
120	MANEET- 18 PGT	MALE	A	3.89	39.57	99.77	89.69	1.92	2.42	52715	18.6	53050	18.58	50289	17.62
121	ARUN KUMAR- 16 PGT	MALE	A	3.33	39.25	88.68	82.13	1.99	2.73	52653	17.66	49207	16.65	51303	17.62
124	SATINDER SINGH- 26 UG	MALE	A	4.35	44.91	94.07	85.28	1.9	2.21	56789	20.19	58191	20.76	57078	20.68
125	JAMES MICHAEL- 17 PGT	MALE	A	3.15	41.64	99.93	90.49	2.16	2.52	63330	24.36	62365	23.62	62546	23.66
127	SHASHANK ATREY- 26 UG	MALE	A	4.16	42.73	98.08	89.08	1.97	2.48	53147	18.33	53838	18.09	55269	19.38
133	PRIYANKA KAUSHIK- 18 PGT	FEMALE	A	5.21	33.25	94.45	83.4	2.34	4	39105	12.15	44387	13.72	43283	13.53
136	JUTHIKA MOLLA- 25 UG	FEMALE	A	3.41	45.5	93.41	90.5	1.94	2.38	56354	21.65	53943	19.85	57269	21.52
139	QUAMAR SULTANA- 26 UG	FEMALE	A	3.02	39.5	85.34	82.26	2.21	2.82	61587	23.55	56382	20.42	56771	20.11
143	AFSANA- 23 UG	FEMALE	A	3.76	40.63	93.73	87.69	1.93	2.29	54428	18.3	55006	18.36	56402	19.31
144	DIVYA BHARADWAJ- 18 PGT	FEMALE	A	3.81	40.37	94.35	89.44	1.92	2.41	52994	18.5	52841	17.78	49934	16.3
147	IRESHA MADURANGANI- 23 UG	FEMALE	A	3.72	41.84	88.18	86.58	1.9	2.29	52333	17.42	52049	17.26	55921	19.95
149	VEENA- 27 UG	FEMALE	A	3.64	41.44	93.35	88.54	1.96	2.36	56308	21.2	54538	19.72	53938	19.65
152	KUNDAN KAUT CHANDRAN- 16 PGT	MALE	A	4.59	38.09	89.87	90.66	1.86	2.37	51180	17	52011	17.35	44744	14.66
156	AFRUSANNASNY AM- 24 UG	FEMALE	A	4.4	43.18	97.14	92.73	2.19	2.59	57257	20.77	60556	21.22	60686	21.79
157	ALEFIA MASFATIA- 25 UG	FEMALE	A	3.4	35.58	89.62	78.82	2.09	2.87	50255	17.41	47338	15.5	48234	16.2
168	SATARUPA SADHUKAN- 18 PGT	FEMALE	A	4.32	41.11	91.03	86.33	2.02	2.45	59074	22.15	58305	21.04	50863	17.79
181	JULKA KUMARI TRIPTI- 25 UG	FEMALE	A	4.03	38.99	80.27	74.05	2.41	3.17	52272	18.35	56964	20.52	61255	23.22
182	DEEPAK KUMAR CHAUDHARY- 18 PGT	MALE	A	3.14	40.33	94.47	90.29	1.94	2.57	51167	16.84	47509	15.16	50983	16.71
183	JAVEED IQBAL- 16 PGT	MALE	A	3.51	34.62	87.95	82.66	2.13	3.35	40926	11.95	42680	12.51	49398	15.44
185	ANGIRA CHAKRABORTY- 28 UG	FEMALE	A	3.87	44.46	97.83	95.4	2.22	2.55	59766	23.4	62050	25.01	60352	25.15
188	SAVITA GOSAI- 16 PGT	FEMALE	A	4.78	39.22	91.11	91.32	2.01	2.55	54846	18.8	55446	18.91	45669	15.61
189	AYESHA NAAZ- 16 PGT	FEMALE	A	3.3	38	92.5	85.31	1.99	2.46	53068	18.85	51996	17.45	52332	17.66
190	GURJEEV SINGH- 28 UG	MALE	A	3.51	44.12	93.57	92.13	2.25	2.67	62429	24.11	61201	23.51	61719	24.03
193	DHANASHREE VETTATHU- 24 UG	FEMALE	A	4.34	40.61	99.61	88.24	1.92	2.28	55013	19.28	54496	18.71	53266	18.23
197	RAJIB PURKAIT- 17 PGT	MALE	A	3.2	37.52	98.8	95.53	1.93	2.45	51760	16.5	51057	16.4	52735	17.46
198	VIVEK TIWARI- 28 UG	MALE	A	3.12	42.03	98.35	94.18	2.2	2.55	62372	23.91	62304	23.69	61991	24.18
201	DHIRAJ DEBNATH- 17 PGT	MALE	A	4.61	38.77	84.87	84.03	1.96	2.53	51280	16.71	50629	16.35	51813	17.01
206	CHANDRA MOHAN- 28 UG	MALE	A	4.2	44.93	98.52	93.98	2.1	2.55	60553	22.12	59798	21.48	60323	21.69
208	PALLAVI KUMARI- 28 UG	FEMALE	A	3.95	38.76	97.43	86.13	2.14	3.09	50537	16.3	49641	16.03	49352	16.41
209	ANWESHA DUBEY- 27 UG	FEMALE	A	4.62	31.19	77.73	76.3	2.29	4.12	37110	11.38	36192	10.63	42439	13.42
210	POONAM RANI- 18 PGT	FEMALE	A	3.88	41.62	88.47	80.98	2.13	2.76	55094	20.35	57485	21.28	58228	21.64
212	MUAZZAM JAMEEL- 17 PGT	MALE	A	3.92	42.21	96.08	87.78	1.92	2.37	51454	18.45	54435	19.43	53590	19.06
217	DOMINA ANTONY- 27 UG	FEMALE	A	3.95	35.93	82.48	79.82	2.5	5.07	49705	17.81	52734	18.36	49118	16.62
220	DEEPSHIKA DRUVEDI- 25 UG	FEMALE	A	3.49	44.43	93.44	93.65	2.01	2.56	58168	21.17	54533	18.98	53676	19.22
223	SHIVANI SHARMA- 28 UG	FEMALE	A	4.42	49.01	96.33	88.81	2.14	2.49	64225	25.95	66756	26.86	61998	25.22
224	SHAGUFTHA ANJUM- 16 PGT	FEMALE	A	4	41.84	94.5	88.23	2.38	3.16	64285	18.71	60795	19.03	61255	21.3
227	SAYAN ROY- 24 UG	MALE	A	2.9	40.4	93.57	87.97	2.34	3.15	55208	20.21	57397	21.45	54361	20.28
233	ANISA AFROZ- 24 UG	FEMALE	A	2.97	39.06	85.99	83.33	2.06	2.6	55735	21.24	50059	18.52	49207	18.58
237	KANCHAN RAWAT- 23 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
238	AWARENLA IMCHEN-28 UG	FEMALE	A	4.09	40.91	95.72	80.48	2.29	3.48	56701	21.62	49911	18.23	48513	16.87
241	HEMANT KUMAR- 16 PGT	MALE	A	3.82	42.75	99.33	84.78	1.88	2.49	48500	16.26	47092	15.9	48044	16.38
244	TSHEWANG DENDUP- 28 UG	MALE	A	2.67	45.59	97.43	87.96	2.17	2.56	66917	26.13	64366	24.34	60919	23.21
247	DAKA- 18 PGT	FEMALE	A	4.51	44.32	93.49	92.04	2.85	5.72	60857	23.83	64489	25.18	57782	23.28
248	AZHARUDDIN SEKH- 26 UG	MALE	A	3.82	40.45	95.3	90.3	2.02	2.52	54924	20	53797	18.91	55190	19.71

GROUP A- BELLADONNA-6 GROUP- EPI 1 (1ST WEEK- RUN IN PERIOD -(PLACEBO))

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
101	SHANTHIADHIKARI- 16 PGT	MALE	A	3.04	46.5	96.77	90.95	2.28	2.61	64631	24.95	64742	25.27	63937	24.88
102	NIMI DEBBARMA- 25 UG	FEMALE	A	3.76	46.22	97.1	91.93	1.96	2.36	58392	21.49	57144	20.24	58472	21.1
106	HOZAIFA AYUBI- 23 UG	MALE	A	4.31	39.09	91.22	83.79	2	2.43	56813	20.17	51131	17.55	54159	19.17
113	SAGAR SAHA- 28 UG	MALE	A	2.48	43.53	97.12	93.11	2.28	2.77	61710	23.95	59568	22.64	62907	23.96
117	SUBHASHREE MODAK- 28 UG	FEMALE	A	3.3	46.09	95.35	89.45	2.34	2.54	65959	29.33	64756	27.17	65036	27.49
119	MONIKA VASHISHT- 25 UG	FEMALE	A	3.56	39.83	83.02	75.28	2.28	3.31	51874	18.21	52417	18.23	56873	21.18
120	MANEET- 18 PGT	MALE	A	3.79	34.43	93.33	87.47	1.94	2.82	41427	13.28	42353	13.82	41410	14.15
121	ARUN KUMAR- 16 PGT	MALE	A	3.53	37.85	97.05	76.28	2.23	3.49	47789	16.64	46492	15.77	48047	16.91
124	SATINDER SINGH- 26 UG	MALE	A	4.08	40.92	94.19	87.75	2.41	4.02	55195	19.3	54533	18.56	53967	18.9
125	JAMES MICHAEL- 17 PGT	MALE	A	2.39	37.89	99.13	97.18	2.36	2.7	61364	23.82	59935	23.37	61157	23.77
127	SHASHANK ATREY- 26 UG	MALE	A	3.48	37.36	88.92	84.09	1.95	2.8	45455	15.38	45048	15.15	47298	17.01
133	PRIYANKA KAUSHIK- 18 PGT	FEMALE	A	5.1	38.12	94.46	88.42	2.07	3.18	47587	15.91	48289	16.14	41481	13.75
136	JUTHIKA MOLLA- 25 UG	FEMALE	A	4.06	40.54	93.56	80.55	2.23	3.33	52714	18.58	48134	16.13	48659	17
139	QUAMAR SULTANA- 26 UG	FEMALE	A	3.38	40.12	92.97	86.28	2.17	2.66	58556	21.82	57296	20.96	55138	19.98
143	AFSANA- 23 UG	FEMALE	A	3.74	40.82	91.94	85.29	1.93	2.33	56058	20.04	52378	18.3	52736	18.6
144	DIVYA BHARADWAJ- 18 PGT	FEMALE	A	3.16	40.69	83.14	80.35	1.9	2.49	53167	18.22	50472	16.73	50077	16.09
147	IRESHA MADURANGANI- 23 UG	FEMALE	A	4.09	39.22	96.54	90.3	1.91	2.31	53209	18.67	54622	18.78	51700	17.86
149	VEENA- 27 UG	FEMALE	A	3.06	36.69	97.2	89.39	2.07	2.53	56822	20.5	53011	18.84	54237	19.38
152	KUNDAN KAUT CHANDRAN- 16 PGT	MALE	A	4.02	32.74	75.74	77.62	2.14	3.56	43430	14.46	42357	13.27	37909	11.71
156	AFRUSANNASNY AM- 24 UG	FEMALE	A	3.34	40.9	98.51	95.15	2.18	2.67	59490	21.7	57493	20.41	59822	21.84
157	ALEFIA MASFATIA- 25 UG	FEMALE	A	3.71	43.35	97.63	91.21	2.47	4.76	54032	20.41	54125	19.92	54321	20.57
168	SATARUPA SADHUKAN- 18 PGT	FEMALE	A	4.07	45.47	94.34	93.81	1.87	2.13	58298	22.33	58623	21.54	53207	20.34
181	JULKA KUMARI TRIPTI- 25 UG	FEMALE	A	2.69	38.63	97.34	88.63	2.1	2.54	54830	20.04	56404	20.42	57539	20.83
182	DEEPAK KUMAR CHAUDHARY- 18 PGT	MALE	A	3.41	40.73	90.86	89.88	1.91	2.48	53864	17.95	48966	15.66	50007	15.95
183	JAVEED IQBAL- 16 PGT	MALE	A	3.94	33.7	82.95	76.7	2.29	4.03	44651	13.96	40159	11.84	41929	12.84
185	ANGIRA CHAKRABORTY- 28 UG	FEMALE	A	3.26	41	95.66	91.06	2.18	2.58	58436	22.81	61108	23.75	54806	21.21
188	SAVITA GOSAI- 16 PGT	FEMALE	A	4.1	37.35	89.89	76.11	1.91	2.38	48627	17.02	49208	16.35	46790	16.43
189	AYESHA NAAZ- 16 PGT	FEMALE	A	3.18	37.7	90.29	86.78	1.87	2.3	49370	18.1	49392	17.62	47139	17.11
190	GURJEEV SINGH- 28 UG	MALE	A	3.14	42.27	95.3	92.84	2.06	2.4	60576	22.36	59664	21.86	58282	20.74
193	DHANASHREE VETTATHU- 24 UG	FEMALE	A	4.33	40.58	98.78	86.86	1.92	2.38	50417	17.57	50987	17.51	50647	17.87
197	RAJIB PURKAIT- 17 PGT	MALE	A	3.14	40.03	97.78	94.2	1.98	2.53	53245	18.12	51318	17.73	52089	18.79
198	VIVEK TIWARI- 28 UG	MALE	A	3.2	52.59	93.73	90.89	2.53	2.92	69677	30.15	70916	31.34	72008	32.06
201	DHIRAJ DEBNATH- 17 PGT	MALE	A	4.37	38.9	94.89	91.56	1.85	2.42	47549	15.11	48958	15.56	48944	15.86
206	CHANDRA MOHAN- 28 UG	MALE	A	4	42.16	90.11	86.9	2.28	2.96	62482	23.84	60782	22.49	59362	21.72
208	PALLAVI KUMARI- 28 UG	FEMALE	A	4.07	37.77	89.96	70.61	2.09	3.1	49732	17.43	46606	16.06	44435	15.53
209	ANWESHA DUBEY- 27 UG	FEMALE	A	4.28	40.74	92.82	91.77	1.96	2.35	55401	19.65	54287	19.08	53359	18.93
210	POONAM RANI- 18 PGT	FEMALE	A	3.52	39.07	95.49	89.6	2	2.56	53308	19.09	52332	17.85	52547	18.43
212	MUAZZAM JAMEEL- 17 PGT	MALE	A	3.5	38.05	91.04	85.54	2.05	2.82	53339	17.83	53580	17.97	49569	16.48
217	DOMINA ANTONY- 27 UG	FEMALE	A	4.06	40.59	98.2	89.55	2.15	2.67	56323	21.14	57348	21.39	57358	21.51
220	DEEPSHIKA DRUVEDI- 25 UG	FEMALE	A	3.58	40.64	98.26	87.29	1.99	2.67	51692	18.31	47093	15.61	49831	17.08
223	SHIVANI SHARMA- 28 UG	FEMALE	A	4.05	48.01	96.47	90.28	2.04	2.38	62189	24.45	63201	24.45	62263	23.75
224	SHAGUFTHA ANJUM- 16 PGT	FEMALE	A	4.34	48.56	99.76	93.12	2.18	2.64	61225	23.02	61319	22.94	62442	24.74
227	SAYAN ROY- 24 UG	MALE	A	3.38	41.34	98.83	90.18	2.01	2.54	53068	18.84	54957	19.93	54229	19.5
233	ANISA AFROZ- 24 UG	FEMALE	A	3.42	42.23	97.26	93.9	1.99	2.4	57660	21.66	53405	19.34	55283	20.09
237	KANCHAN RAWAT- 23 UG	FEMALE	A	4.14	38.62	85.62	81.15	1.83	2.33	49422	14.18	46343	13.74	48665	16.74
238	AWARENLA IMCHEN-28 UG	FEMALE	A	3.86	45.89	96.16	90.3	2.01	2.5	55754	20.77	55016	20.33	59386	22.73
241	HEMANT KUMAR- 16 PGT	MALE	A	3.47	42.83	96.99	89.11	1.79	2.26	49130	16.66	45817	15.1	48427	17
244	TSHEWANG DENDUP- 28 UG	MALE	A	3.17	54.73	95.47	93.15	2.13	2.4	67209	28	65375	27.42	67308	29.05
247	DAKA- 18 PGT	FEMALE	A	3.8	39.37	82.78	82.01	1.96	2.39	56488	21.16	55036	19.52	52028	18.27
248	AZHARUDDIN SEKH- 26 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

GROUP A- BELLADONNA 6 GROUP- EPI 2 (2ND WEEK- INTERVENTION PERIOD)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
								EPI_2							
101	SHANTHIADHIKARI- 16 PGT	MALE	A	3.29	50.22	97.79	90.11	2.3	2.69	64587	26.24	66628	27.62	64534	26.99
102	NIMI DEBBARMA- 25 UG	FEMALE	A	3.79	41.3	95	89.33	1.95	2.5	55738	19.93	50017	17.19	50659	17.82
106	HOZAIFA AYUBI- 23 UG	MALE	A	3.73	42.67	90.12	88.09	2.12	2.61	59231	21.79	57476	20.41	58618	21.35
113	SAGAR SAHA- 28 UG	MALE	A	2.46	41.76	98.54	92.19	2.22	2.61	60811	24.1	58135	22.21	59640	23.41
117	SUBHASHREE MODAK- 28 UG	FEMALE	A	3.08	42.5	99.83	90.31	2.5	2.91	64477	27.21	63706	26.29	64188	26.33
119	MONIKA VASHISHT- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
120	MANEET- 18 PGT	MALE	A	3.67	38.28	91.15	89.41	2.01	2.92	46838	16.77	44973	15.53	44533	15.35
121	ARUN KUMAR- 16 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
124	SATINDER SINGH- 26 UG	MALE	A	3.46	45.73	98.95	90.66	2.43	3.02	64066	25.88	63374	25.28	66745	26.7
125	JAMES MICHAEL- 17 PGT	MALE	A	2.46	41.45	98.42	90.53	3.1	3.88	67656	27.46	67151	27.17	70740	28.46
127	SHASHANK ATREY- 26 UG	MALE	A	3.95	44.22	90.07	83.52	2.01	2.64	54500	20.72	51816	19.21	52616	20.01
133	PRIYANKA KAUSHIK- 18 PGT	FEMALE	A	5.17	42.92	89.91	85.82	2.68	6.21	47021	16.39	55164	19.44	49151	17.89
136	JUTHIKA MOLLA- 25 UG	FEMALE	A	2.97	40.38	87.31	86.89	2.21	2.79	61800	23.7	54775	21.02	52557	20.24
139	QUAMAR SULTANA- 26 UG	FEMALE	A	3.8	44.66	92.47	85.94	2.21	2.7	58981	23.64	58772	22.62	57368	22.43
143	AFSANA- 23 UG	FEMALE	A	4.48	40.83	88.71	82.13	1.98	2.47	57433	20.81	52857	18.68	52263	18.54
144	DIVYA BHARADWAJ- 18 PGT	FEMALE	A	3.54	42.48	94.02	94.09	1.89	2.34	54551	18.93	52676	17.75	51608	17.18
147	IRESHA MADURANGANI- 23 UG	FEMALE	A	3.81	44	93.69	87.96	1.89	2.25	56071	21.24	54141	20.07	49534	18.51
149	VEENA- 27 UG	FEMALE	A	3.62	41.31	97.55	92.28	2.08	2.65	57314	21.21	56204	20.35	57175	20.66
152	KUNDAN KAUT CHANDRAN- 16 PGT	MALE	A	4.44	38.46	86.63	82.74	1.92	2.6	47440	16.33	49347	17.01	45451	15.17
156	AFRUSANNASNY AM- 24 UG	FEMALE	A	3.56	44.6	96.63	89.9	2.07	2.45	59241	22.18	61298	22.25	59336	21.49
157	ALEFIA MASFATIA- 25 UG	FEMALE	A	3.4	40.99	99.18	92.41	1.96	2.4	53755	19.66	52014	18.87	54326	20
168	SATARUPA SADHUKAN- 18 PGT	FEMALE	A	3.71	50.27	98.19	91.72	2.05	2.36	63146	25.46	64511	25	63396	25.23
181	JULKA KUMARI TRIPTI- 25 UG	FEMALE	A	2.8	36.41	98.5	85.96	2.24	3	54682	19.8	52121	19.24	50795	18.72
182	DEEPAK KUMAR CHAUDHARY- 18 PGT	MALE	A	3.79	39.18	89.95	87.89	1.86	2.44	49684	16.73	44610	14.3	46127	15.19
183	JAVEED IQBAL- 16 PGT	MALE	A	3.24	38.24	98.84	89.82	2.15	3.51	44696	14.73	42649	13.81	44565	15.44
185	ANGIRA CHAKRABORTY- 28 UG	FEMALE	A	3.64	45.88	97.3	94.92	2.13	2.39	61175	24.69	63400	25.02	62665	24.96
188	SAVITA GOSAI- 16 PGT	FEMALE	A	4.86	37.62	89.16	88.76	3	7.87	52241	19.18	53901	18.73	44753	16.09
189	AYESHA NAAZ- 16 PGT	FEMALE	A	3.41	39.08	85.5	87.49	2.31	4.64	50965	18.81	51790	18.52	47796	17.07
190	GURJEEV SINGH- 28 UG	MALE	A	3.5	44.44	96.45	91.87	2.11	2.51	61105	23.03	59658	22.24	57601	21.71
193	DHANASHREE VETTATHU- 24 UG	FEMALE	A	3.96	43.05	95.25	92.42	2	2.5	56067	20.34	55777	19.9	54062	19.66
197	RAJIB PURKAIT- 17 PGT	MALE	A	3.95	36.32	96.32	90.76	2.18	3.08	51424	17.16	49469	16.45	48671	16.16
198	VIVEK TIWARI- 28 UG	MALE	A	3.78	40.16	98.07	90.4	1.97	2.42	54956	18.73	52935	17.75	55299	19.13
201	DHIRAJ DEBNATH- 17 PGT	MALE	A	3.91	47.91	91.14	89.85	1.89	2.29	56515	21.11	55311	20.25	56941	21.48
206	CHANDRA MOHAN- 28 UG	MALE	A	3.33	50.88	99.47	91.75	3.18	5.06	70051	29.54	67013	28.49	65427	28.15
208	PALLAVI KUMARI- 28 UG	FEMALE	A	3.35	38.31	92.16	89.82	2.01	2.89	50849	17.09	47796	15.83	48120	16.48
209	ANWESHA DUBEY- 27 UG	FEMALE	A	6.26	34.35	89.68	78.39	2.58	5.43	37011	12.89	35597	11.11	40756	12.85
210	POONAM RANI- 18 PGT	FEMALE	A	3.59	43.14	98.99	92.25	1.94	2.35	56469	21.4	53923	19.69	56055	20.92
212	MUAZZAM JAMEEL- 17 PGT	MALE	A	3.77	43.07	97.73	87.69	1.94	2.36	55677	20.91	54977	20.3	52493	19.37
217	DOMINA ANTONY- 27 UG	FEMALE	A	4.05	40.95	89.77	82.15	2.36	3.09	59878	22.6	60245	22.6	58669	21.89
220	DEEPSHIKA DRUVEDI- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
223	SHIVANI SHARMA- 28 UG	FEMALE	A	4.23	54.36	98.86	94.52	2.13	2.45	65593	28.52	65501	27.66	66077	28.07
224	SHAGUFTHA ANJUM- 16 PGT	FEMALE	A	3.83	38.42	85.89	80.78	2.02	2.63	54570	20.75	49956	17.65	49046	17.48
227	SAYAN ROY- 24 UG	MALE	A	3.35	41.64	91.34	80.95	2.02	2.6	55985	21.27	55737	21.22	47693	17.51
233	ANISA AFROZ- 24 UG	FEMALE	A	4.06	40	85.3	83.21	1.96	2.42	56278	19.9	53149	18.23	48830	16.73
237	KANCHAN RAWAT- 23 UG	FEMALE	A	3.6	48.45	94.64	94.07	1.86	2.19	59846	21.49	58757	21.03	54225	19.84
238	AWARENLA IMCHEN-28 UG	FEMALE	A	3.98	47.02	96.05	74.93	2.33	3.34	54720	21.13	53806	20.26	58096	22.73
241	HEMANT KUMAR- 16 PGT	MALE	A	3.07	34.73	89.92	88.9	2.13	3.5	43603	13.78	37628	11.04	39944	12.72
244	TSHEWANG DENDUP- 28 UG	MALE	A	2.61	39.82	97.24	88.2	2.34	3.1	55925	20.74	54147	19.82	57748	21.49
247	DAKA- 18 PGT	FEMALE	A	4.41	38.28	96.74	90.68	2.28	3.26	51878	19.19	52311	19.65	51674	18.88
248	AZHARUDDIN SEKH- 26 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

GROUP A- BELLADONNA-6C GROUP- EPI 3 (3RD WEEK- ANTIDOTE WEEK)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
101	SHANTHIADHIKARI- 16 PGT	MALE	A	2.95	39.19	90.63	88.79	2.06	2.56	56857	20.94	53147	19.2	51857	18.63
102	NIMI DEBBARMA- 25 UG	FEMALE	A	3.81	38.03	95.7	91.18	2.06	2.74	54779	19.07	51756	17.52	50711	17.4
106	HOZAIFA AYUBI- 23 UG	MALE	A	3.79	43.5	87.54	83.08	2.08	2.57	62899	24.4	56688	20.9	54281	20.43
113	SAGAR SAHA- 28 UG	MALE	A	2.34	47.73	96.41	90	2.36	2.61	72716	30.39	68275	27.29	69134	27.38
117	SUBHASHREE MODAK- 28 UG	FEMALE	A	3.31	38.27	89.89	86.31	2.45	3.14	60786	24.23	55657	20.88	56391	20.18
119	MONIKA VASHISHT- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
120	MANEET- 18 PGT	MALE	A	4.21	35.53	88.48	82.51	1.95	2.73	47130	16.18	48607	16.24	41818	13.35
121	ARUN KUMAR- 16 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
124	SATINDER SINGH- 26 UG	MALE	A	3.62	43.98	88.92	88.02	2.07	2.52	60657	22.91	57920	21.69	56699	21.14
125	JAMES MICHAEL- 17 PGT	MALE	A	2.52	49.32	95.26	90.67	2.55	2.82	72721	32.16	69282	30.44	71385	31.65
127	SHASHANK ATREY- 26 UG	MALE	A	4.16	42.86	95.51	85.53	1.97	2.57	53254	19.66	53556	19.39	51825	18.81
133	PRIYANKA KAUSHIK- 18 PGT	FEMALE	A	5.17	35.03	97.82	87.17	2.8	6.54	40966	13.1	44729	14.23	38563	12.41
136	JUTHIKA MOLLA- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
139	QUAMAR SULTANA- 26 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
143	AFSANA- 23 UG	FEMALE	A	3.83	43.38	99.57	91.65	2.04	2.51	59982	21.63	55628	19.58	58157	20.8
144	DIVYA BHARADWAJ- 18 PGT	FEMALE	A	3.26	43.19	92.31	89.83	1.9	2.35	56173	20.75	53525	19.56	51413	18.29
147	IRESHA MADURANGANI- 23 UG	FEMALE	A	4.06	38.56	98.74	88.5	2.02	2.71	51242	17.38	49578	16.58	51272	17.76
149	VEENA- 27 UG	FEMALE	A	5.01	38.7	83.41	79.43	2.54	4.8	55310	20.93	52840	19.43	48428	17.54
152	KUNDAN KAUT CHANDRAN- 16 PGT	MALE	A	4.2	37.61	92.78	88.1	1.88	2.5	48937	15.64	50590	16.3	47635	15.51
156	AFRUSANNASNY AM- 24 UG	FEMALE	A	3.92	43.37	93.18	83.74	2.06	2.43	55718	20.33	59320	21.89	58039	22.02
157	ALEFIA MASFATIA- 25 UG	FEMALE	A	3.49	39.36	87.6	84.55	1.93	2.48	52139	19.22	50466	18.36	48319	17.64
168	SATARUPA SADHUKAN- 18 PGT	FEMALE	A	4.08	49.73	91.21	92.18	2.05	2.34	63440	25.94	65563	25.8	58730	22.79
181	JULKA KUMARI TRIPTI- 25 UG	FEMALE	A	2.72	39.27	97.6	94.31	2.17	2.84	57739	21.31	53659	19.87	52718	19.83
182	DEEPAK KUMAR CHAUDHARY- 18 PGT	MALE	A	3.84	31.84	97.71	92.28	1.97	2.95	42473	12.73	38742	11.13	42248	12.83
183	JAVEED IQBAL- 16 PGT	MALE	A	3.44	39.07	99.03	91.8	2.09	3.19	45772	15.38	44042	14.44	46653	15.97
185	ANGIRA CHAKRABORTY- 28 UG	FEMALE	A	3.71	44.49	99.77	89.55	2.24	2.61	59422	23	63416	24.36	63062	24.54
188	SAVITA GOSAI- 16 PGT	FEMALE	A	4.44	35.18	92.2	88.93	2.17	3.54	44233	15.48	46504	15.27	45193	15.91
189	AYESHA NAAZ- 16 PGT	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
190	GURJEEV SINGH- 28 UG	MALE	A	3.51	53.77	95.9	90.84	2.3	2.51	70617	29.59	72678	30.28	71037	29.77
193	DHANASHREE VETTATHU- 24 UG	FEMALE	A	4.14	43.18	97.49	93.77	1.98	2.37	56637	21.28	58447	22.11	54132	20.32
197	RAJIB PURKAIT- 17 PGT	MALE	A	3.91	41.77	96.54	90.58	2.15	2.71	54946	19.27	56178	20.28	58181	20.79
198	VIVEK TIWARI- 28 UG	MALE	A	3.8	42.34	94.92	90.6	2.13	2.72	56340	20.58	55001	19.61	56921	20.69
201	DHIRAJ DEBNATH- 17 PGT	MALE	A	4.31	39.75	99.06	89.58	1.94	2.91	47336	15.81	47818	16.36	49800	17.84
206	CHANDRA MOHAN- 28 UG	MALE	A	3.97	38.72	98.92	85.63	2.21	2.98	55444	20.11	55930	20.19	52381	18.64
208	PALLAVI KUMARI- 28 UG	FEMALE	A	3.93	34.57	94.71	81.26	2.26	3.73	44085	14.23	43066	13.37	45884	14.64
209	ANWESHA DUBEY- 27 UG	FEMALE	A	4.44	38.68	99.7	81.83	2.08	2.99	47600	16.22	47588	15.72	49969	17.29
210	POONAM RANI- 18 PGT	FEMALE	A	3.51	47.22	94.18	90.23	1.98	2.35	59268	23.13	57104	21.47	58495	22.24
212	MUAZZAM JAMEEL- 17 PGT	MALE	A	3.39	37.15	98.15	89.04	2.01	2.87	46786	15.11	46597	15.25	49409	16.41
217	DOMINA ANTONY- 27 UG	FEMALE	A	4.32	41.92	96.96	86.83	2.29	3.26	54015	19.64	55931	20.39	56203	21.31
220	DEEPSHIKA DRUVEDI- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
223	SHIVANI SHARMA- 28 UG	FEMALE	A	3.95	54.4	95.11	90.95	2.09	2.29	70736	30.73	68575	28.9	67921	28.57
224	SHAGUFTHA ANJUM- 16 PGT	FEMALE	A	4.72	43.62	91.09	87.09	1.96	2.35	58424	21.1	58110	20.42	55508	19.62
227	SAYAN ROY- 24 UG	MALE	A	3.06	43.69	85.19	81.44	2.13	2.48	62254	24.46	64277	24.83	59796	22.8
233	ANISA AFROZ- 24 UG	FEMALE	A	4.5	46.11	92.41	84.49	1.96	2.31	59748	22.53	55973	20	55863	20.67
237	KANCHAN RAWAT- 23 UG	FEMALE	A	3.59	49.76	94.91	93.57	1.92	2.19	60588	23.58	61831	24.26	58640	22.86
238	AWARENLA IMCHEN-28 UG	FEMALE	A	3.54	52.44	89.79	87.7	2.2	2.57	62659	25.34	62731	26.34	67884	29.27
241	HEMANT KUMAR- 16 PGT	MALE	A	3.44	38.48	98.81	90.84	1.81	2.41	43564	14.51	40271	12.84	42886	14.2
244	TSHEWANG DENDUP- 28 UG	MALE	A	3.73	40.66	94.51	93.71	2.47	3.43	56740	20.7	59140	20.99	55349	19.49
247	DAKA- 18 PGT	FEMALE	A	4.23	40.55	93.82	89.87	2	2.45	51391	19.1	53150	19.84	55254	21.48
248	AZHARUDDIN SEKH- 26 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

94

GROUP- A - BELLADONNA-6C GROUP- EPI-4 (4TH WEEK- AFTER WASHOUT PERIOD)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
101	SHANTHIADHIKARI- 16 PGT	MALE	A	3.44	41.77	98.68	86.64	2.29	2.95	59823	23.26	55715	20.75	54435	20.68
102	NIMI DEBBARMA- 25 UG	FEMALE	A	3.76	45.95	97.59	87.81	2	2.41	56870	21.16	58682	22.1	59186	22.57
106	HOZAIFA AYUBI- 23 UG	MALE	A	4.13	37.28	92.2	90.14	2.12	2.82	54745	18.9	50982	16.89	51842	18.15
113	SAGAR SAHA- 28 UG	MALE	A	2.54	40.72	94.53	90.85	2.24	2.63	61853	23.76	60643	22.8	60090	22.35
117	SUBHASHREE MODAK- 28 UG	FEMALE	A	3.25	35.66	97.29	90.44	2.28	3.07	53781	19.4	50956	17.85	53121	18.42
119	MONIKA VASHISHT- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
120	MANEET- 18 PGT	MALE	A	3.64	42.91	93.94	89.8	1.86	2.37	48868	17.69	50996	17.98	50947	18.69
121	ARUN KUMAR- 16 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
124	SATINDER SINGH- 26 UG	MALE	A	4.63	44.19	90.78	87.63	2.07	2.65	58666	21.69	56815	20.83	53142	19.73
125	JAMES MICHAEL- 17 PGT	MALE	A	2.9	39.12	89.89	82.81	2.25	2.64	62772	23.39	58895	21.3	61348	21.75
127	SHASHANK ATREY- 26 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
133	PRIYANKA KAUSHIK- 18 PGT	FEMALE	A	4.5	45.11	97.53	88.95	2.06	3.06	53948	19.4	54893	19.43	48403	17.42
136	JUTHIKA MOLLA- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
139	QUAMAR SULTANA- 26 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
143	AFSANA- 23 UG	FEMALE	A	3.7	40.35	99.41	89.76	1.99	2.4	57203	19.38	54079	18.36	55973	18.98
144	DIVYA BHARADWAJ- 18 PGT	FEMALE	A	3.15	58.07	97.4	90.65	2.02	2.32	68022	26.48	63891	24.25	62648	22.53
147	IRESHA MADURANGANI- 23 UG	FEMALE	A	3.87	35.99	95.7	90.48	1.95	2.53	49849	16.43	47535	15.07	49058	15.71
149	VEENA- 27 UG	FEMALE	A	3.85	41.64	96.85	94.21	2.16	2.73	59775	23.2	56958	21.54	56309	21.05
152	KUNDAN KAUT CHANDRAN- 16 PGT	MALE	A	3.65	41.77	93.5	92.53	1.84	2.34	51194	17.8	52627	17.81	50223	17.23
156	AFRUSANNASNY AM- 24 UG	FEMALE	A	3.57	43.7	93.88	87.47	1.97	2.35	54113	20.79	55687	20.74	58237	22.19
157	ALEFIA MASFATIA- 25 UG	FEMALE	A	3.16	39.84	88.62	80.91	2.18	3.08	56317	20.17	50547	17.82	51304	18.16
168	SATARUPA SADHUKAN- 18 PGT	FEMALE	A	4.03	38.89	94.81	90.25	1.97	2.39	54345	19.08	55756	19.31	53714	18.81
181	JULKA KUMARI TRIPTI- 25 UG	FEMALE	A	2.9	42.05	92.03	87.21	2.15	2.64	64486	24.68	54962	20.74	54478	20.43
182	DEEPAK KUMAR CHAUDHARY- 18 PGT	MALE	A	3.63	43.03	94.68	90.49	1.97	2.57	55122	18.17	50686	16.44	53786	17.82
183	JAVEED IQBAL- 16 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
185	ANGIRA CHAKRABORTY- 28 UG	FEMALE	A	4.29	45.46	90.83	92.76	2.44	3.35	63175	24.86	67485	26	55674	22.02
188	SAVITA GOSAI- 16 PGT	FEMALE	A	4.74	38.06	91.06	88.73	2.06	2.77	51829	18.38	52923	18.04	49135	17.22
189	AYESHA NAAZ- 16 PGT	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
190	GURJEEV SINGH- 28 UG	MALE	A	3.37	35.49	97.87	92.22	1.97	2.47	53243	17.98	50944	17.3	49750	16.85
193	DHANASHREE VETTATHU- 24 UG	FEMALE	A	7.77	42.89	96.59	80.91	1.78	2.14	54598	20.12	47343	16.28	29622	10.31
197	RAJIB PURKAIT- 17 PGT	MALE	A	3.91	39.79	90.65	91.61	2.17	3.01	52741	19.17	51569	18.83	50429	18.08
198	VIVEK TIWARI- 28 UG	MALE	A	3.46	46.83	89.75	92.35	2.03	2.38	57147	22.28	58238	22.53	59085	23.77
201	DHIRAJ DEBNATH- 17 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
206	CHANDRA MOHAN- 28 UG	MALE	A	3.67	45.81	98.33	83.06	2.37	2.82	62563	23.86	64324	24.47	64938	24.67
208	PALLAVI KUMARI- 28 UG	FEMALE	A	4.49	33.31	97.72	76.73	2.27	3.93	41711	13.01	36318	10.93	43088	14.46
209	ANWESHA DUBEY- 27 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
210	POONAM RANI- 18 PGT	FEMALE	A	4.38	35.36	94.88	87.93	2.07	2.78	48008	16.08	51303	17.12	50985	17.23
212	MUAZZAM JAMEEL- 17 PGT	MALE	A	3.3	36.54	96.48	87.65	2.08	2.94	49725	16.3	50010	16.43	48855	16.16
217	DOMINA ANTONY- 27 UG	FEMALE	A	4.39	43.11	97.23	93.38	2.02	2.47	55490	21.01	59352	22.44	55177	20.79
220	DEEPSHIKA DRUVEDI- 25 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
223	SHIVANI SHARMA- 28 UG	FEMALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
224	SHAGUFTHA ANJUM- 16 PGT	FEMALE	A	4.08	42.64	94.06	89.36	1.93	2.29	58735	21.16	55436	19.75	55633	20.6
227	SAYAN ROY- 24 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
233	ANISA AFROZ- 24 UG	FEMALE	A	3.71	46.71	99.61	93.64	2.06	2.63	58014	22.3	57937	22.06	56902	22.05
237	KANCHAN RAWAT- 23 UG	FEMALE	A	5.05	29.83	89.37	87.53	2.03	3.46	41928	13.3	41196	13.08	35401	10.73
238	AWARENLA IMCHEN-28 UG	FEMALE	A	3.49	38.58	99.45	96.6	1.96	2.58	50709	16.81	47994	16.02	48632	16.67
241	HEMANT KUMAR- 16 PGT	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
244	TSHEWANG DENDUP- 28 UG	MALE	A	2.49	47.67	96.12	94.38	2.17	2.62	59981	24.33	61445	24.58	62294	24.9
247	DAKA- 18 PGT	FEMALE	A	3.48	44.66	95.45	87.96	2.32	4	57686	22.73	57620	22.49	56204	22.76
248	AZHARUDDIN SEKH- 26 UG	MALE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

GROUP B- BELLADONNA-200 GROUP -EPI 0 (PRE INTERVENTION READING)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
105	ABHINAV RAJ- 16 PGT	MALE	B	3.37	40.54	88.23	88.95	1.99	2.6	53383	19.12	50891	18	49719	17.59
110	HIMA TS- 27 UG	FEMALE	B	3.36	38.32	96.16	91.25	2.15	2.57	58579	21.83	56042	20.47	57588	21.8
111	NAYAB AMIR- 28 UG	MALE	B	3.45	43.98	98.12	90.86	2.15	2.54	61277	23.7	61694	23.56	59487	23.33
112	AK MIJANUR- 28 UG	MALE	B	4.21	37.67	99.61	86.81	2.13	3.22	52874	18.48	53183	17.96	50053	16.89
114	ANKITA AICH- 26 UG	FEMALE	B	4.2	40.1	86.63	84.5	2.04	2.52	58377	19.87	57055	18.98	56024	18.47
116	SANGEETA VENKATESH- 27 UG	FEMALE	B	4.27	52.16	92.95	87.83	1.99	2.3	62135	24.04	62701	23.63	61531	23.47
118	MANTASHA HASAN- 27 UG	FEMALE	B	3.07	32.29	93.65	85.92	2.19	3.31	43510	13.65	43743	14.43	44694	14.89
122	APURBA MAHATO- 25 UG	MALE	B	4.17	37.81	98.46	87.96	1.97	2.47	54989	19.3	53257	18.48	51760	18.82
123	SUHISNA DAS- 26 UG	FEMALE	B	2.64	42.79	95.85	94.67	2.22	2.52	63945	25.35	60588	23.89	63627	25.12
128	AVARANJIKA- 19 PGT	FEMALE	B	3.53	46.39	94.77	90.65	1.88	2.19	56779	22.34	55072	20.83	56231	22.28
129	LAXMIDHAR SAHOO- 27 UG	MALE	B	3.47	51.81	99.89	93.69	1.94	2.21	63875	23.33	61352	21.92	63292	23.57
130	NAMRATA JAISWAL- 27 UG	FEMALE	B	3.41	44.43	98.41	90.37	2.44	3.25	62140	24.22	61078	22.84	61254	23.69
131	NAVIN PRAKASH RAY- 17 PGT	MALE	B	3.47	51.81	99.89	93.69	1.94	2.21	63875	23.33	61352	21.92	63292	23.57
132	NASIMUDDIN AHMED- 28 UG	MALE	B	3.81	44.72	97.98	82.34	2.18	2.75	57257	22.49	58918	23.12	60986	24.31
134	PRABHAT KIRAN- 23 UG	MALE	B	3.71	41.32	84.38	76.5	1.88	2.42	53071	18.51	49043	16.33	48230	16.13
145	DEEPSHIKA SHARMA- 28 UG	FEMALE	B	3.21	44.12	95.21	89.46	2.21	2.96	59129	22.13	57180	21.64	55761	21.22
146	VYSHEK- 27 UG	MALE	B	2.95	47.08	98.45	92.59	2.86	5.09	68435	27.78	63689	25.16	69992	28.14
148	ARJIT SEN- 26 UG	MALE	B	3.71	42.08	99.53	92.42	1.93	2.31	54504	18.58	55043	19.15	55632	19.25
158	ANANYA ADHIKARI- 26 UG	FEMALE	B	4.34	44.91	98.04	91.05	2.12	2.54	57645	22.77	59224	22.44	61537	23.67
160	RASHMI UTTAM-18 PGT	FEMALE	B	4.45	42.7	95.27	88.82	2.11	2.7	54125	20.17	56938	21.34	54319	20.52
162	ARCHIMEDES AMIN- 27 UG	MALE	B	4.94	30.67	96.03	83.31	2.33	4.46	37094	11.01	33010	9.28	39026	12.07
164	DINITHI UPEKSHA- 25 UG	FEMALE	B	4.19	39.61	96.59	90.27	2.18	2.69	55994	21.04	54853	20.65	56951	22.07
167	POUJITHAN- 28 UG	MALE	B	4.4	41.63	83.92	79.34	2.48	3.65	54078	18.63	57144	19.9	60060	21.78
169	WANBHAHBIANG RANI- 28 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
170	MUKTA JAIN – 28 UG	FEMALE	B	3.31	45.28	96.11	86.21	2.35	2.9	61056	24.47	60278	24.06	62326	25.58
172	RANJEET MAURYA- 28 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
173	VINAY KUMAR- 23 UG	MALE	B	4.24	41.59	96.47	90.85	1.88	2.53	48819	16.06	48667	16.08	49183	16.92
175	DEEPAK PANDEY- 17 PGT	MALE	B	4.65	34.6	80.63	82.47	2.19	3.58	46862	16.09	40358	13.3	40810	13.68
176	SANGHAMITRA DAS- 26 UG	FEMALE	B	4.16	39.56	99.54	86.25	2.14	2.75	55370	19	55239	19.27	56737	20.18
178	ANKITA AICH- 26 UG	FEMALE	B	3.68	43.91	92.73	90.37	1.91	2.2	60435	22.26	56029	20.07	56460	20.96
186	SUBHRANIL SAHA- 17 PGT	MALE	B	4.47	32.97	95.84	62.47	2.52	4.61	43446	14.68	39577	12.97	42022	14.14
191	NITIN KUMAR SAKLANI- 17 PGT	MALE	B	3.68	41.4	98.92	89.01	1.93	2.61	49509	17.32	50903	17.49	48607	17.09
195	LILY ANAL- 18 PGT	FEMALE	B	3.81	41.13	80.63	74.65	1.89	2.31	54864	19.6	53538	18.41	49034	16.19
196	NEETU KUMARI- 28 UG	FEMALE	B	4.02	40.02	96.58	84.4	1.91	2.38	54783	18.26	51738	16.53	49805	16.63
200	ANIKET RAJ- 28 UG	MALE	B	4.26	41.13	88.08	88.29	2.11	2.71	57393	21.38	56753	20.22	51023	17.93
202	SEETHA LAKSHMI- 24 UG	FEMALE	B	3.71	37.87	71.39	69.94	2.55	4.76	43075	13.74	44154	14.8	53918	19.28
203	ABHISHEK GUPTA- 28 UG	MALE	B	4.48	42.08	87.77	84.95	1.99	2.47	58178	22.15	57629	21.33	51326	18.74
205	SUPRIYA SINGH- 26 UG	FEMALE	B	4.75	44.76	90.64	92.04	1.99	2.32	60977	22.52	60147	21.59	55865	19.84
213	DIVYA JYOTI ANAND- 27 UG	FEMALE	B	3.47	48.3	93.33	84.98	2.45	2.88	66646	28.7	67034	28.25	70263	30.36
218	SHARY KRISHNA- 18 PGT	FEMALE	B	4.2	39.42	93.7	85.06	1.99	2.85	48258	16.16	46920	15.17	46904	15.45
221	ASHUTOSHA KUMAR- 17 PGT	MALE	B	3.09	39.15	95.37	85.55	1.91	2.63	47960	16.39	46999	15.48	45623	14.82
225	HEMAL MANDI- 27 UG	MALE	B	5.14	45.48	99.7	90.26	3.34	8	58765	24.75	66797	26.77	62131	25.54
229	NIRBHAY KUMAR- 27 UG	MALE	B	4.85	49.02	95.41	88.92	2.34	3.65	58556	21.85	61419	22.55	57364	21.68
230	BINAY PRATAP SINGH- 27 UG	MALE	B	4.76	43.86	87.67	85.92	2.05	2.63	58409	21.53	56743	19.81	54113	18.84
231	YASHFEEN KHALDA- 28 UG	FEMALE	B	3.8	43.52	99.07	88.85	2.11	2.63	57879	22.22	54363	20.2	58144	22.16
235	ANKITA DHAR- 28 UG	FEMALE	B	3.11	42.53	92.19	85.83	2.09	2.66	57458	21.08	54734	19.39	56378	20.4
239	SOUMYENDU DEBNATH- 26 UG	MALE	B	4.13	38.41	86.15	88	2.22	2.83	58459	20	58080	19.11	51951	16.87
242	AAKASH DEEP DAS- 23 UG	MALE	B	4.37	38.62	96.36	86.96	2.26	3.28	52607	18.42	55121	18.94	56509	19.56
243	SHUBHABRATA DAS- 28 UG	MALE	B	3.63	42.77	98.29	95.78	2.03	2.54	57851	20.87	56775	19.91	57465	20.69
245	CHRISTINA LALHRIATPUII-27 UG	FEMALE	B	3.57	51.04	98	90.72	2.43	2.78	62289	27.03	71833	31	68946	30.4

GROUP B- BELLADONNA-200 GROUP- EPI 1 (1ST WEEK- RUN IN PERIOD -(PLACEBO))

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
105	ABHINAV RAJ- 16 PGT	MALE	B	3.33	44.17	96.38	92.67	1.96	2.41	54723	20.26	55470	20.29	53383	19.96
110	HIMA TS- 27 UG	FEMALE	B	2.76	38.85	97.55	94.1	2.29	2.61	60138	23.63	58071	22.9	58818	23.15
111	NAYAB AMIR- 28 UG	MALE	B	3.38	39.62	96.93	91.37	2.17	2.72	55070	21.49	57003	22.13	54585	21.71
112	AK MIJANUR- 28 UG	MALE	B	3.56	50.64	96.91	91.96	2.09	2.66	62246	25.19	62027	24.45	60962	24.19
114	ANKITA AICH- 26 UG	FEMALE	B	3.94	43.35	82.47	81.94	1.96	2.34	59735	22.83	55427	20.01	51847	19.05
116	SANGEETA VENKATESH- 27 UG	FEMALE	B	5.32	33.34	93.17	89.06	2.47	5.05	39568	12.83	38515	11.48	37221	11.2
118	MANTASHA HASAN- 27 UG	FEMALE	B	3.6	33.9	82.05	84.96	2.31	3.94	48044	16.36	42575	13.74	43424	14.39
122	APURBA MAHATO- 25 UG	MALE	B	3.75	44.6	97.4	92.54	2.01	2.4	58208	22.86	57150	21.81	57446	22.17
123	SUHISNA DAS- 26 UG	FEMALE	B	2.93	40.63	94.32	89.83	2.26	2.56	60907	23.26	61387	23.11	63927	24.7
128	AVARANJIKA- 19 PGT	FEMALE	B	3.93	40.67	92.04	88.58	1.86	2.29	52573	19.53	50021	17.56	48395	17.2
129	LAXMIDHAR SAHOO- 27 UG	MALE	B	3.36	38.23	91.32	85.07	2.07	3.02	47275	16.33	44464	14.79	47092	16.21
130	NAMRATA JAISWAL- 27 UG	FEMALE	B	3.07	41.34	94.19	91.84	2.38	2.83	62850	26.29	59432	24.43	55921	23.29
131	NAVIN PRAKASH RAY- 17 PGT	MALE	B	3.36	38.23	91.32	85.07	2.07	3.02	47275	16.33	44464	14.79	47092	16.21
132	NASIMUDDIN AHMED- 28 UG	MALE	B	3.76	54.97	95.05	93.92	2.14	2.36	71351	29.73	69266	28.12	69462	28.7
134	PRABHAT KIRAN- 23 UG	MALE	B	3.35	42.94	89.01	87.77	1.83	2.28	53861	18.84	51945	17.4	50385	16.99
145	DEEPSHIKA SHARMA- 28 UG	FEMALE	B	3.11	41.19	88.12	86.02	2.17	3	56000	21.19	52837	19.89	51707	18.45
146	VYSHEK- 27 UG	MALE	B	3.01	37.19	94.7	86.39	2.18	2.93	53608	19.79	49921	17.96	50095	18.34
148	ARJIT SEN- 26 UG	MALE	B	3.73	43.29	93.7	86.11	1.9	2.26	55304	20.21	53710	19.36	54213	19.43
158	ANANYA ADHIKARI- 26 UG	FEMALE	B	4.59	42.63	91.1	85.46	2.06	2.51	60252	22.58	56418	20.45	55410	20.04
160	RASHMI UTTAM-18 PGT	FEMALE	B	4.23	40.37	94.44	91.66	1.93	2.48	53299	18.19	50186	16.35	51858	17.03
162	ARCHIMEDES AMIN- 27 UG	MALE	B	5.72	22.92	68.99	62.02	2.49	5.88	21714	5.56	21333	5.36	27934	7.76
164	DINITHI UPEKSHA- 25 UG	FEMALE	B	3.86	41.56	97.23	93	2.41	2.73	63307	24.29	63025	24.22	63298	24.18
167	POUJITHAN- 28 UG	MALE	B	3.84	50.49	89.39	84.23	2.31	3	59932	23.67	62145	24.81	65823	27.59
169	WANBHAHBIANG RANI- 28 UG	MALE	B	3.78	37.26	95.34	87.88	2.09	2.95	51043	17.7	49150	16.77	48771	16.98
170	MUKTA JAIN – 28 UG	FEMALE	B	3.24	40.78	96.44	88.71	2.14	2.59	59543	23.15	58592	22.28	58475	21.93
172	RANJEET MAURYA- 28 UG	MALE	B	3.72	51.42	88.7	79.75	1.89	2.2	62555	24.41	57567	21.15	55832	20.39
173	VINAY KUMAR- 23 UG	MALE	B	4.09	33.78	93.22	80.84	1.88	2.71	42165	12.21	40545	11.47	41839	12.48
175	DEEPAK PANDEY- 17 PGT	MALE	B	3.74	42.49	97.23	90.91	1.86	2.27	51540	17.78	52094	18.21	54234	19.53
176	SANGHAMITRA DAS- 26 UG	FEMALE	B	2.67	40.71	97.28	93.46	2.12	2.66	55525	21.73	56577	21.65	56967	22.1
178	ANKITA AICH- 26 UG	FEMALE	B	3.97	44.99	97.99	96.05	2.14	2.48	64375	23.61	60805	22.38	57764	22.46
186	SUBHRANIL SAHA- 17 PGT	MALE	B	3.76	37.87	99.73	76.76	2.7	4.77	48800	17.23	49847	17.55	51344	18.21
191	NITIN KUMAR SAKLANI- 17 PGT	MALE	B	3.57	41.39	92.25	91.91	1.84	2.43	50884	16.97	48949	16.02	45917	14.99
195	LILY ANAL- 18 PGT	FEMALE	B	3.98	36.93	98.41	90.73	1.91	2.51	46845	15.54	46866	15.28	47046	15.48
196	NEETU KUMARI- 28 UG	FEMALE	B	3.19	51.73	96.3	92.87	2.53	2.66	75020	34.46	72054	32.61	71001	31.92
200	ANIKET RAJ- 28 UG	MALE	B	4.4	59.35	93.48	91.39	2.02	2.18	67512	28.49	70789	29.82	61992	26.11
202	SEETHA LAKSHMI- 24 UG	FEMALE	B	3.95	42.05	96.64	89.38	1.89	2.29	54628	18.76	54756	18.84	52825	18.67
203	ABHISHEK GUPTA- 28 UG	MALE	B	4.19	38.64	89.67	83.4	2.04	2.76	55636	19.75	55994	19.52	49859	17.18
205	SUPRIYA SINGH- 26 UG	FEMALE	B	4.46	43.2	92.36	89.05	1.98	2.38	58041	21.42	56295	19.96	54661	19.01
213	DIVYA JYOTI ANAND- 27 UG	FEMALE	B	2.76	39.3	91.66	86.4	2.09	2.53	57704	22.56	54301	20.71	57923	22.63
218	SHARY KRISHNA- 18 PGT	FEMALE	B	4.21	39.91	98.77	91.84	1.8	2.24	50677	16.77	49691	15.74	50226	16.11
221	ASHUTOSHA KUMAR- 17 PGT	MALE	B	3.15	41.74	90.47	83.28	1.83	2.33	49170	15.73	50041	15.86	50550	16.88
225	HEMAL MANDI- 27 UG	MALE	B	2.49	40.97	90.55	89.22	2.87	5.33	62539	25.97	60343	24.52	59184	24.51
229	NIRBHAY KUMAR- 27 UG	MALE	B	4.85	39.88	92.17	87.6	2.64	5.53	48727	17.33	48424	16.76	46842	16.77
230	BINAY PRATAP SINGH- 27 UG	MALE	B	4.11	41.67	90.66	83.04	1.91	2.42	55063	18.37	50956	16.4	50969	16.72
231	YASHFEEN KHALDA- 28 UG	FEMALE	B	3.61	37.64	88.75	81.08	1.96	2.5	53168	18.18	49872	16.98	48653	16.35
235	ANKITA DHAR- 28 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
239	SOUMYENDU DEBNATH- 26 UG	MALE	B	3.39	41.71	96.52	87.65	2.03	2.57	55364	20.52	53953	19.53	55263	20.17
242	AAKASH DEEP DAS- 23 UG	MALE	B	4.15	39.49	95.7	90.23	2.03	2.47	55443	19.53	53556	18.25	54744	19.06
243	SHUBHABRATA DAS- 28 UG	MALE	B	3.37	54.53	98.92	92.04	1.96	2.26	62709	24.91	61529	24.19	62303	25.26
245	CHRISTINA LALHRIATPUII-27 UG	FEMALE	B	2.96	41.27	94.64	89.65	2.28	2.9	58614	23.34	57529	22.1	55649	21.79

97

GROUP B- BELLADONNA 200 GROUP- EPI 2 (2ND WEEK- INTERVENTION PERIOD)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
									EPI 2						
105	ABHINAV RAJ- 16 PGT	MALE	B	3.56	48.92	94.16	88.81	2.12	2.62	59934	23.45	60325	23.86	58808	23.44
110	HIMA TS- 27 UG	FEMALE	B	3.23	40.22	99.87	93.95	2.31	2.58	65362	24.45	62977	23.75	63681	24.25
111	NAYAB AMIR- 28 UG	MALE	B	3.22	39.11	96.49	89.38	2	2.37	55380	20.98	53549	19.51	52388	19.47
112	AK MIJANUR- 28 UG	MALE	B	3.9	40.57	92.46	87.41	2.01	2.73	55590	20.35	53014	18.62	50750	17.55
114	ANKITA AICH- 26 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
116	SANGEETA VENKATESH- 27 UG	FEMALE	B	4.27	56.95	96.71	95.54	2	2.19	67110	28.02	65936	27.57	64146	27.62
118	MANTASHA HASAN- 27 UG	FEMALE	B	2.62	40.77	94.85	86.38	2.07	2.76	52536	17.89	50841	17.24	55011	19.91
122	APURBA MAHATO- 25 UG	MALE	B	3.93	43.63	95.86	92.76	2.12	2.54	59845	22.53	59733	22.25	63112	24.31
123	SUHISNA DAS- 26 UG	FEMALE	B	2.21	41.14	97.97	93.7	2.43	2.72	64936	26.35	60775	24.39	63803	25.93
128	AVARANJIKA- 19 PGT	FEMALE	B	4.27	50.01	94.75	93.97	1.95	2.28	56927	22.22	61795	23.6	61595	24.14
129	LAXMIDHAR SAHOO- 27 UG	MALE	B	3.13	52.7	98.9	88.28	1.94	2.24	61829	24.02	61950	23.29	60492	23.55
130	NAMRATA JAISWAL- 27 UG	FEMALE	B	3.52	45.36	95	91.53	2.37	2.82	59236	25.58	65677	27.21	66135	28.42
131	NAVIN PRAKASH RAY- 17 PGT	MALE	B	3.13	52.7	98.9	88.28	1.94	2.24	61829	24.02	61950	23.29	60492	23.55
132	NASIMUDDIN AHMED- 28 UG	MALE	B	3.88	44.39	96.57	89.62	2	2.33	58661	21.91	57460	20.92	58036	21.68
134	PRABHAT KIRAN- 23 UG	MALE	B	4.42	35.34	92.74	81.59	2.02	3.14	42558	14.11	39038	12.54	40773	13.5
145	DEEPSHIKA SHARMA- 28 UG	FEMALE	B	3.39	39.62	94.66	87.81	2.01	2.58	54820	19.04	53605	18.46	54529	19.12
146	VYSHEK- 27 UG	MALE	B	3.48	45.06	91.98	87.65	2.43	4.48	61638	24.99	56150	21.93	57420	22.84
148	ARJIT SEN- 26 UG	MALE	B	3.63	55.99	95.02	90.37	1.93	2.13	64068	25.38	65579	25.46	62821	24.48
158	ANANYA ADHIKARI- 26 UG	FEMALE	B	4.29	52.09	96.53	90	2.1	2.47	64570	26.1	60072	23.26	64357	25.58
160	RASHMI UTTAM-18 PGT	FEMALE	B	4.34	46.58	98.7	91.7	2.07	2.62	59546	23.98	60159	23.52	53647	20.92
162	ARCHIMEDES AMIN- 27 UG	MALE	B	4.85	26.68	99.51	87.53	2.57	5.84	33879	8.92	26692	6.51	33667	9.17
164	DINITHI UPEKSHA- 25 UG	FEMALE	B	5.01	37.63	92.97	89.75	2.67	5.49	48948	17.93	54805	19.82	55165	20.24
167	POUJITHAN- 28 UG	MALE	B	4.25	42.41	98.46	93.01	2.14	2.78	56921	20.67	57794	21.08	58700	21.89
169	WANBHAHBIANG RANI- 28 UG	MALE	B	3.69	44.65	96.13	88.54	2.05	2.4	58718	21.76	59141	22.18	61882	23.55
170	MUKTA JAIN – 28 UG	FEMALE	B	2.47	41.37	87.08	84.34	2.27	2.8	58280	22.93	57223	22.67	60379	24.81
172	RANJEET MAURYA- 28 UG	MALE	B	3.86	39.2	80.45	79.53	1.91	2.48	51435	17.96	46985	15.64	44809	14.85
173	VINAY KUMAR- 23 UG	MALE	B	4.12	41.13	94.83	87.66	1.89	2.6	48528	15.83	47822	15.41	46663	15.47
175	DEEPAK PANDEY- 17 PGT	MALE	B	4.2	42.9	99.09	85.98	1.94	2.36	53554	18.77	56389	20.45	54812	20
176	SANGHAMITRA DAS- 26 UG	FEMALE	B	2.34	52.01	98.98	92.13	2.45	2.77	72150	31.14	70593	31.12	74816	33.11
178	ANKITA AICH- 26 UG	FEMALE	B	3.56	41.9	97.85	95.37	2.05	2.51	56312	20.65	54608	19.63	57456	21.14
186	SUBHRANIL SAHA- 17 PGT	MALE	B	2.8	40.94	98.61	91.2	2.32	3.4	55133	20.01	50538	17.85	53305	19.1
191	NITIN KUMAR SAKLANI- 17 PGT	MALE	B	3.32	45.66	99.72	90.03	1.91	2.47	53308	18.74	51472	18.41	51814	18.99
195	LILY ANAL- 18 PGT	FEMALE	B	3.77	39.43	99.96	88.71	1.86	2.39	46120	16.22	48322	16.98	47107	16.81
196	NEETU KUMARI- 28 UG	FEMALE	B	3.28	37.62	86.83	86.45	2.3	2.81	61552	23.83	57108	21.87	55590	20.33
200	ANIKET RAJ- 28 UG	MALE	B	3.59	42.23	90.87	85.32	1.89	2.33	53835	19.1	50905	17.22	49122	16.92
202	SEETHA LAKSHMI- 24 UG	FEMALE	B	3.96	45.93	91.56	90.97	2.03	2.36	61847	22.83	63270	23.23	56272	20.36
203	ABHISHEK GUPTA- 28 UG	MALE	B	5.27	52.03	98.46	88.91	2.01	2.27	65227	24.99	67280	26.05	62458	24.95
205	SUPRIYA SINGH- 26 UG	FEMALE	B	4.19	54.92	96.22	95.04	1.98	2.16	67117	27.41	62684	24.26	62003	24.85
213	DIVYA JYOTI ANAND- 27 UG	FEMALE	B	3.5	49.44	99.24	93.85	2.22	2.51	67611	28.82	66171	27.77	68255	29.69
218	SHARY KRISHNA- 18 PGT	FEMALE	B	3.73	38.93	97.11	92.89	1.85	2.38	47887	15.5	49040	15.7	49302	16.05
221	ASHUTOSHA KUMAR- 17 PGT	MALE	B	3.49	38.47	91.88	79.2	1.98	2.83	48352	15.96	46438	14.9	44341	14.15
225	HEMAL MANDI- 27 UG	MALE	B	2.41	37.19	92.96	83.91	2.26	2.61	59355	23.1	55896	21.51	58141	22.51
229	NIRBHAY KUMAR- 27 UG	MALE	B	4.67	41.42	94.98	77.09	2.34	3.75	50938	17.96	50298	17.78	52572	19.65
230	BINAY PRATAP SINGH- 27 UG	MALE	B	4.99	49	91.93	88.22	1.97	2.38	62785	23.32	59378	21.21	57097	21.11
231	YASHFEEN KHALDA- 28 UG	FEMALE	B	3.16	44.01	89.76	85.54	2.07	2.47	62391	22.96	57904	21.14	58768	21.46
235	ANKITA DHAR- 28 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
239	SOUMYENDU DEBNATH- 26 UG	MALE	B	3.62	53.05	99.5	90.25	2.18	2.5	66630	25.89	67437	26.89	62282	25.62
242	AAKASH DEEP DAS- 23 UG	MALE	B	4.28	41.29	93.84	89.15	1.96	2.36	56639	20.74	54810	19.23	54836	19.77
243	SHUBHABRATA DAS- 28 UG	MALE	B	3.43	43.75	96.05	90.71	1.87	2.27	54912	18.73	54029	17.94	53411	18.8
245	CHRISTINA LALHRIATPUII-27 UG	FEMALE	B	3	50.08	98.9	88.81	2.44	2.89	65460	27.74	67174	28.08	69058	29.2

98

GROUP B- BELLADONNA-200 GROUP- EPI 3 (3RD WEEK- ANTIDOTE WEEK)													
					EPI 3								
ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
105	ABHINAV RAJ- 16 PGT	MALE	B	3.53	41.24	97.12	87.74	2.2	2.87	53860	19.7	56316	21.15	55474	21.34
110	HIMA TS- 27 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
111	NAYAB AMIR- 28 UG	MALE	B	3.79	36.14	96.01	91.29	2.1	2.88	50440	18.44	50299	17.64	49715	17.25
112	AK MIJANUR- 28 UG	MALE	B	3.6	42.75	88.86	85.87	1.96	2.53	54196	20.61	51918	19.07	50898	18.2
114	ANKITA AICH- 26 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
116	SANGEETA VENKATESH- 27 UG	FEMALE	B	3.93	40.82	84.79	83.23	1.93	2.37	56027	20.14	53077	18.18	53285	18.31
118	MANTASHA HASAN- 27 UG	FEMALE	B	2.62	41.99	84.92	81.23	2.04	2.78	56711	20.82	50385	17.8	53352	19.16
122	APURBA MAHATO- 25 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
123	SUHISNA DAS- 26 UG	FEMALE	B	3.19	41.73	91.56	89.26	2.33	2.82	61468	24.18	60108	23.48	59906	23.33
128	AVARANJIKA- 19 PGT	FEMALE	B	3.92	47.78	98.68	84.65	1.94	2.26	55398	21.78	57471	22.13	58632	23.51
129	LAXMIDHAR SAHOO- 27 UG	MALE	B	3.06	42.38	92.87	91.74	1.93	2.37	55825	19.66	52459	17.51	51905	17.59
130	NAMRATA JAISWAL- 27 UG	FEMALE	B	3.72	32.98	96.85	90.7	2.45	3.82	51700	19.1	51854	18.34	46675	17.62
131	NAVIN PRAKASH RAY- 17 PGT	MALE	B	3.06	42.38	92.87	91.74	1.93	2.37	55825	19.66	52459	17.51	51905	17.59
132	NASIMUDDIN AHMED- 28 UG	MALE	B	3.89	48.82	98.93	91.77	2.12	2.4	64096	25.42	62557	24.73	61907	24.99
134	PRABHAT KIRAN- 23 UG	MALE	B	3.19	49.39	99	92.64	1.87	2.29	56360	21.21	53886	19.91	55480	20.83
145	DEEPSHIKA SHARMA- 28 UG	FEMALE	B	3.75	42.34	89.22	84.25	2.02	2.61	56512	20.65	54012	19.38	51487	18.37
146	VYSHEK- 27 UG	MALE	B	3.32	38.49	89.12	85.61	2.13	2.87	58922	21.15	54364	19.17	50366	17.67
148	ARJIT SEN- 26 UG	MALE	B	3.8	44.48	94.69	93.47	1.94	2.31	56446	20.91	54825	20.3	52448	19
158	ANANYA ADHIKARI- 26 UG	FEMALE	B	5.01	49.53	87.02	83.91	2.04	2.45	60049	23.06	61281	23.26	64684	25.7
160	RASHMI UTTAM-18 PGT	FEMALE	B	3.96	39.8	96.61	92.32	1.9	2.45	50900	16.98	49465	16.16	51372	17.21
162	ARCHIMEDES AMIN- 27 UG	MALE	B	6.53	30.28	90.03	64.47	2.53	5.69	29014	8.88	25688	7.21	33181	10.06
164	DINITHI UPEKSHA- 25 UG	FEMALE	B	4.15	41.1	98.29	85.56	2.26	2.82	57410	22.13	58429	22.69	58711	23.14
167	POUJITHAN- 28 UG	MALE	B	3.64	40.8	90.92	82.97	2.18	2.86	60083	22.16	53865	19.14	53090	19.8
169	WANBHAHBIANG RANI- 28 UG	MALE	B	3.45	38.19	97.67	89.71	1.96	2.43	51253	18.22	53870	19.1	52438	18.55
170	MUKTA JAIN – 28 UG	FEMALE	B	2.27	36.68	95.99	91.7	2.34	2.88	61130	23.9	56365	21.23	58199	21.61
172	RANJEET MAURYA- 28 UG	MALE	B	3.64	38.18	79.39	78.14	1.88	2.49	51723	17.16	45199	14.04	44789	14.01
173	VINAY KUMAR- 23 UG	MALE	B	4.75	45.9	91.55	86.16	1.91	2.48	52096	18.09	52539	18.51	50383	17.85
175	DEEPAK PANDEY- 17 PGT	MALE	B	4.13	48.12	97.3	91.59	1.96	2.48	58680	21.94	57369	21.41	56231	20.88
176	SANGHAMITRA DAS- 26 UG	FEMALE	B	2.78	42.07	94.09	86.11	2.23	2.73	60949	24.48	58620	23.36	60717	23.95
178	ANKITA AICH- 26 UG	FEMALE	B	3.73	42.98	86.29	85.46	1.95	2.38	58406	21.91	51852	18.69	53874	19.99
186	SUBHRANIL SAHA- 17 PGT	MALE	B	2.6	39.55	94.13	81.48	2.11	2.86	55132	18.39	50427	16.5	52840	18.69
191	NITIN KUMAR SAKLANI- 17 PGT	MALE	B	3.82	36.56	84.38	83.94	1.97	2.9	46377	15.61	45146	14.83	41235	12.79
195	LILY ANAL- 18 PGT	FEMALE	B	3.69	41.58	97.56	94.86	1.9	2.35	52255	18.31	53483	18.66	50809	18.14
196	NEETU KUMARI- 28 UG	FEMALE	B	3.81	48.82	94.56	89.93	2.55	2.89	70648	30.51	69284	29.84	67250	29.01
200	ANIKET RAJ- 28 UG	MALE	B	4.84	40.96	97.59	91.44	1.98	2.5	51570	17.51	53511	18.02	50947	17.19
202	SEETHA LAKSHMI- 24 UG	FEMALE	B	3.56	47.19	97.72	87.3	1.99	2.5	55626	20.62	54347	20.16	56451	21.46
203	ABHISHEK GUPTA- 28 UG	MALE	B	4.59	46.48	92.11	89.17	2.01	2.47	62225	23.74	59360	22.25	55502	20.95
205	SUPRIYA SINGH- 26 UG	FEMALE	B	4.41	46.27	95.23	91.09	1.93	2.27	58662	20.92	57636	19.93	57806	20.68
213	DIVYA JYOTI ANAND- 27 UG	FEMALE	B	3.32	35.65	93.17	87.18	1.98	2.47	53983	19.24	51370	18.02	51016	18.11
218	SHARY KRISHNA- 18 PGT	FEMALE	B	3.88	40.78	99.91	81.73	1.85	2.36	50391	15.98	50527	15.97	51446	16.78
221	ASHUTOSHA KUMAR- 17 PGT	MALE	B	3.5	35.21	83.02	83.94	1.93	2.82	46921	14.79	42766	13.02	40243	12.19
225	HEMAL MANDI- 27 UG	MALE	B	1.97	40.74	90.49	91.61	2.37	2.71	64241	25.6	60734	24.05	63082	24.61
229	NIRBHAY KUMAR- 27 UG	MALE	B	4.65	40.73	92.25	89.68	2.54	5.24	53581	19.15	53991	18.86	49407	17.76
230	BINAY PRATAP SINGH- 27 UG	MALE	B	4.26	47.07	91.18	89.27	2	2.48	58912	22.23	57596	21.33	56278	20.45
231	YASHFEEN KHALDA- 28 UG	FEMALE	B	3.88	40.56	98.54	85.79	2.04	2.51	54194	18.75	52298	18.35	54291	19.63
235	ANKITA DHAR- 28 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
239	SOUMYENDU DEBNATH- 26 UG	MALE	B	3.27	40.6	95.18	84.17	2.48	3.2	61819	23.87	57329	21.67	56609	21.82
242	AAKASH DEEP DAS- 23 UG	MALE	B	4.44	44.61	92.78	92.05	2.13	2.96	59437	22.24	57493	20.15	53916	19.41
243	SHUBHABRATA DAS- 28 UG	MALE	B	3.92	40.93	97.23	88.4	1.87	2.34	49456	16.86	49926	16.92	50342	18
245	CHRISTINA LALHRIATPUII-27 UG	FEMALE	B	3.09	37.45	84.74	86.39	2	2.51	52157	19.23	50745	17.69	50684	17.72

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
105	ABHINAV RAJ- 16 PGT	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
110	HIMA TS- 27 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
111	NAYAB AMIR- 28 UG	MALE	B	3.66	45.25	99.32	92.86	2.3	2.74	62067	24.6	60799	23.63	60598	24.23
112	AK MIJANUR- 28 UG	MALE	B	3.74	44.1	99.99	90.66	1.98	2.59	55390	20.57	55449	20	54932	20.15
114	ANKITA AICH- 26 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
116	SANGEETA VENKATESH- 27 UG	FEMALE	B	4.42	45.9	91.9	88.49	1.97	2.39	60436	22.65	56977	20.65	54240	19.84
118	MANTASHA HASAN- 27 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
122	APURBA MAHATO- 25 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
123	SUHISNA DAS- 26 UG	FEMALE	B	3.21	44.82	93.85	91.11	2.3	2.67	66392	27.13	63156	25.55	60910	25.18
128	AVARANJIKA- 19 PGT	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
129	LAXMIDHAR SAHOO- 27 UG	MALE	B	3.17	43.74	94.24	92.02	1.86	2.24	56311	19.36	52783	17.55	53187	18.43
130	NAMRATA JAISWAL- 27 UG	FEMALE	B	3.55	35.91	92.3	87.12	2.33	3.21	51962	21.1	53876	20.29	50590	20.08
131	NAVIN PRAKASH RAY- 17 PGT	MALE	B	3.03	37.66	98.1	94.3	1.97	2.6	49957	16.86	47581	15.36	48439	16.08
132	NASIMUDDIN AHMED- 28 UG	MALE	B	3.81	47.6	95.06	88.72	2.14	2.54	64478	24.04	62090	23.45	62815	24.13
134	PRABHAT KIRAN- 23 UG	MALE	B	3.98	34.99	96.66	84.97	2.07	3.21	44855	13.91	41329	12.44	46412	14.46
145	DEEPSHIKA SHARMA- 28 UG	FEMALE	B	3.25	44.18	91.19	80.12	2.14	2.72	60662	23.07	59126	22.49	57353	21.59
146	VYSHEK- 27 UG	MALE	B	4.5	37.43	95.8	89.09	2.25	3.29	50311	17.71	51243	17.69	50782	18.15
148	ARJIT SEN- 26 UG	MALE	B	3.9	43.32	98.35	95.41	1.88	2.21	53000	18.55	55648	19.69	55320	19.38
158	ANANYA ADHIKARI- 26 UG	FEMALE	B	5.17	40.71	91.84	89.58	1.98	2.44	55713	18.72	56599	18.6	58503	20.46
160	RASHMI UTTAM- 18 PGT	FEMALE	B	4.11	43.45	95.2	90.5	1.98	2.57	55076	19.33	52540	18.11	54632	19.41
162	ARCHIMEDES AMIN- 27 UG	MALE	B	4.25	32.5	88.86	86.37	2.56	5.28	38505	11.22	37319	10.64	40910	12.71
164	DINITHI UPEKSHA- 25 UG	FEMALE	B	5.06	36.76	95.28	90.06	3.16	8.85	52399	20.01	55043	20.34	50459	18.41
167	POUJITHAN- 28 UG	MALE	B	4.21	35.52	95.93	91.55	2.28	3.36	51897	18.33	50636	17.59	50494	17.4
169	WANBHAHBIANG RANI- 28 UG	MALE	B	3.57	39.09	99.68	92.88	2.09	2.62	53694	19.8	53599	19.73	52265	19.87
170	MUKTA JAIN – 28 UG	FEMALE	B	2.47	46.59	99.65	97.44	2.38	2.64	67579	27.79	65663	26.89	68321	28.58
172	RANJEET MAURYA- 28 UG	MALE	B	3.41	34.68	92.42	91.24	1.98	2.9	45911	14.27	40843	12.07	43835	13.7
173	VINAY KUMAR- 23 UG	MALE	B	5.93	29.49	97.86	78.39	2.11	3.69	33269	9.07	36116	9.95	35582	10.1
175	DEEPAK PANDEY- 17 PGT	MALE	B	4.08	41.29	88.87	91.39	1.9	2.41	53277	18.07	50934	17.8	49489	17.41
176	SANGHAMITRA DAS- 26 UG	FEMALE	B	3.1	44.1	97.99	88.88	2.26	2.64	62281	24.46	61591	24.4	66796	26.62
178	ANKITA AICH- 26 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
186	SUBHRANIL SAHA- 17 PGT	MALE	B	2.66	37.47	97.18	89.06	2.14	3.05	51428	18.38	48304	16.99	51671	18.64
191	NITIN KUMAR SAKLANI- 17 PGT	MALE	B	3.68	38.26	87.91	83.82	2.07	3.17	44731	13.75	47015	15.1	50117	16.57
195	LILY ANAL- 18 PGT	FEMALE	B	3.65	43.82	89.87	90.21	1.92	2.28	54909	20.58	55095	19.89	53821	19.42
196	NEETU KUMARI- 28 UG	FEMALE	B	4.26	44.75	96.87	88.91	2.49	2.92	65402	25.99	68693	26.98	68040	26.79
200	ANIKET RAJ- 28 UG	MALE	B	4.13	47.12	91.06	88.29	2.03	2.41	62523	22.58	61552	21.94	55130	19.68
202	SEETHA LAKSHMI- 24 UG	FEMALE	B	3.53	44.93	96.64	92.97	1.97	2.47	57284	20.85	55040	19.57	55640	19.97
203	ABHISHEK GUPTA- 28 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
205	SUPRIYA SINGH- 26 UG	FEMALE	B	4.68	42.92	91.17	88.72	1.96	2.32	58386	20.93	56790	18.64	54269	17.74
213	DIVYA JYOTI ANAND- 27 UG	FEMALE	B	3.02	34.33	94.36	84.47	2.09	2.73	51874	18.26	50898	17.9	51129	18.47
218	SHARY KRISHNA- 18 PGT	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
221	ASHUTOSHA KUMAR- 17 PGT	MALE	B	3.49	32.43	91.63	86.6	1.97	3.01	41571	12.34	40724	11.75	40258	11.63
225	HEMAL MANDI- 27 UG	MALE	B	2.35	35.31	91	81.71	2.36	3.08	55425	21.01	51466	19.04	54406	20.92
229	NIRBHAY KUMAR- 27 UG	MALE	B	4.97	38.64	99.64	87.8	2.71	5.94	49151	16.92	48455	16.3	46729	16.27
230	BINAY PRATAP SINGH- 27 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
231	YASHFEEN KHALDA- 28 UG	FEMALE	B	3.34	39.95	97.29	89.1	1.96	2.32	56515	20.33	52840	18.76	55539	19.91
235	ANKITA DHAR- 28 UG	FEMALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
239	SOUMYENDU DEBNATH- 26 UG	MALE	B	3.05	44.65	97.34	90.61	2.47	2.97	65811	25.94	64344	25.1	63227	24.97
242	AAKASH DEEP DAS- 23 UG	MALE	B	4.66	40.11	96.04	93.97	1.96	2.49	50464	19.14	52847	19.19	49038	18.04
243	SHUBHABRATA DAS- 28 UG	MALE	B	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
245	CHRISTINA LALHRIATPUII-27 UG	FEMALE	B	3.47	38.58	82.8	82.38	2.09	2.67	52681	18.66	53834	19.18	54273	20.04

GROUP- B - BELLADONNA-200 GROUP- EPI-4 (4TH WEEK- AFTER WASHOUT PERIOD)

EPI 4

GROUP C- PLACEBO GROUP -EPI 0 (PRE INTERVENTION READING)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
103	ASHWANI- 18 PGT	MALE	C	7.17	42.77	90.72	90.84	2.09	2.51	60737	19.13	59316	18.01	55923	17.54
104	RAJDEEP SAHA- 26 UG	MALE	C	3.8	46.94	96.32	90.93	2.02	2.56	56205	21.71	55025	21.3	54734	21.71
107	SUDHARSANAN P- 27 UG	MALE	C	2.92	49.69	98.45	93.09	1.88	2.38	55080	20.22	53425	19.76	56862	21.68
108	MANIKA- 18 PGT	FEMALE	C	8.76	22.69	39.92	33.2	2.4	5.72	16893	4.45	18934	5.05	29542	8.13
109	PUJA RANI- 17 PGT	FEMALE	C	3.94	43.73	95.8	93.71	2.02	2.59	52577	19.27	55962	20.19	53805	19.68
115	BUDDHADEB CHAKRABORTY- 16PGT	MALE	C	3.04	39.17	99.87	89.34	1.89	2.42	49973	16.81	47131	15.48	50598	17.63
126	QUHELY GHOSH- 26 UG	FEMALE	C	2.6	38.62	99.71	90.13	2.35	2.78	62136	23.95	59898	24.33	59236	23.19
135	DEEPAK KR CHOUDHARY- 18 PGT	MALE	C	4.11	37.58	97.14	91.79	1.99	2.87	46541	15.22	46710	15.09	44808	15.48
137	SANIYA PARWEEN- 26 UG	FEMALE	C	3.25	42.62	99.45	91.67	1.95	2.36	55075	20.31	55373	19.64	55814	19.78
138	MANEESHA SUNDAR- 24 UG	FEMALE	C	3.79	41.13	99.29	90.79	2.15	2.65	54454	19.26	56646	19.9	56148	19.55
140	MIR UMAYER AHMED- 25 UG	MALE	C	3.5	38.92	98.34	85.36	2.02	2.7	49515	16.07	50041	16.2	51102	16.9
141	ANUPAM- 25 UG	FEMALE	C	3.28	39.18	96.44	89.18	2.25	3.03	54526	19.46	53797	18.7	54823	19.43
142	KHURSIDA NONJAI- 27 UG	FEMALE	C	4.61	51.55	94.38	91.26	1.94	2.41	58308	21.43	60408	22.33	55367	21.41
150	MANOJ GHOSH- 26 UG	MALE	C	3.78	40.86	93.13	88.36	2.81	6.02	60320	23.88	60169	23.42	58283	22.89
151	PRAGYA JOSHI- 25 UG	FEMALE	C	5.31	34.86	88.28	86.87	2.08	3.01	46981	14.16	42532	12.3	42740	12.62
153	SHAHIDUL ISLAM- 27 UG	MALE	C	3.02	45.3	92.23	92.71	2.14	2.45	66133	25.99	63751	24.69	63290	23.68
154	JYOTI PODDAR- 24 UG	FEMALE	C	4.2	41.99	96.39	92.15	2.23	2.88	57368	20.18	58791	21.27	59913	22.29
155	FARHAT JABEEN- 27 UG	FEMALE	C	3.85	38.4	99.46	94.33	1.91	2.28	52383	18.86	53913	18.76	55313	19.61
159	DIPTIMOYEE PAL- 26 UG	FEMALE	C	4.33	39.91	87.65	90.43	1.93	2.29	56809	19.6	54272	17.68	51769	17.45
161	DEBIKA NASKER- 16 PGT	FEMALE	C	5.64	43.44	97.44	90	2.26	2.81	55746	20.12	58083	20.12	61457	21.71
163	JYOTI SMITA-27 UG	FEMALE	C	4.21	43.75	94.45	90.1	2.28	3.71	51731	18.26	50473	16.43	50708	16.96
165	SATYABRAT ROY- 28 UG	MALE	C	4.3	39.73	89.21	88.87	1.82	2.3	51733	16.26	50014	15.12	46861	14.47
166	SHYAMAGHANA BARIK- 26 UG	MALE	C	3.46	40.29	94.81	92.44	2.01	2.49	54525	19.48	53534	18.39	54499	18.53
171	MANOJ GHOSH- 27 UG	MALE	C	2.98	41.51	97.87	84.73	2.3	2.92	57940	22.08	58002	22.02	60379	23.23
174	SOUMYA BEHERA- 26 UG	MALE	C	3.37	42.36	87.54	89.19	2.25	2.88	55637	18.73	57920	20.08	62848	22.65
177	RAJAT ARYA- 26 UG	MALE	C	3.91	38.64	94.45	90.65	2.24	3.73	46803	14.73	42047	12.52	46245	14.45
179	SHWETHA SINHA- 28 UG	FEMALE	C	3.93	42.44	99.15	93.37	2.14	2.54	59653	21.72	59895	22.23	58049	22.01
180	SABA PARVEEN- 27 UG	FEMALE	C	4.34	34.62	99.26	86.22	2.04	2.77	48231	15.42	50279	15.79	51739	16.41
184	BANASRI ROY- 27 UG	FEMALE	C	4.36	58.38	93.98	85.46	2.04	2.35	63998	26.19	66310	26.86	71762	29.7
187	KUSAL PRADEEP- 27 UG	MALE	C	4.22	40.3	92.64	85.72	2.02	2.91	53248	17.05	51257	16.42	47797	15.88
192	ARUNAVA NATH- 17 PGT	MALE	C	4.79	37.88	96.9	87.49	2.15	2.9	51429	18.23	53677	18.72	52724	18.52
194	ALSA SASI KUMAR- 27 UG	FEMALE	C	4.79	39.21	98.43	87.2	2.17	2.84	55472	20.48	56468	20.89	51584	18.44
199	SANJUKTA MANDAL- 24 UG	FEMALE	C	3.86	42.43	86.93	85.95	1.96	2.37	58777	21.44	54982	19.41	51383	18.18
204	ASHITA NAS- 27 UG	MALE	C	3.25	41.7	91.68	89.98	2.15	2.48	61106	22.57	58108	21.13	60680	22
207	SUBHRAJIT PAUL- 26 UG	MALE	C	3.22	37.58	81.36	73.54	1.93	2.54	54584	18.6	50040	16.47	47620	15.09
211	SADDAM MIRZA- 25 UG	MALE	C	4.08	36.81	91.82	76.85	2.19	3.35	48852	14.52	48194	15.15	48842	17.16
214	MEENAL PANDEY- 18 PGT	FEMALE	C	4.32	40.2	85.14	85.61	2.15	2.93	54634	19.93	54013	19.31	49779	17.44
215	KOMAL SHARMA- 16 PGT	FEMALE	C	6.24	40.04	96.7	87.27	2.24	2.81	50568	17.36	53229	16.67	51496	16.76
216	SHABNAM REYAZ- 26 UG	FEMALE	C	4.54	37.3	97.98	85.55	1.92	2.42	49395	16.94	52366	17.8	52134	18.1
219	ARCHANA KANOJIYA- 26 UG	FEMALE	C	3.8	38.75	89.06	82.74	2.39	2.92	61653	24.24	60197	23.62	56718	22.02
222	KAPIL KUMAR SHAW- 17 PGT	MALE	C	5.35	32.08	61.35	59.32	2.1	3.35	44217	14.26	40140	12.82	34032	10.9
226	CHINMAYEE DHALI- 27 UG	FEMALE	C	3.99	37.06	91.29	93	2.12	2.94	52224	18.52	48776	16.29	50300	17.06
228	JATIN RAJ- 27 UG	MALE	C	3.47	45.38	83.35	81.97	2.1	2.5	67040	25.71	61747	22.59	57406	20.53
232	SUSMIT DUTTA- 16 PGT	MALE	C	3.29	47.58	97.72	94.51	2.39	2.74	68163	28.41	69401	28.39	68760	27.87
234	NIHARIKA SHAW- 26 UG	FEMALE	C	4.23	37.2	91.12	90.29	1.96	2.63	51608	16.3	50774	15.63	48449	14.99
236	MANJEET SINGH- 16 PGT	FEMALE	C	3.46	39.58	95.95	91.49	1.89	2.42	52717	17.89	48264	15.9	50481	16.94
240	SARMIN TASLIMA- 24 UG	FEMALE	C	3.8	37.99	86.23	76.77	2.01	2.83	47087	15.5	47130	15.08	50143	17.89
246	ROHIT KUMAR PRIYA- 26 UG	MALE	C	3.03	43.34	88.2	87.9	2.01	2.38	61714	24.18	55585	20.38	54620	20.18
249	UTPAL BISWAS- 27 UG	MALE	C	3.71	42.11	93.91	86.83	2.08	2.52	58419	21.84	57080	20.8	58507	21.41
250	JITENDRA PATEL- 26 UG	MALE	C	2.84	38.87	86.09	82.22	2.03	2.92	52224	17.54	45456	14.05	46513	14.37

GROUP C- PLACEBO GROUP- EPI 1 (1ST WEEK- RUN IN PERIOD -(PLACEBO))

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
103	ASHWANI- 18 PGT	MALE	C	3.35	36.87	93.05	91.48	1.82	2.34	49537	15.75	47316	14.54	46912	14.56
104	RAJDEEP SAHA- 26 UG	MALE	C	4.47	37.12	97.12	88.77	2.09	3.02	45779	15.39	43834	13.89	48259	16.51
107	SUDHARSANAN P- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
108	MANIKA- 18 PGT	FEMALE	C	3.37	41.01	94.93	87.35	2	2.55	55357	18.21	52983	17.4	55903	19.15
109	PUJA RANI- 17 PGT	FEMALE	C	3.83	39.83	97.54	92.21	2.01	2.4	54857	18.99	53145	18.46	52852	19.08
115	BUDDHADEB CHAKRABORTY- 16PGT	MALE	C	3.49	33.77	89.83	79.48	2.27	3.92	43213	13.9	37882	11.24	41660	12.77
126	QUHELY GHOSH- 26 UG	FEMALE	C	2.52	34.15	98.25	90.86	2.88	4.31	56260	21.2	55169	20.88	57595	21.22
135	DEEPAK KR CHOUDHARY- 18 PGT	MALE	C	3.99	33.54	88.95	73.46	2.07	3.35	39041	12.07	39712	12.34	42895	14.85
137	SANIYA PARWEEN- 26 UG	FEMALE	C	3.88	45.12	92.02	85.56	1.98	2.41	59248	22.29	56478	20.36	52768	19.58
138	MANEESHA SUNDAR- 24 UG	FEMALE	C	3.17	42.91	99.54	91.14	2.28	2.8	57877	21.63	56832	20.73	58709	21.54
140	MIR UMAYER AHMED- 25 UG	MALE	C	3.55	40.88	92.07	92.19	2	2.63	53399	18.2	51656	17.48	51118	17.26
141	ANUPAM- 25 UG	FEMALE	C	3.19	42.44	95.28	88.95	2.02	2.43	58478	21.78	57844	21.08	58999	22
142	KHURSIDA NONJAI- 27 UG	FEMALE	C	4.22	40.45	89.49	82.79	1.93	2.64	48796	16.79	46445	15.49	49019	17
150	MANOJ GHOSH- 26 UG	MALE	C	3.38	40.34	99.73	88.99	2.21	2.75	56764	21.19	58476	21.98	59602	22.45
151	PRAGYA JOSHI- 25 UG	FEMALE	C	4.29	37.21	99.92	94.25	1.92	2.63	47940	14.97	45718	13.49	46141	14.46
153	SHAHIDUL ISLAM- 27 UG	MALE	C	3.51	45.85	95.42	92.87	2.02	2.35	61404	23.15	60812	23.32	60902	23.88
154	JYOTI PODDAR- 24 UG	FEMALE	C	4.32	41.43	98.59	92.77	1.96	2.4	51323	18.67	53378	19.4	53220	19.72
155	FARHAT JABEEN- 27 UG	FEMALE	C	4.62	37.97	92.78	90.27	2.09	2.89	52171	18.62	52800	18.81	48596	17.94
159	DIPTIMOYEE PAL- 26 UG	FEMALE	C	4.4	47.85	98.46	95.1	1.98	2.4	58281	21.18	56802	20.57	57512	21.52
161	DEBIKA NASKER- 16 PGT	FEMALE	C	4.1	40.14	87.21	83.44	1.95	2.44	56001	20.22	54866	19.08	50562	17.42
163	JYOTI SMITA-27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
165	SATYABRAT ROY- 28 UG	MALE	C	4	54.17	95.21	93.29	1.74	1.95	58918	21.64	58184	21.37	55891	20.84
166	SHYAMAGHANA BARIK- 26 UG	MALE	C	3.04	38.92	96.51	89.06	1.84	2.29	49633	17.79	48107	16.9	48622	17.19
171	MANOJ GHOSH- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
174	SOUMYA BEHERA- 26 UG	MALE	C	2.78	45.09	94.91	88.79	2.17	2.65	59195	23.28	58251	22.98	64604	26.14
177	RAJAT ARYA- 26 UG	MALE	C	3.79	42.17	92.88	85.54	1.97	2.73	50366	16.54	47425	15.11	50916	17.21
179	SHWETHA SINHA- 28 UG	FEMALE	C	3.85	41.07	92.9	87.35	2.03	2.35	56744	21.63	58311	21.6	54242	19.7
180	SABA PARVEEN- 27 UG	FEMALE	C	4.28	36.86	93.35	82.92	1.97	2.46	52569	19.01	51247	17.76	51950	17.6
184	BANASRI ROY- 27 UG	FEMALE	C	4.2	40.86	97.67	88.65	1.88	2.41	48922	16.51	49255	16.7	54292	19.03
187	KUSAL PRADEEP- 27 UG	MALE	C	3.73	35.18	75.17	68.11	1.96	2.81	50303	15.46	43944	12.4	38505	11.2
192	ARUNAVA NATH- 17 PGT	MALE	C	4.78	40.54	99.05	94.79	2.81	6.03	50642	19.08	55005	20.16	52446	19.64
194	ALSA SASI KUMAR- 27 UG	FEMALE	C	4.01	38.83	96.77	94.87	2.02	2.52	55389	19.26	54299	18.27	54538	18.84
199	SANJUKTA MANDAL- 24 UG	FEMALE	C	3.99	41.97	95.48	93.02	1.89	2.26	54268	19.22	54163	18.53	53920	18.67
204	ASHITA NAS- 27 UG	MALE	C	3.55	38.49	94.14	88.63	2.03	2.47	56364	19.49	53706	18.51	55436	19.08
207	SUBHRAJIT PAUL- 26 UG	MALE	C	3.38	40.3	88.33	87.9	1.96	2.59	54243	19.87	48050	16.79	47852	16.84
211	SADDAM MIRZA- 25 UG	MALE	C	4.13	39.27	88.64	77.95	2.04	2.86	46013	15.06	48230	16.15	50798	17.67
214	MEENAL PANDEY- 18 PGT	FEMALE	C	5.03	36.23	88.78	85.78	2.2	3.45	46025	12.8	53061	15.24	44556	14.45
215	KOMAL SHARMA- 16 PGT	FEMALE	C	7.38	48.37	91.77	84.65	2.24	2.68	64608	20.69	60777	19.4	59871	20.6
216	SHABNAM REYAZ- 26 UG	FEMALE	C	4.65	39.77	94.24	90.83	1.89	2.24	53783	18.52	55540	18.75	51104	17.84
219	ARCHANA KANOJIYA- 26 UG	FEMALE	C	3.6	42	95.18	89.7	2.65	2.87	65745	26.96	66868	27.67	65067	27.16
222	KAPIL KUMAR SHAW- 17 PGT	MALE	C	4.01	41.52	99.33	91.9	1.89	2.35	52820	18.25	49845	16.84	49484	17.03
226	CHINMAYEE DHALI- 27 UG	FEMALE	C	6.51	24.95	77.91	68.77	2.74	6.28	35640	10.51	30290	8.12	32276	8.84
228	JATIN RAJ- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
232	SUSMIT DUTTA- 16 PGT	MALE	C	3.02	47.35	90.76	85.22	2.22	2.56	66279	27.39	65283	26.54	66524	27.01
234	NIHARIKA SHAW- 26 UG	FEMALE	C	4.1	37.76	94.92	91.2	1.97	2.74	50316	16.5	46962	14.45	46007	14.72
236	MANJEET SINGH- 16 PGT	FEMALE	C	3.8	38.3	94.59	92.76	1.96	2.66	52103	17.29	46678	14.83	48176	15.4
240	SARMIN TASLIMA- 24 UG	FEMALE	C	3.32	45.22	95.82	90.75	1.99	2.41	60466	22.87	55148	20.96	55069	20.76
246	ROHIT KUMAR PRIYA- 26 UG	MALE	C	3.23	47.86	95.27	89.8	2.03	2.34	61597	24.28	60474	23.87	60705	24.47
249	UTPAL BISWAS- 27 UG	MALE	C	3.5	38.82	98.05	91.58	1.99	2.68	50948	17.02	53067	18.38	51559	18.5
250	JITENDRA PATEL- 26 UG	MALE	C	4.06	33.56	97.09	82.14	2.48	4.92	40412	12.98	33643	9.67	42799	13.85

GROUP C- PALCEBO GROUP- EPI 2 (2ND WEEK- INTERVENTION PERIOD)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
103	ASHWANI- 18 PGT	MALE	C	3.39	40.62	89.27	89.3	1.84	2.33	50864	17.37	48875	16.22	48053	16.69
104	RAJDEEP SAHA- 26 UG	MALE	C	3.56	37.4	96.91	92.72	2.2	2.96	50710	18.77	51825	19.16	54915	20.51
107	SUDHARSANAN P- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
108	MANIKA- 18 PGT	FEMALE	C	7.59	21.89	52.08	55.63	2.52	6.01	19456	4.81	19584	5.03	30204	8.51
109	PUJA RANI- 17 PGT	FEMALE	C	3.66	43.32	93.77	89.53	2.1	2.55	57830	22.17	56732	21.08	56957	21.8
115	BUDDHADEB CHAKRABORTY- 16PGT	MALE	C	3.86	34.89	87.27	77.11	2.09	3.28	44915	15.53	40050	12.73	42349	13.76
126	QUHELY GHOSH- 26 UG	FEMALE	C	5.13	34.56	82.28	62.01	2.68	5.2	43681	14.77	44555	14.86	50850	18.39
135	DEEPAK KR CHOUDHARY- 18 PGT	MALE	C	3.1	45.64	96.64	96.3	1.87	2.29	55983	20.66	53674	19.51	54975	20.65
137	SANIYA PARWEEN- 26 UG	FEMALE	C	3.99	34.76	70.21	68.71	2.21	3.61	47370	16.97	43707	15.13	39529	13.06
138	MANEESHA SUNDAR- 24 UG	FEMALE	C	2.88	41.81	91.99	92.35	2.13	2.64	57857	21.2	53859	19.27	57205	20.44
140	MIR UMAYER AHMED- 25 UG	MALE	C	3.88	39.55	96.66	87.05	1.97	2.68	48683	16.9	46844	15.9	46611	15.87
141	ANUPAM- 25 UG	FEMALE	C	3.61	38.99	94.91	91.76	1.97	2.55	52057	18.55	51217	17.96	50121	17.92
142	KHURSIDA NONJAI- 27 UG	FEMALE	C	4.3	42.17	95.13	81.48	2.2	3.56	48543	17.08	46056	15.44	44271	15.89
150	MANOJ GHOSH- 26 UG	MALE	C	4.09	43.33	98.87	88.14	2.16	2.67	55818	22.17	59018	22.04	58827	22.91
151	PRAGYA JOSHI- 25 UG	FEMALE	C	3.84	42.47	96.68	93.59	1.83	2.31	49029	16.82	48418	16.36	50566	17.75
153	SHAHIDUL ISLAM- 27 UG	MALE	C	3.31	44.44	87.95	85.03	2.02	2.42	63020	23.61	57507	20.83	56183	20.35
154	JYOTI PODDAR- 24 UG	FEMALE	C	4.16	39.85	85.75	81.61	2.04	2.5	51891	18.23	53480	19.32	56066	20.99
155	FARHAT JABEEN- 27 UG	FEMALE	C	3.94	43.27	95.31	83.48	2.11	2.65	58402	23.25	59164	22.76	57141	21.92
159	DIPTIMOYEE PAL- 26 UG	FEMALE	C	4.24	44.45	97.15	89.15	2	2.6	55867	21.13	55078	20.45	51946	19.23
161	DEBIKA NASKER- 16 PGT	FEMALE	C	4.03	41.8	87.02	87.1	1.93	2.3	57262	20.46	55130	19.17	53166	18.96
163	JYOTI SMITA-27 UG	FEMALE	C	4.98	35.73	91.47	76.71	2.68	5.61	43656	13.66	41178	12.13	43374	14.29
165	SATYABRAT ROY- 28 UG	MALE	C	3.72	37.15	91.68	90.94	1.9	2.66	47704	14.39	44137	12.8	43760	12.85
166	SHYAMAGHANA BARIK- 26 UG	MALE	C	3.6	46.84	97.11	91.57	2.31	4.03	57287	22.62	57190	22.43	55507	21.78
171	MANOJ GHOSH- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
174	SOUMYA BEHERA- 26 UG	MALE	C	3.19	50.63	99.99	91.14	2.74	3.35	69431	28.53	70007	28.17	75704	31.44
177	RAJAT ARYA- 26 UG	MALE	C	3.22	37.96	93.14	84.62	2.07	3.18	43780	13.85	43586	13.57	47211	15.31
179	SHWETHA SINHA- 28 UG	FEMALE	C	3.78	42.1	92.2	90.01	2.15	2.79	57225	22.44	55212	20.78	53794	20.34
180	SABA PARVEEN- 27 UG	FEMALE	C	4.16	40.11	94.77	86.16	2.12	2.78	54945	20.41	52947	19.19	54548	20.27
184	BANASRI ROY- 27 UG	FEMALE	C	3.97	47.53	95.91	87.45	2.09	2.72	57038	22.04	54783	20.23	58303	22.63
187	KUSAL PRADEEP- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
192	ARUNAVA NATH- 17 PGT	MALE	C	4.9	39.91	98.67	90.16	2.14	3.05	50858	19.08	55965	20.84	51098	19.66
194	ALSA SASI KUMAR- 27 UG	FEMALE	C	4.32	40.25	96.44	93.59	2.14	2.66	58807	20.56	58958	20.4	56320	19.63
199	SANJUKTA MANDAL- 24 UG	FEMALE	C	3.46	46.07	98.98	91.77	2.04	2.42	61632	22.89	59928	21.9	61289	22.93
204	ASHITA NAS- 27 UG	MALE	C	3.19	37.39	97.51	91.48	2.48	3.34	58390	21.3	56219	19.81	58530	20.49
207	SUBHRAJIT PAUL- 26 UG	MALE	C	2.95	52.85	99.43	94.19	1.93	2.21	65674	25.55	60926	23.18	60969	23.53
211	SADDAM MIRZA- 25 UG	MALE	C	4.34	37.21	94.27	87.71	2.02	2.75	48402	16.27	48002	15.81	46670	15.52
214	MEENAL PANDEY- 18 PGT	FEMALE	C	4.99	35.44	82.73	76.8	3.63	11.46	39065	13.95	50567	18.8	45860	17.41
215	KOMAL SHARMA- 16 PGT	FEMALE	C	3.55	40.01	88.29	88.47	1.83	2.33	51112	18.24	46048	15.93	45868	16.18
216	SHABNAM REYAZ- 26 UG	FEMALE	C	3.67	33.99	92.96	81.67	2	2.85	44219	15.61	46917	15.78	46697	16.38
219	ARCHANA KANOJIYA- 26 UG	FEMALE	C	3.87	37.73	93.15	90.33	2.7	4.46	55497	22.45	57907	23.75	57466	24.24
222	KAPIL KUMAR SHAW- 17 PGT	MALE	C	3.94	41.17	98.63	91.33	1.98	2.55	52863	17.39	51546	16.94	52139	18.13
226	CHINMAYEE DHALI- 27 UG	FEMALE	C	3.82	39.11	93.73	91.08	2.08	2.6	58242	20.51	54677	18.57	55902	18.56
228	JATIN RAJ- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
232	SUSMIT DUTTA- 16 PGT	MALE	C	3.14	42.03	95.28	84.67	2.5	3	72341	21.61	69412	22.35	64806	22.03
234	NIHARIKA SHAW- 26 UG	FEMALE	C	3.72	51.78	98.2	93.54	1.85	2.13	60475	22.58	59768	21.65	59339	22.38
236	MANJEET SINGH- 16 PGT	FEMALE	C	3.52	40.72	94.27	86.65	1.98	2.73	52089	18.24	46651	15.53	50015	17.13
240	SARMIN TASLIMA- 24 UG	FEMALE	C	4.26	45.37	98.77	84.3	2.11	2.91	55532	21.1	53346	20.37	52780	20.14
246	ROHIT KUMAR PRIYA- 26 UG	MALE	C	3.23	48.05	96.44	94.52	2.06	2.42	61134	24.59	58896	22.46	59357	23
249	UTPAL BISWAS- 27 UG	MALE	C	7.06	38.6	95.79	86.32	2.45	3.49	52013	16.67	54067	17.1	50987	15.99
250	JITENDRA PATEL- 26 UG	MALE	C	2.96	38.27	87.58	87.46	1.93	2.72	49815	17.05	43446	13.59	45415	14.97

GROUP C- PLACEBO GROUP- EPI 3 (3RD WEEK- ANTIDOTE WEEK)

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
103	ASHWANI- 18 PGT	MALE	C	3.73	41.15	89.51	90.33	1.86	2.34	54860	18.58	50734	16.79	49766	16.68
104	RAJDEEP SAHA- 26 UG	MALE	C	3.92	44.83	98	85.99	2.33	3.14	56787	21.82	56937	22.23	59117	23.4
107	SUDHARSANAN P- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
108	MANIKA- 18 PGT	FEMALE	C	3.41	45.31	77.51	71.75	2.04	2.53	54957	19.02	54893	19.63	63376	23.96
109	PUJA RANI- 17 PGT	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
115	BUDDHADEB CHAKRABORTY- 16PGT	MALE	C	3.86	34.89	87.27	77.11	2.09	3.28	44915	15.53	40050	12.73	42349	13.76
126	QUHELY GHOSH- 26 UG	FEMALE	C	3.8	43.62	94.7	87.01	2.11	2.7	56305	21.37	55452	20.73	57204	21.24
135	DEEPAK KR CHOUDHARY- 18 PGT	MALE	C	3.83	35.8	99.82	87.45	1.95	2.69	46760	14.65	46166	14.25	46483	15.16
137	SANIYA PARWEEN- 26 UG	FEMALE	C	3.58	35.84	95.23	80.21	2.3	3.77	46884	15.94	42790	13.78	45938	15.52
138	MANEESHA SUNDAR- 24 UG	FEMALE	C	3.14	43.67	97.76	93.53	2.08	2.51	58413	21.72	55543	19.85	59816	22.39
140	MIR UMAYER AHMED- 25 UG	MALE	C	3.53	40.01	95.08	86.04	2	2.56	53330	18.14	53060	18.09	53618	18.93
141	ANUPAM- 25 UG	FEMALE	C	3.38	36.31	99.87	91.7	2.01	2.58	49706	17.53	51157	17.92	49157	17.1
142	KHURSIDA NONJAI- 27 UG	FEMALE	C	3.67	33.94	99.13	77.55	2.02	3.12	42760	13.52	38694	11.79	42887	14.17
150	MANOJ GHOSH- 26 UG	MALE	C	3.94	35.68	91.18	76.87	2.5	4.17	50123	17.78	47830	16.29	48282	17.18
151	PRAGYA JOSHI- 25 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
153	SHAHIDUL ISLAM- 27 UG	MALE	C	3.25	44.11	97.28	89.01	1.98	2.44	56945	20.89	53191	19.46	56579	21.59
154	JYOTI PODDAR- 24 UG	FEMALE	C	4.1	39.51	85.61	85.9	1.9	2.36	52545	19.17	50044	17.82	49212	17.1
155	FARHAT JABEEN- 27 UG	FEMALE	C	3.52	43.8	94.37	91.95	2.02	2.42	59921	23.06	57469	21.54	57329	22.19
159	DIPTIMOYEE PAL- 26 UG	FEMALE	C	3.91	37.96	97.27	90.51	1.92	2.45	50878	17.47	48730	16.23	50296	17.02
161	DEBIKA NASKER- 16 PGT	FEMALE	C	4.82	42.7	90.04	86.66	2.56	4.46	53733	19.47	55120	19.23	56407	20.6
163	JYOTI SMITA-27 UG	FEMALE	C	4.3	37.91	81.88	80.89	1.97	2.78	50224	17.62	45161	14.85	46483	15.37
165	SATYABRAT ROY- 28 UG	MALE	C	4.08	43.49	88.13	84.13	1.85	2.27	54485	18.04	50492	16.32	50349	16.68
166	SHYAMAGHANA BARIK- 26 UG	MALE	C	3.11	39.22	97.27	86.86	2.01	2.58	51875	18.71	51844	18.91	52375	19.34
171	MANOJ GHOSH- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
174	SOUMYA BEHERA- 26 UG	MALE	C	2.6	40.29	97.11	87.11	2.31	3.01	53625	20.7	55527	21.42	59790	23.69
177	RAJAT ARYA- 26 UG	MALE	C	3.55	42.03	98.57	93.19	2.05	2.94	49693	16.23	49248	16.19	51357	17.42
179	SHWETHA SINHA- 28 UG	FEMALE	C	3.92	45.65	98.55	91.32	2.16	2.56	60931	24.17	61335	24.06	60214	24.09
180	SABA PARVEEN- 27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
184	BANASRI ROY- 27 UG	FEMALE	C	4.19	38.27	94.14	88.13	1.98	2.56	50850	17.96	47436	15.77	45385	15.71
187	KUSAL PRADEEP- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
192	ARUNAVA NATH- 17 PGT	MALE	C	5.18	38.83	96.2	94.91	2.12	2.81	51005	18.77	55069	19.39	52987	19.11
194	ALSA SASI KUMAR- 27 UG	FEMALE	C	5.28	38.46	94.88	87.81	2.51	3.46	54743	19.52	53807	18.99	53912	19.47
199	SANJUKTA MANDAL- 24 UG	FEMALE	C	3.89	43.74	90.12	87.83	1.98	2.4	57958	21.52	56144	19.78	54841	19.34
204	ASHITA NAS- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
207	SUBHRAJIT PAUL- 26 UG	MALE	C	2.97	39.69	93.22	85.19	1.88	2.37	52513	18.53	48825	16.83	49060	17.06
211	SADDAM MIRZA- 25 UG	MALE	C	4.18	33.49	86.83	76.65	2.25	3.62	40259	12.49	44228	13.68	46405	15.44
214	MEENAL PANDEY- 18 PGT	FEMALE	C	5.78	36.77	91.35	87.23	2.41	3.92	41807	15.12	52642	19.57	44644	17.39
215	KOMAL SHARMA- 16 PGT	FEMALE	C	3.83	41.96	95.25	94.23	1.93	2.46	51123	18.73	50011	17.94	50473	18.53
216	SHABNAM REYAZ- 26 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
219	ARCHANA KANOJIYA- 26 UG	FEMALE	C	5.4	39.32	99.35	90.61	2.63	3.08	61376	23.45	63129	24.2	60313	23.88
222	KAPIL KUMAR SHAW- 17 PGT	MALE	C	3.8	39.69	92.5	91.5	1.93	2.47	52118	17.22	51585	17.26	48645	16.41
226	CHINMAYEE DHALI- 27 UG	FEMALE	C	3.48	34.44	99.99	88.22	2.34	3.77	49688	16.55	43681	13.6	48220	15.54
228	JATIN RAJ- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
232	SUSMIT DUTTA- 16 PGT	MALE	C	3.21	44.79	97.9	87.47	2.26	2.71	62348	24.15	63158	24.94	63622	24.65
234	NIHARIKA SHAW- 26 UG	FEMALE	C	4.05	40.68	87.67	86.13	1.9	2.46	53704	18.21	49766	16.41	48071	16.02
236	MANJEET SINGH- 16 PGT	FEMALE	C	3.28	40.53	86.15	88.21	1.89	2.44	54607	19.21	48149	16.01	49652	16.39
240	SARMIN TASLIMA- 24 UG	FEMALE	C	10	40.98	90.21	79.53	1.94	2.44	49878	19.62	55540	21.11	58101	21.41
246	ROHIT KUMAR PRIYA- 26 UG	MALE	C	3.1	41.78	96.02	93.15	1.96	2.4	55142	20.34	51245	18.62	52287	19.65
249	UTPAL BISWAS- 27 UG	MALE	C	3.93	38.42	99.15	80.75	2.02	2.93	50078	17.21	48473	16.46	50017	17.89
250	JITENDRA PATEL- 26 UG	MALE	C	3.31	34.19	89.43	79.47	2.26	3.9	45218	15.07	38825	11.81	40958	12.68

ID	SUBJECT- NAME & BATCH	GENDER	GROUP	EMOTIONAL PRESSURE	ENERGY	L/R SYMMETRY	ORGANS BALANCE	ENTROPY COEFFICIENT	FORM COEFFICIENT	L_AREA	L_ENERGY	F_AREA	F_ENERGY	R_AREA	R_ENERGY
103	ASHWANI- 18 PGT	MALE	C	3.83	45.62	98.67	92.23	1.93	2.32	57781	21.03	59477	21.29	56014	20.14
104	RAJDEEP SAHA- 26 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
107	SUDHARSANAN P- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
108	MANIKA- 18 PGT	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
109	PUJA RANI- 17 PGT	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
115	BUDDHADEB CHAKRABORTY- 16PGT	MALE	C	3.52	32.39	88.07	78.63	2.14	3.59	39951	13.23	35854	10.74	38836	12.3
126	QUHELY GHOSH- 26 UG	FEMALE	C	3.88	38.44	99.36	92.23	2.32	3.51	50574	19.13	48769	17.9	51111	19
135	DEEPAK KR CHOUDHARY- 18 PGT	MALE	C	3.83	38.21	74.45	76.36	1.92	2.55	52026	18.29	49279	16.33	46028	14.88
137	SANIYA PARWEEN- 26 UG	FEMALE	C	3.32	38.06	83.34	72.87	2.2	3.33	47404	16.14	45004	14.76	50213	17.98
138	MANEESHA SUNDAR- 24 UG	FEMALE	C	4.53	44.69	86.54	86.03	2.47	3.75	60168	22.72	56021	19.83	55772	19.84
140	MIR UMAYER AHMED- 25 UG	MALE	C	4.22	33.76	90.81	80.48	2.11	3.38	41996	14.05	39400	12.7	39540	13.03
141	ANUPAM- 25 UG	FEMALE	C	3.34	44.3	99.33	92.72	1.99	2.35	57866	23.1	56878	22.01	56605	22.16
142	KHURSIDA NONJAI- 27 UG	FEMALE	C	3.7	38.14	97.46	87.18	1.92	2.65	48061	16.16	44169	14.18	47490	16.01
150	MANOJ GHOSH- 26 UG	MALE	C	4	33.65	89.13	71.45	2.5	4.24	49486	17.5	45113	14.77	46633	15.44
151	PRAGYA JOSHI- 25 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
153	SHAHIDUL ISLAM- 27 UG	MALE	C	3.18	39.78	88.81	84.85	2.16	3.08	55409	20.03	52144	18.31	52063	18.98
154	JYOTI PODDAR- 24 UG	FEMALE	C	8.35	41.44	91.63	83.24	2.34	2.84	56196	19.2	53935	17.53	55980	19.22
155	FARHAT JABEEN- 27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
159	DIPTIMOYEE PAL- 26 UG	FEMALE	C	4.3	51.16	99.25	88.91	1.97	2.26	61459	24.31	62791	24.21	61426	24.16
161	DEBIKA NASKER- 16 PGT	FEMALE	C	3.84	46.67	91.69	86.97	2.08	2.55	62891	24.37	59571	22.11	57371	21.2
163	JYOTI SMITA-27 UG	FEMALE	C	4.57	33.85	86.03	74.93	2.19	3.65	43755	14.81	39089	11.81	42057	13.03
165	SATYABRAT ROY- 28 UG	MALE	C	3.71	37.61	92.47	94.65	2.01	2.75	49905	16.19	50912	16.34	48758	15.23
166	SHYAMAGHANA BARIK- 26 UG	MALE	C	2.85	43.3	94.62	93.85	2.02	2.42	56691	21.08	56435	20.51	55550	20.56
171	MANOJ GHOSH- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
174	SOUMYA BEHERA- 26 UG	MALE	C	3.42	40.87	91.14	89.95	2.67	5.27	58029	20.87	57251	20.87	58698	22.34
177	RAJAT ARYA- 26 UG	MALE	C	3.52	41.57	97.8	92.31	1.95	2.79	50230	16.88	45929	15.36	47364	16.52
179	SHWETHA SINHA- 28 UG	FEMALE	C	4.13	33.83	77.56	74.2	2.18	3.26	45890	16.72	46650	16.51	43157	14.48
180	SABA PARVEEN- 27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
184	BANASRI ROY- 27 UG	FEMALE	C	4.29	40.32	90.81	84.39	1.93	2.4	50518	17.29	49676	16.36	52337	18.83
187	KUSAL PRADEEP- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
192	ARUNAVA NATH- 17 PGT	MALE	C	3.97	47.65	98	81.99	2.38	3.52	60739	25.39	59983	24.08	55486	22.48
194	ALSA SASI KUMAR- 27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
199	SANJUKTA MANDAL- 24 UG	FEMALE	C	3.72	45.5	92.82	88.42	2.03	2.37	61205	23.61	59546	22.68	59293	22.62
204	ASHITA NAS- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
207	SUBHRAJIT PAUL- 26 UG	MALE	C	2.97	42.5	89.51	83.16	1.93	2.43	55859	19.93	52257	18.16	52597	18.63
211	SADDAM MIRZA- 25 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
214	MEENAL PANDEY- 18 PGT	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
215	KOMAL SHARMA- 16 PGT	FEMALE	C	3.41	38.14	98.66	84.86	1.88	2.52	44388	15.89	43677	15.3	46602	16.38
216	SHABNAM REYAZ- 26 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
219	ARCHANA KANOJIYA- 26 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
222	KAPIL KUMAR SHAW- 17 PGT	MALE	C	3.85	36.84	67.6	63.34	2.25	3.97	51207	18.36	48646	17.02	44891	15.31
226	CHINMAYEE DHALI- 27 UG	FEMALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
228	JATIN RAJ- 27 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
232	SUSMIT DUTTA- 16 PGT	MALE	C	3.46	45.42	98.26	90.25	2.05	2.51	57684	21.02	57983	21.15	60308	22.89
234	NIHARIKA SHAW- 26 UG	FEMALE	C	4.28	39.05	94.99	89.87	1.9	2.47	51872	16.45	49439	14.83	48692	15.37
236	MANJEET SINGH- 16 PGT	FEMALE	C	3.43	42.45	93.28	89.88	1.92	2.4	54515	19.3	49400	17	53411	18.43
240	SARMIN TASLIMA- 24 UG	FEMALE	C	2.54	45.52	95.92	90.96	2.26	2.72	61327	25.33	60890	25.36	64501	27.24
246	ROHIT KUMAR PRIYA- 26 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
249	UTPAL BISWAS- 27 UG	MALE	C	3.8	45.97	97.93	92.72	1.99	2.36	56761	20.7	59185	21.39	60391	22.41
250	JITENDRA PATEL- 26 UG	MALE	C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

GROUP- C - PLACEBO GROUP- EPI-4 (4TH WEEK- AFTER WASHOUT PERIOD) — EPI 4